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Abstract
Despite advances in controlling diabetes, diabetic macular oedema remains 
the leading cause of blind registration in the working population in England 
and Wales.  The only proven effective treatment for diabetic macular 
oedema is laser photocoagulation.  However this treatment has limited 
benefits since it reduces the chance of moderate visual loss by 
approximately 50% and is unlikely to improve visual acuity.  
Intravitreal steroids have been used in the treatment for diabetic macular 
oedema.  Initial pilot studies suggest it can decrease retinal thickening and 
increase visual acuity in the long-term.  Vascular endothelial growth factor  is 
thought to play a critical role during the pathogenesis of diabetic macular 
oedema.  The mechanism of action of both steroids and vascular endothelial 
growth factor on permeability has still to be fully elucidated.  The aims of this 
thesis were to establish a reliable model of retinal microvascular endothelial 
cells and to characterise cellular changes following exposure to 
corticosteroids or vascular endothelial growth factor.  Separate clinical work 
was aimed at evaluating the benefits of steroid treatment alone or combined 
with pars plana vitrectomy as a treatment of diabetic macular oedema.  We 
also aimed to identify any prognostic indicators for treatment by both 
examining the morphological features of diabetic macular oedema observed 
on optical coherence tomography and by assaying the vascular endothelial 
growth factor concentration in the ocular fluids of eyes with diabetic macular 
oedema.  
Our results show that our retinal and brain microvascular endothelial cells 
were morphologically very similar; in particular with respect to the spatial 
localization of junctional proteins.  Vascular endothelial growth factor led to 
an increase in the permeability and a decrease in the staining of the Diabetic Macular Oedema:  The role of steroids and VEGF
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junctional proteins.  By using signal transduction inhibitors, we showed that 
vascular endothelial growth factor-induced permeability and vascular 
endothelial growth factor-induced zonula occludens-1 loss occurred via 
different pathways suggesting that zonula occludens-1 loss was unlikely to 
be the downstream effector of vascular endothelial growth factor-induced 
permeability.   Hydrocortisone leads to a decrease in permeability and an 
increase in the junctional expression of a number of tight junctional proteins.  
Both hydrocortisone and triamcinolone were able to inhibit vascular 
endothelial growth factor but not lysophosphatidic acid induced permeability 
suggesting that steroids are able to counteract the effects of certain but all 
vasoactive compounds.  Overall our results suggested that steroids and 
VEGF lead to opposing effects on microvascular endothelial cells.  
Our randomized controlled trial showed that intravitreal triamcinolone was no 
more beneficial than laser photocoagulation for persistent diabetic macular 
oedema.  A retrospective analysis of the morphological characteristics 
observed on Optical coherence tomography did not provide any 
characteristic that was prognostic of the outcome of intervention.  
Additionally, an exploratory case series of pars plana vitrectomy with 4 mg 
intravitreal triamcinolone was unable to show that combined treatment was 
of benefit in the long-term.  Lastly the intraocular concentration of vascular 
endothelial growth factor was not predictive of the outcome of treatment.  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.1 Diabetes Mellitus 
Diabetes Mellitus (DM) is a metabolic disorder that is characterised by 
chronic hyperglycaemia, with disturbances in the metabolism of 
carbohydrate, fat and protein, secondary to an absolute or relative lack of the 
hormone insulin (World Health Organisation, 1985). It is estimated that 
approximately 1.3 million people (2%) have been diagnosed with diabetes in 
the UK (National Institute for Health and Clinical Excellence, 2008) and there 
are a further 1 million people undiagnosed in the community (British Medical 
Association, 2004). 
The clinical diagnosis of DM is often prompted by symptoms such as 
increased thirst and urine volume, recurrent infections, unexplained weight 
loss and, in severe cases, drowsiness and coma.  High levels of glycosuria 
are usually present.  For symptomatic patients, a single random blood 
glucose estimation in excess of the 10 mmol /l for venous blood and 11.1 
mmol/l for capillary blood is diagnostic (World Health Organisation, 1985).  
For asymptomatic individuals, at least one additional abnormal plasma or 
blood glucose result is required (for example a fasting glucose of above 7) or 
an abnormal oral glucose tolerance test is essential (World Health 
Organisation, 1985).  
DM is classified as type 1, type 2 or gestational DM.  Other types of DM such 
as maturity onset diabetes of the young, which is due to single gene defects, 
exist but are very rare (Vaxillaire and Froguel, 2006).  Additionally, extensive 
damage to the pancreas for example following chronic pancreatitis or cystic 
fibrosis, may result in secondary DM.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Type 1 DM is characterized by the loss of insulin-producing beta cells of the 
islets of Langerhans in the pancreas, leading to a deficiency of insulin.  The 
majority of type 1 DM is caused by T-cell-mediated autoimmune attack of the 
beta cell (Rother, 2007) but it may also also be idiopathic.  
Type 1 DM accounts for about 10% of DM cases in North America and 
Europe (2004).  Obesity is generally not a feature.  Sensitivity and 
responsiveness to insulin are usually normal, especially in the early stages. 
It traditionally affects children but not exclusively.  The principal treatment is 
the administration of artificial insulin, without which, diabetic ketoacidosis 
often results in coma or death.
Type 2 DM is due to insulin resistance / sensitivity, combined with reduced 
insulin secretion which may become absolute.  The defective 
responsiveness to insulin involves the insulin receptor, however the specific 
pathogenesis is unknown (Sesti et al., 2001).  In the early stages the 
predominant abnormality is reduced insulin sensitivity, characterized be 
elevated levels of insulin in the blood.  At this stage, hyperglycaemia can be 
reversed by a variety of measures and medications that improve insulin 
sensitivity or reduce glucose production by the liver.  As the disease 
progresses the therapeutic replacement of insulin often becomes necessary.  
Type 2 DM may go unnoticed for years because symptoms are typically mild 
or non-existent.
There are numerous theories as to the exact cause and mechanism of type 
2 DM.  Central obesity is known to be a predisposing factor.  Abdominal fat 
produces a group of hormones called adipokines that may possibly impair 
glucose tolerance (Arner, 2005).  Increasing physical activity and weight loss 
can restore insulin sensitivity.  Other factors include aging and family history.  Diabetic Macular Oedema:  The role of steroids and VEGF
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In the last decade, type 2 DM has increasingly begun to affect children and 
adolescents, likely in connection with the increased prevalence of childhood 
obesity (Rosenbloom A, 2003).
The preponderance of DM in some families suggests a familial pattern of 
inheritance however the genetics of type 2 DM are complex and not 
completely understood, but presumably this disease is related to multiple 
genes and most patients demonstrate 2 defects in glucose handling; insulin 
resistance and some degree of insulin deficiency. 
Gestational diabetes resembles type 2 DM and occurs in about 2%–5% of all 
pregnancies and may improve or disappear after delivery.  It is fully treatable 
but requires careful medical supervision throughout the pregnancy.
However, about 20%–50% of affected women develop type 2 diabetes later 
in life.
Chronic hyperglycaemia results in increased morbidity and mortality from 
both macrovascular and microvascular complications.  Diabetic 
complications account for at least five per cent of NHS costs (Currie et al., 
1997).  Macrovascular complications cause diseases such as coronary heart 
disease, stroke and peripheral vascular disease, while microvascular 
complications affect the kidney, eye and peripheral nervous system.  
Patients who show evidence of end-organ damage for example diabetic 
neuropathy or advanced diabetic retinopathy have a 1.76 times higher risk of 
mortality compared to uncomplicated DM cases (Swerdlow and Jones, 
1996).  
Throughout the world, the incidence of diabetes continues to rise. It is 
estimated that the incidence will double between 1997 and 2010 (Amos et Diabetic Macular Oedema:  The role of steroids and VEGF
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al., 1997).  Risk factors for the development of type 2 diabetes include 
obesity, physical inactivity, ageing and genetic predisposition (Zimmet, 1999)  
In fact increasing urbanization and the introduction of a western diet has a 
significant impact on the rising incidence of DM.    Diabetic Macular Oedema:  The role of steroids and VEGF
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1.2 Biochemical and cellular consequences of 
hyperglycaemia
Hyperglycaemia is known to be the primary pathogenic factor in the 
development of diabetic complications (1998a).  However the mechanism by 
which hyperglycaemia induces diabetic complications remains unclear and 
several interrelated pathways have been implicated.  
The retina is one of the few tissues, which does not require insulin to 
transport glucose into the cell. Instead, a glucose transporter (GLUT-1) 
facilitates glucose entry into retinal endothelial cells (Sone et al., 2000).  As a 
consequence, hyperglycaemia leads to high intracellular glucose levels, 
resulting in an increased flux of glucose via the sorbitol pathway (Fig 1.1.1) 
(Crabbe and Goode, 1998).  Aldose reductase is the first enzyme in this 
pathway and it has a low affinity for glucose.  During normoglyaemia, 
metabolism of glucose by this pathway is a very small percentage of the total 
glucose use.  In contrast, in a hyperglycaemic environment, increased 
intracellular glucose results in increased enzymatic concentration of sorbitol. 
The reduction of glucose to sorbitol consumes NADPH.  NADPH is normally 
required for regenerating glutathione and therefore a reduction in its 
concentration increases intracellular oxidative stress (Lee and Chung, 1999).  
It has also been proposed that oxidation of sorbitol by NAD+ increases the 
cytosolic NADH/NAD+ ratio, a pathway that eventually increases advanced 
glycoslyation endproduct (AGE) precursors and protein kinase C (PKC) 
activation (Williamson et al., 1993).  Studies of the inhibition of the sorbitol 
pathway in vivo have failed to prevent diabetic retinopathy although a 
positive effect on diabetic neuropathy has been observed (1990). Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 1.1:  Schematic representation of the sorbitol pathway
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Advanced glycation end products (AGEs) are found in increased amounts in 
diabetic retinal vessels (Stitt et al., 1997).  They are formed when excess 
carbohydrates causes glycation of protein side-chains in a non-enzymatic 
way (Stitt et al., 1997).  Intracellular proteins modified by AGE have altered 
functions (Giardino et al., 1994) and modified extracellular proteins interact 
abnormally with other matrix components.  For example, AGE modification of 
collagen IV decreases endothelial cell adhesion (Haitoglou et al., 1992).  
Lastly modified plasma proteins, bind to AGE receptors and increase the 
production of reactive oxygen species (Tsuji and Sakurai, 1998).  
Hyperglycaemia induces de novo synthesis of the second messenger 
diacylgylcerol (DAG), which leads to selective activatation of PKC 
isoenzymes in particular PKC-beta (Koya and King, 1998).  PKC is also 
activated indirectly by increased activity through the sorbitol pathway (Keogh 
et al., 1997), as well as through ligation of AGE receptors (Portilla et al., 
2000).   Activation of PKC has many effects such as blood flow abnormalities 
in the retinal and renal circulations (Ishii et al., 1996), probably by depressing 
nitric oxide production (Craven et al., 1994);, increasing VEGF production 
(Williams et al., 1997); vascular occlusion by increasing TGF-beta, collagen 
and fibronectin expression (Studer et al., 1993) and by inhibiting the 
expression of fibrinolytic inhibitor PAI-1 (Feener et al., 1996).  
Shunting of excess intracellular glucose into the hexosamine pathway might 
also cause several manifestations of diabetic complications (Kolm-Litty et al., 
1998).  Activation of the hexosamine pathway leads to changes in the gene 
expression such as a reduction in the transcription of transforming growth 
factor alpha and beta and PAI-1 as well as alteration the function of some 
proteins for example PKC.   Diabetic Macular Oedema:  The role of steroids and VEGF
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Diabetes has also been found to induce the production of inflammatory 
mediators suggesting a role for anti-inflammatory agents such as steroids.  
The adhesion of leukocytes to the retinal vasculature is oneof the earliest 
events in experimental diabetes (Miyamoto et al., 1999).  Enhancedvascular 
permeability, endothelial cell damage, and capillarynonperfusion are some 
of the pathological consequences of diabeticretinal leukocyte adhesion 
(Miyamoto et al., 1999;Joussen et al., 2001).  
When neutralizing anti-intercellularadhesion molecule-1 (ICAM-1) antibodies 
are administered tonewly diabetic animals, retinalleukocyte adhesion is 
suppressed (Miyamoto et al., 1999;Joussen et al., 2001).
  In nondiabetic 
subjects, ICAM-1 is localized within the choriocapillaris.  In contrast during 
diabetes, there is a significant elevation of ICAM-1 in both the choroidal 
vasculature and within retinal blood vessels (P < 0.05) (McLeod et al., 1995)
and consequently elevated neutrophil levels in the choroid and retina are 
observed (McLeod et al., 1995).  Furthermore, when experimentally induced 
diabetic animals are treated with anti-VEGF antibodies both retinal ICAM-1 
mRNA and leukocyte adhesion are suppressed (Joussen et al., 2002).  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.3 Blood Retinal Barrier and vascular permeability
The retina is a transparent layer of neural tissue that functions to capture 
photons of light, convert the photochemical energy into electrical energy and 
to transmit this to the brain to be interpreted as visual images.  Its function 
depends on intact communication of all cell types; neurons, microglia, Müller 
and pigment epithelium, and requires a highly defined environment in order 
to maintain its function.  The retina has exceptionally high metabolic 
demands which are met by a blood supply which is well separated from the 
neuroretina by the blood-retinal barrier (BRB).  
The BRB is formed at 2 levels, the inner and outer BRBs.  The inner BRB is 
formed by the retinal vasculature while the outer BRB is composed of the 
retinal pigment epithelium (RPE).  
The RPE is critical for normal function of the photoreceptors and control of 
fluid volume and ionic concentrations in the subretinal space.  In diabetes, 
failure of the RPE to effectively move fluid out of the retina may contribute to 
the persistence and progression of macular oedema.  Some studies of 
experimental diabetes have demonstrated that structural and functional 
alterations of the RPE precede changes in the retinal vasculature (Kirber et 
al., 1980;Vinores et al., 1989;Klein et al., 1980;Tso et al., 1980).  Structural 
changes in the RPE include dilation of the smooth endoplasmic reticulum, 
thickening of the basal laminae of the RPE and Bruchs membrane, dilation 
and redundancy of basal membrane infoldings, formation of large vacuoles, 
and focal necrosis (Vinores et al., 1989;Grimes et al., 1984).  Reduced 
barrier function has been demonstrated using tracers such as fluorescence 
or HRP (Kirber et al., 1980;Tso et al., 1980).  Additionally, the choroid 
(McLeod and Lutty, 1994) from patients with diabetes demonstrated Diabetic Macular Oedema:  The role of steroids and VEGF
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angiopathic changes consisting of extensive capillary dropout, beaded 
capillaries, neovascularization, and Bruch's membrane degeneration.  
Although theses structural changes in the RPE and choriocapillaris of 
diabetics have been described (Vinores et al., 1990;Yanoff M, 2002), the 
retinal vasculature is the predominant siteof leakage during diabetic 
retinopathy (Vinores et al., 1989).
The inner BRB is composed of the endothelium of the retinal capillary 
vessels (Cunha-Vaz et al., 1975;Foulds, 1990), which are adapted to this 
function by a lack of fenestrations and transport vesicles (Greenwood, 
1992;Raviola, 1977) and by forming highly specialized junctions between the 
cells (Stewart and Tuor, 1994).  The retinal capillary vessels comprise 2 plexi 
of blood vessels, the superficial and the deep layers.  Distinctions exist 
among retinal vascular beds.  The superficial vessels develop in the 
presence of a rich network of astrocytic processes that is largely absent in 
the deep plexus (Gariano et al., 1996) and certain agents differentially 
interfere with murine superficial and deeper retinal vessel growth  (Dorrell et 
al., 2002).  
The endothelium is surrounded and supported by pericytes and glial cells 
(astrocytes and müller cells).  In this respect it is structurally similar to the 
blood-brain barrier (BBB) which is also formed by microvascular endothelial 
cells, supported by pericytes and astrocytes.  However the BBB is a more 
permeable barrier and has less pericytes per endothelial cell ((Stewart and 
Tuor, 1994).
Pericytes are modified smooth muscle cells that regulate retinal vascular 
flow by dilating and contracting (Hirschi and D'Amore, 1996).  Loss of Diabetic Macular Oedema:  The role of steroids and VEGF
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pericytes represents an early feature of DR and correlates with the formation 
of microaneurysms (Speiser et al., 1968a).  Glial cells regulate retina 
metabolism and modulate the function of both neurons and blood vessels 
(Speiser et al., 1968b;Gardner et al., 1999).  
Increased permeability may occur by two broad mechanisms.  Transport of 
substances between cells is referred to a paracellular transport while 
transcellular transport refers to the movement of substances through the cell.  
Permeation through the paracellular space of endothelial cells is intuitively 
the main route.  The relevance of this pathway has been underlined by 
numerous studies that imply inter-endothelial junction proteins in regulating 
vascular permeability in vitro and in vivo. Nevertheless, Hofman et al 
(Hofman et al., 2000) demonstrated an increase in retinal permeability for 
plasma proteins induced by VEGF is predominantly caused by an increase 
in active trans-endothelial transport via pinocytotic vesicles.
1.4 Endothelial cell-cell junctions 
The inner BRB forms a physiological barrier and comprises a single layer of 
non-fenestrated endothelial cells. Cell-to-cell junctional complexes are 
composed of regulated protein structures including adherens junctions and 
tight junctions (fig 1.2).   Diabetic Macular Oedema:  The role of steroids and VEGF
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1.4.1 Adherens junctions
Adherens junctions (AJ) are ubiquitously distributed along the vascular tree 
andare expressed in both blood and lymphatic vessels.  They are composed 
of transmembrane proteins, predominantly cadherins and junction-
associated proteins, predominantly catenins, that can also be found in the 
cytoplasm and nucleus (Ben-Ze'ev and Geiger, 1998).   
1.4.1.1 VE Cadherin
Vascular endothelial cadherin (VEC) represents the major transmembrane 
component of AJ in capillary endothelial cells.  It forms a dynamic complex 
with the catenins.  When the cells are subconfluent or detaching and 
migrating, phosphorylated VEC is associated with p120 and beta-catenin.  
However when cells are confluent, VEC looses itstyrosine phosphorylation 
and associates also with gamma-catenin and the actin cytoskeleton 
(Breviario et al., 1995). 
VEC is largely responsible for morphogenesis and maintenance of the 
vasculature by establishing cell-cell contact (Carmeliet et al., 1999).  Mutant 
VEC genes are lethal in the early embryonic stage due to collapse of the 
vascular network and circulatory insufficiency  (Carmeliet et al., 1999).  
Additionally, VEC has a role in the maintenance of the endothelial barrier 
illustrated by the increased permeability in response to anti-VEC antibodies 
injected in experimental animal models (Corada et al., 1999). 
The extracellular domain of VEC is involved in endothelial cell-to-cell 
adhesion.  It consists of five cadherin-like repeats that form a rigid, rodlike
structure.  Dimers between VEC molecules can either occur between Diabetic Macular Oedema:  The role of steroids and VEGF
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adjacent cells or opposing cells (Shapiro et al., 1995).  Antibodies directed at 
the most distal extracellular domain (EC1), cause a decrease in the barrier 
function of endothelial cell monolayers in vitro and blood vessels in vivo
(Corada et al., 2001).  
1.4.1.2 Catenins 
The catenins belong to family of proteins which contain a large number of 
repeated sequence motif, the armadillo repeat.  The armadillo family 
includes alpha-catenin, beta-catenin, gamma-catenin (also known as 
plakoglobin) and p120.  They form interactions with AJs and the actin 
cytoskeleton (Dejana et al., 2008).  The role of many of these proteins is 
largely undetermined.  They have been known to have a role in gene 
expression and cellular signaling, characterized by their ability to translocate 
to the nucleus (Ben-Ze'ev and Geiger, 1998;Cowin and Burke, 1996)  as well 
as a role in paracellular permeability (Navarro et al., 1995).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 1.2:  Schematic diagram illustrating the proteins comprising the 
junctional complexes found between endothelial cells in the blood-retinal 
barrier.
JAM, junctional adhesion molecule; Cl-5, claudin-5; F-actin, filamentous 
actin; ZO-1, 2 and 3, zonula occludens 1, 2 and 3; VEC, vascular endothelial 
cadherin.  
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1.4.2 Tight junctions
Tight junctions (TJ) were first described in epithelial cells as the most apical 
components of the intercellular junctional complex (Cereijido M, 2001b) and 
were first described in epithelial cells   In endothelial cells, they are of similar 
architecture but are spatially intermixed with adherens junctions (Cereijido 
M, 2001b).  On electron microscopy, they appear as regions where the 
plasma membranes from adjacent cells appear to fuse together and 
obliterate the intercellular space (Cereijido M, 2001a).  This area completely 
encircles the cell and consists of anatomising strands of proteins that interact 
with proteins on adjacent cells (Staehelin, 1973).  Like AJ these proteins are 
made up of intramembrane proteins (occludin (Furuse et al., 1993), claudin-5 
(Morita et al., 1999) and junctional adhesion molecule (JAM)) and junction-
associated proteins (ZO-1, ZO-2 and ZO-3 (p130) (Stevenson et al., 
1989;Jesaitis and Goodenough, 1994;Haskins et al., 1998a), 7H6 (Haskins 
et al., 1998b) and cingulin (Stevenson et al., 1989), (fig 1.2).  
Tight junctions perform a number of different functions, including cell-cell 
adhesion and in epithelial cells, establishing cell polarity.  In addition, tissues 
that produce a tight barrier for example the BBB have an increased 
expression of TJ, suggesting their role in endothelial permeability.  
Permeability through the TJ may be altered either by changing the junctional 
constituents, by posttranslational modifications of junctional proteins (Wong, 
1997;Antonetti et al., 1999), or by their interaction with the actin 
cytoskeleton.  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.4.2.1 Occludin
Occludin is a 55.9 – 65 kDa transmembrane protein with 4 membrane 
spanning loops, 2 extracellular loops and cytoplasmic carboxyl (-C) and 
amine (-N) termini.  The carboxyl terminal normally interacts with ZO-1 
(Furuse et al., 1993) but can also interact with ZO-2 and 3 (Haskins et al., 
1998a).  
Occludin is not required for structural integrity of TJ.  In occludin -/- mice an 
overt disruption of vascular barrier is not observed (Saitou et al., 1998).  
Nevertheless, it plays a crucial role in permeability (Matter and Balda, 1999).  
Arterial endothelial cells express an 18-fold greater occludin content and 
have a much high solute barrier than their venous counterparts (Kevil et al., 
1998).  Additionally, pathological models of increased permeability for 
example experimental diabetes is associated with a reduction in occludin 
levels (Antonetti et al., 1998;Barber et al., 2000).  
In MDCK cells, occludin lacking its first extracellular loop is still able to 
colocalise with ZO-1.  In contrast, constructs lacking the second, or both, 
extracellular loops were absent from TJ and were found only on the 
basolateral cell surface, suggesting that the second extracellular domain is 
required for stable assembly of occludin in the TJ (Medina et al., 2000).  
Additionally the second extracellular loop has been implemented in the 
barrier function of the TJ.  Transelectrical resistance is reduced in vitro by a 
synthetic peptide (OCC2) corresponding to the second extracellular domain 
of occludin (Wong and Gumbiner, 1997).Diabetic Macular Oedema:  The role of steroids and VEGF
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1.4.2.2 Claudin 5
Claudin 5 (Cl-5) is a member of a large family of proteins (Hiiragi 1998).  Cl-5 
has a specificity for endothelial cells (Morita et al., 1999), however recently, it 
has also been found in epithelial cells of the choroidal plexus and in the 
abdominal tract (Kiuchi-Saishin et al., 2002;Rahner et al., 2001).  
Similar to occludin, Cl-5 has 4 transmembrane domains, 2 extracellular loops 
and cytoplasmic N and C termini (Morita et al., 1999).  Site-directed
mutations of particular amino acid residues in the first extracellulardomain 
alter the properties of the TJ.  In particular, mutation of Cys 
64 leads to an 
increase in the flux of monosaccharides (Wen et al., 2004).  The importance 
of Cl-5 in the barrier function of cells is further illustrated by the Cl-5 
knockout mouse, where TJ are still formed, but the absence of Cl-5 leads to 
detection of smaller (HRP-conjugatedstreptavidin) but not larger molecules 
(albumin) across the blood brain barrier (Nitta et al., 2003). 
1.4.2.3 Zonula Occludens-1
Zonula occludens-1 (ZO-1) was the first TJ protein to be identified 
(Stevenson et al., 1986).  It is a 225 kDa protein that belongs to the 
membrane associated guanylate kinase family of proteins (MAGuK) that 
contain a region of homology to guanylate kinase (GK) but does not have 
any GK activity.  It is found in TJ bound to occludin (Furuse et al., 1994) and 
with ZO-2 and ZO-3 (Jesaitis and Goodenough, 1994;Haskins et al., 1998a).  
However in cells without occludin, it also is found associated with AJ (Saitou 
et al., 1998) and should therefore not be considered a bona fide TJ marker.Diabetic Macular Oedema:  The role of steroids and VEGF
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ZO-1 serves many functions.  It binds to the actin forming a scaffold with the 
cytoskeleton (Fanning et al., 1998) and it has an integral role in permeability.  
There is evidence that this involves small Rho GTPases (Wojciak-Stothard 
and Ridley, 2002).  Activated RhoA disrupts TJ assembly by inducing Myosin 
light chain dependent actin stress fibers formation and initiating cytoskeleton 
retraction (Dudek and Garcia, 2001).  
ZO-1 is expression is decreased in conditions of increased permeability and 
increases with barrier tightness (Krause et al., 1991).  Furthermore, the 
phosphorylation of ZO-1 leads to a decrease in barrier function (Takeda and 
Tsukita, 1995).  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.5 Vascular Endothelial Growth Factor as a vasoactive and 
angiogenic factor in the retinal vasculature
1.5.1 VEGF
Vascular endothelial growth factor (VEGF) is a family of homodimeric 
glycoproteins with potent vasoactive  (Senger et al., 1983) and angiogenic 
potential (Leung et al., 1989).  The VEGF family includes VEGF A, VEGF B, 
VEGF C, VEGF D, VEGF E, and placental growth factor (PlGF).  
VEGF-A is the most studied isoform and usually referred to as VEGF.  It 
plays a predominant role during embryonic development and in many 
pathological processes.  It is a 36-45 kDa protein with an N-terminal signal 
sequence and a heparin binding domain.  The human gene for VEGF A 
resides on chromosome 6p21.3 (Vincenti et al., 1996). VEGF exists as 
multiple isoforms resulting from alternative pre-mRNA splicing of eight exons 
(fig 1.3)  The isoforms are named according to their amino acid content; for 
example VEGF121, VEGF165 or VEGF 189 and are generically referred to as 
VEGFxxx (Houck et al., 1991;Ferrara, 2004).  All currently described isoforms 
contain exons 1-5 and exon 8.  Exons 6 and 7 code for a heparin-binding 
region and therefore the longer isoforms are matrix bound whilst the shorter 
forms are soluble (Plate and Warnke, 1997).  VEGF 165 is the most 
abundant form in vivo and is partly bound and partly diffusible.  VEGF121, 
and VEGF145 and VEGF165 all induce proliferation of endothelial cells in vitro
and angiogenesis in vivo (Poltorak et al., 1997;Park et al., 1993;Zhang et al., 
1995).  Most cell types produce several VEGF variants simultaneously. 
Usually the 121 and 165 forms are the predominant forms. In contrast, 
VEGF145 expression seems to be more restricted to reproductive organs 
(Poltorak et al., 1997).   Diabetic Macular Oedema:  The role of steroids and VEGF
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Longer extracellular matrix bound forms are released slowly, following
exposure to heparin and heparinases, or more rapidly as bioactive 
fragments, through cleavage by plasmin or urokinase (Plouet et al., 1997). 
The use of alternative 3’ spicing in the exon 8 results in almost identical 
sister isoforms referred to as VEGFxxx and VEGFxxxb (Bates et al., 2002).  
VEGFxxxb isoforms results from distal splicing of exon 8.  The result is that 
the VEGF receptor binding and dimerization domain remain. However, the 
altered C-terminal domain is thought to act as a competitive inhibitor of 
VEGF165.  It binds to the receptor but does not stimulate its full tyrosine 
phosphorylation (Woolard et al., 2004). Therefore expression of these two 
isoform families, regulated by alternative splicing, could determine the 
balance between angiogenic and anti-angiogenic processes.  In agreement 
VEGF165b has been found to inhibit tumour growth (Rennel et al., 2008) and 
proliferative retinopathy (Konopatskaya et al., 2006).  Recent studies also 
suggest that this family of isoforms forms a substantial proportion of the total 
VEGF, ranging from 1% in placental tissues (Bates et al., 2006) to over 95% 
in normal colon tissue (Varey et al., 2008).  The proximal splicing switch 
appears to occur in a number of diseases associated with angiogenesis, 
including diabetic retinopathy (Perrin et al., 2005) and cancers (Varey et al., 
2008). Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 1.3:  Exon structure of VEGF A gene and the generation of splice 
variants.  The VEGF gene consists of eight exons (top).  VEGF isoforms 
result from alternative splicing of these exons.  The isoforms are labelled 
according to the number of encoding amino acids.  All currently described 
isoforms contain exons 1-5 and exon 8.  The heparin-binding region is coded 
by exons 6 and 7. Alternative spicing in the exon 8 results in a sister family 
of isoforms referred to as VEGFxxx and VEGFxxxb.  
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1.5.2 VEGF receptors
VEGF binds several transmembrane tyrosine kinase receptors.  The 
receptors are structurally related to platelet-derived growth factor family of 
receptors, containing seven similar extracellular immunoglobulin domains, a 
single hydrophobic transmembrane domain and a conserved intracellular 
tyrosine kinase domain (Neufeld et al., 1999).  There are three known 
receptors VEGF-R1, 2 and 3 (Neufeld et al., 1999) as well as neuropilin-1, 
which is a co-receptor for VEGF A, enhancing its binding with R2 (Soker et 
al., 1998) (fig 1.4).
VEGF-R1 was the first receptor identified for VEGF and is also a receptor for
PlGF and VEGF-B.   It is expressed on endothelium and on some non-
endothelial cells including haematopoietic stem cells, macrophages and 
monocytes (Peters et al., 1993;Sawano et al., 2001).  VEGFR-1 expression 
on vascular endothelial cells may act as a decoy receptor by inhibiting VEGF 
signalling.  Inactivaton of the VEGFR-1 gene in mice leads to death in-utero 
due to failure of endothelial cells to organise into functional blood vessels
(Fong et al., 1995).  In these animals there is an abnormal increase in 
endothelial progenitor cells.  Expression of altered VEGFR-1 in which the 
tyrosine kinase domain was deleted while the ligand-binding domain 
remained intact was found to be compatible with normal vascular 
development and angiogenesis in transgenic mice, suggesting that VEGFR-
1 signalling is not required for normal development (Hiratsuka et al., 1998).  
Additionally pre-RNA slicing leads to the existence of a soluble form of 
VEGFR-1 without the transmembrane and intracellular domains and as a 
consequence is unable to mediate any signal transduction and therefore is 
likely to function as a decoy receptor which further suggests a negative role 
of VEGFR-1 in vivo (Kendall et al., 1996).Diabetic Macular Oedema:  The role of steroids and VEGF
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In contrast VEGFR-2 binds all VEGF isoforms.  In endothelial cells, VEGFR2 
localization may determine specific signaling events after VEGF stimulation.  
For example, VEGFR2 associated with cadherins at cell-cell junctions may 
facilitate the vascular permeability response (Weis et al., 2004b), whereas 
VEGFR2 associated with [alpha]v integrins ([alpha]v[beta]3 and 
[alpha]v[beta]5) at the cell-matrix interface may influence permeability as 
well as angiogenesis (Reynolds et al., 2002).  
Finally, VEGF-R3 binds VEGF-C and VEGF-D only (Pajusola et al., 1992)
(Finnerty et al., 1993).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 1.4:  Isoforms and receptors of the VEGF family.  There are 3 
signaling tyrosine kinase receptors of the VEGF family (VEGF-R1, VEGF-R2 
and VEGF-R3) and 2 co-receptors, neuropilin -1 and -2.  Different isoforms 
of the VEGF family selectively bind to the various receptors and co-receptors 
as indicated. 
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1.5.3 VEGF and pathology.  
VEGF and its receptors are critical for normal embryologic development 
(Carmeliet et al., 1996) as well as the female reproductive cycle (Ferrara et 
al., 1998).  VEGF receptors are found in other healthy adult organs such as 
the glomerulus of the kidney (Esser et al., 1998), the gastrointestinal mucosa 
(Shifren et al., 1994) and the retinal (Thieme et al., 1995).  Previous studies 
(Carmeliet et al., 1996;Ferrara et al., 1996) have shown that targeted 
deletion of VEGF in mice leads to abnormal vascular development and 
embryonic lethality, emphasizing the critical role for VEGF in blood vessel 
development.  
VEGF is the only angiogenic factor that also potently induces vascular leak.  
It has been implicated in many pathological processes, such as rheumatoid 
arthritis (Fava et al., 1994) and in most human cancers (Volm et al., 
1997;Brown et al., 1995).  Although VEGF-induced angiogenesis is often 
accompanied by a vascular permeability response, VEGF-induced-vascular 
leak is not required for angiogenesis (Eliceiri et al., 1999).  Notably both 
angiogenesis and oedema are central features of diabetic eye disease.   
Hypoxia induces VEGF transcription (Brooks et al., 1998).  Hypoxia 
upregulates the transcription factor hypoxia-inducible factor (HIF)-1x (alpha), 
which binds to the VEGF-A promoter and induces the transcription of VEGF 
and VEGFR1 (Carmeliet et al., 1998;Li et al., 1996a).  The role of HIF in 
diabetic retinopathy is not yet clear but it has been implicated in VEGF 
overexpression and hyperpermeability of the blood-retinal barrier in diabetes 
(Poulaki et al., 2002). Diabetic Macular Oedema:  The role of steroids and VEGF
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1.5.3.1 VEGF and DMO
VEGF levels are elevated in the vitreous of eyes with diabetic macular 
oedema (Funatsu et al., 2002;Patel et al., 2006c).  Elevated VEGF mRNA is 
found in the ganglion cell layer as well as the inner and outer nuclear layers,
and an increase in VEGF protein is found in the inner retina in close 
proximity to capillaries (Hammes et al., 1998).  In a model of diabetic 
retinopathy, blood–retina barrier breakdown was both prevented and 
reversed by VEGF inhibition (Qaum et al., 2001). 
The mechanisms underlying VEGF-induced permeability are unclear. VEGF 
increases permeability via multiple mechanisms, including leukocyte-
mediated endothelial injury (Joussen et al., 2001) and dissolution of tight 
junctions (Antonetti et al., 1999).  The amount and duration of VEGF 
exposure that are required for BRB breakdown may be less than that for 
neovascularisation (Tolentino et al., 1996;Tolentino et al., 2002).  However 
neovascularisation is also characterised by vascular permeability and some 
investigators have speculated that vascular permeability is an antecedent 
and required step for neovascularisation to take place (Dvorak et al., 1991).  
Furthermore, VEGF has been implicated in the disruption of the RPE and a 
reduction in the regulated removal of subretinal fluid.  VEGF produces a 
significant drop in transepithelial electrical resistance in both RPE cell lines 
(ARPE-19) and primary porcine RPE cells (Ablonczy and Crosson, 2007).  
This response was only observed following apical administration and this 
and further work suggests that apically-oriented VEGF-R2 receptors are 
responsible for this effect (Ablonczy and Crosson, 2007).Diabetic Macular Oedema:  The role of steroids and VEGF
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1.6 Diabetes and the Retina
Diabetic microvascular complications cause damage to the retinal 
vasculature resulting in diabetic retinopathy (DR), which is the most common 
cause of blind registration in the working population in England and Wales 
(Bunce and Wormald, 2008).  
The Diabetic Control and Complications Trial (DCCT) showed that DR tends 
to cluster in families (1997a).  This and the differences in the frequency of 
disease in ethnic populations (Guillausseau et al., 1997) suggest that genetic 
disposition maybe important in DR.  Additionally, there are distinct 
morphological manifestations of DR.  Some subjects show maculopathy and 
others showing much more extensive retinal vascular disease, however, it is 
unclear whether these different morphologies represent distinct pathogenetic 
mechanisms.  Imperatore undertook a genome-wide scan for susceptibility 
genes for DR (and nephropathy) in families using affected sib-pair linkage 
analysis.  There were indications that elements on chromosomes 3 and 9 
influenced both nephropathy and retinopathy, but no clear genomic region 
was designated for retinopathy alone (Imperatore et al., 1998).  
DR can be separated into two different subtypes, diabetic maculopathy and 
diabetic retinopathy.  Diabetic maculopathy occurs when the 
microvasculopathy affects the macula, threatens the central visual acuity and 
may be present at any level of retinopathy.  Diabetic retinopathy arises when 
the microvasculopathy leads to visible changes in the rest of the retina.  
Diabetic retinopathy falls into two clinical stages: nonproliferative diabetic 
retinopathy and proliferative diabetic retinopathy.Diabetic Macular Oedema:  The role of steroids and VEGF
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In the Wisconsin Epidemiologic Study of Diabetic Retinopathy, 3.6% of type 
1 diabetics had a visual acuity of 20/200 or less in the better eye and in type 
2 diabetes, 1.6% had a VA of 20/200 or less (Moss et al., 1998).  
Diabetic maculapathy (DMO) affects approx 29% of diabetic patients with 
disease duration of 20 years of more and accounts for 80% of blind 
registration due to diabetic retinopathy (McMeel et al., 1977;Patz et al., 
1973).  The incidence of DMO is directly proportional to the severity of 
diabetic retinopathy (Henricsson et al., 1999).   Diabetic Macular Oedema:  The role of steroids and VEGF
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1.6.1 Non-proliferative and proliferative diabetic retinopathy
Prior to any clinically detectable changes in the retina, microvascular 
changes such as death of retinal pericytes (KUWABARA and COGAN, 1963)
and basement membrane thickening occur and lead to an altered 
microvascular blood flow.  Capillary closure is a predominant pathological 
feature associated with microaneurysms and becomes more evident as the 
disease progresses (ASHTON, 1953).  Endothelial adhesive properties are 
changed resulting in increased leukocyte and platelet adhesion and 
fibrinolysis (Miyamoto et al., 1998;Ceriello et al., 1993).  Subtle alteration in 
vascular permeability are also observed.
Non-proliferative diabetic retinopathy (NPDR) occurs when the first clinically 
detectable lesions of DR are seen.  These consist of microaneuryms, retinal 
haemorrhages, cotton wool spots, exudates and subsequently vascular 
changes such as beading, looping and intraretinal microvascular 
abnormalities (IRMAs).  
In the natural course of DR, approximately 50% of patients with very severe 
NPDR progress to PDR within 1 year (1991b).  Proliferative diabetic 
retinopathy (PDR) develops secondary to capillary closure.  The resultant 
retinal ischaemia upregulates growth factors such as VEGF leading to 
neovascular proliferation on the surface of the retina.  These represent an 
attemptto supply oxygenated blood to the hypoxic retina.  However, these 
blood vessels are fragile and haemorrhage easily.  The Diabetic Retinopathy 
Study demonstrated that without laser treatment, the 5 year risk of severe 
visual loss (SVL),(<5/200) was 50% (1976;1978).  The 5 year risk of SVL 
following early pan retinal photocoagulation is 2-6% (1991b).  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.6.2 Diabetic Maculopathy
Arteriolar dilation and an increase in retinal blood flow is characteristic of 
early DR (Skovborg et al., 1969;Kohner et al., 1975).  Hyperglycemia leads 
to an increase in retinal blood by altering perfusion pressure and due to a 
lack of compensatory autoregulation during diabetes (Sinclair et al., 1982).   
This is detected clinically (Kohner et al., 1975) as well as in experimental 
hyperglycemia (Atherton et al., 1980).  With the relative rise of perfusion 
pressure, increased exudation into the retina especially through the diseased 
vessels in diabetics, explains the early exudative features of DR.  The 
increased perfusion pressure may also contribute to the production of 
microaneurysms by exerting pressure on the vessel wall weakened by the 
loss of pericytes (Addison et al., 1970).
Vascular leakage may also occur in response to capillary closure.  Hypoxia 
and thus macular ischaemia can result from a number of factors.  Increased 
basement membrane thickening reduces the bore of affected vessels which 
results in an increase in resistance.  Blood flow is also restricted by 
haematological abnormalities, including increased plasma viscosity due to 
increased fibrinogen levels (Lowe et al., 1980) and red cell aggregation 
(Peduzzi et al., 1984).  Additionally leucocyte adhesion to the vascular 
endothelium and upregulation of adhesion molecules such as ICAM-1 play 
an important role in producing retinal hypoxia.  
Macular ischaemia is characterised by enlargement of the foveal avascular 
zone (FAZ) and / or perifoveal capillary drop-out on fundus fluorescein 
angiography and is at present untreatable.  The presence of macular 
ischaemia may have a negative effect on the visual outcome of treatment 
(Chung et al., 2008).  It is associated with BRB breakdown and the formation Diabetic Macular Oedema:  The role of steroids and VEGF
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the macular oedema.  Additionally, hypoxia itself has been shown to produce 
alterations in the TJ proteins (Witt et al., 2003) correlating with increased 
permeability.  
Diabetic macular oedema (DMO) is characterised by thickening of the retina 
within 2 disc diameters of the fovea.  The oedema is caused by an increase 
in permeability of the inner BRB and in decreased efflux of fluid, which leads 
to an accumulation of intraretinal fluid, primarily in the inner and outer 
plexiform layers.  
Retinal thickening can be appreciated only with stereoscopic viewing of the 
retina.  However other clinical signs such as microaneurysms and exudates 
act as monocular clues to its existence.  Microaneurysms are thought to play 
a significant role by acting as sources for fluid and lipid transudation (chang 
S, 2002).  Data from a study by Klein et. al. (Klein et al., 1995) showed that 
the increase in the number of retinal microaneurysms at the 4-year follow-up 
was associated with increased incidence of Clinically significant macular 
oedema (CSMO) at the 10-year follow-up.  The United Kingdom Prospective 
Diabetes Study (UKPDS) reported similar findings (Kohner et al., 1999).  
However, whether the formation of the microaneurysms per se is the cause
or, whether the microaneurysms are part of a morphological signal of 
another pathophysiological process is largely unknown.  
DMO can be classified as focal and diffuse.  Focal DMO is primarily caused 
by focal leakage from microaneurysms, dilated retinal capillaries or IRMAs.  
Clusters of microaneuryms may be seen in areas of circinate exudates with 
fluid and fundus fluorescein angiography confirms that the microaneurysms 
leak.  Diffuse DMO is caused by generalised leakage from dilated capillaries 
throughout the posterior pole and is generally associated with capillary loss.  Diabetic Macular Oedema:  The role of steroids and VEGF
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CSMO was defined by the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) as DMO in which central visual acuity was threatened (table 1.1).
The preponderance of diabetic retinopathy varies between type 1 and type 2 
diabetics.  Patients with type 1 diabetics tend to have a higher incidence of 
PDR (10% in type 1 DM compared with 5% in Type 2 DM) (Zander, BJO, 
2000), while patients with type 2 DM have a higher prevalence of 
maculopathy (53% type 2 DM compared with 42% type 1 DM) (Zander et al., 
2000).  
The best estimate of the natural history in eyes with DMO comes from the 
treatment group in the ETDRS in which focal/grid photocoagulation was 
deferred.  This study found that the incidence of moderate visual loss 
(MVL),(defined as a loss of 15 letters on the ETDRS chart) if treatment was 
deferred was 8% at 1 year, 16% at 2 years, and 24% at 3 years in 
comparison to the incidence of MVL if treatment was given immediately of 
5% at 1 year, 7% at 2 years, and 12% at 3 years, which corresponds to a 
50% risk reduction (1985).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 1.1:  Definition of clinically significant macular oedema (CSMO) as set 
out in the Early Treatment of Diabetic Retinopathy Study (ETDRS) (1985)
Thickening of the retina at or within 500 µm of the centre of the macula.
Hard exudates at or within 500 µm of the centre of the macula if associated 
with thickening of adjacent retina.
A zone or zones of retinal thickening 1 disc diameter or larger, any part of 
which is within 1 disc diameter of the centre of the macula.Diabetic Macular Oedema:  The role of steroids and VEGF
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1.7 Current management of Diabetic Macular Oedema
The morbidity associated with DMO can be reduced by primary prevention, 
regular screening, early detection and timely treatment.
1.7.1 Primary prevention 
The DCCT examined the role of tight blood glucose control with routine 
management of type I diabetes. There was a 26% reduction in the risk of 
development and progression of DMO in the tight control group over 9 year 
of follow-up period. (1995).  Following the DCCT, the expectation was 
generated that a similar improvement in the incidence of diabetic 
complications would occur in type II diabetes.  The United Kingdom 
Prospective Diabetes Study (UKPDS) addressed the issue of tight glycaemic 
control in type II patients (Stratton et al., 2000).  The UKPDS demonstrated 
at 10 years, a 17% reduction in the risk of progression of retinopathy, a 29% 
reduction in the need for laser treatment and a 16% reduction in the risk of 
legal blindness in the in the intensively treated group (1998b).  It is 
interesting to note that both the DCCT and the UKPDS, took 10 years to 
show a difference between the treatment groups and this should be kept in 
mind for novel therapies.  
Unfortunately, perfect glycaemic control remains elusive in many patients 
and there is a rise in glycated haemoglobin levels despite intensive 
treatment over a 10-year period. Type I diabetic patients appear to obtain 
greater benefit from tight glycaemic control than those with type II diabetes 
(McCormack and Greenhalgh, 2000), however this is at the risk of significant 
hypoglycaemic events (1991c).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Other risk factors associated with DMO include age, male gender, systolic 
blood pressure, proteinuria (Klein et al., 1984) and hyperlipidaemia (Chew et 
al., 1996)
Hypertension at baseline is associated with a 40% increase in the risk of 
DMO (Klein et al., 1998).  In normal subjects, the retinal vasculature is 
autoregulated over widely varying levels of systemic perfusion pressure.  
However, in diabetic eyes autoregulation of the retinal circulation is impaired, 
leading to increased flow, which is proportional to the systemic blood 
pressure.  Increased retinal blood flow is also found during, pregnancy, and 
autonomic neuropathy, all of which are associated with an increase in 
diabetic retinopathy.  In contrast, conditions that reduce retinal blood flow 
such as carotid artery stenosis and elevated intraocular pressure appear to 
offer protection from diabetic retinopathy (Archer, 1999).  
The UKPDS assessed the effect of blood pressure treatment on diabetic 
retinopathy.  Patients with hypertension were randomised to either tight 
control of blood pressure (<150/85 mmHg) with a beta-blocker or an 
angiotensin converting enzyme inhibitor (with additional agents if required), 
or to less tight pressure control, (<180/105) avoiding the use of beta-blockers
or ACE inhibitors.  After 7 years follow-up, there was a 35% reduction in the 
progression of DR in the tight control group.  At 9 years, there was 47% 
reduction in the risk of MVL and the need for photocoagulation was reduced 
by 35% in the tight control group (of which 78% was macular 
photocoagulation) (Adler et al., 2000).  No benefit of the ACE inhibitor 
(captopril) over the beta-blocker (atenolol) was observed (Adler et al., 2000).  
However, the benefit of ACE inhibitors in delaying the ocular complications 
of diabetes in addition to their blood pressure lowering effect is likely but less Diabetic Macular Oedema:  The role of steroids and VEGF
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well confirmed.  The role of Renin-Angiotensin System (RAS) in the eye 
appears to be involved in regulation of blood flow (Ferrari-Dileo et al., 1996)
and IOP (Constad et al., 1988;Giardina et al., 1990).  Renin, angiotensiogen 
and ACE have been identified in human eyes along with their corresponding 
mRNA suggesting it is locally produced (Wagner et al., 1996).  Additionally 
the levels are not related to circulating levels (Kohler et al., 1997;Danser et 
al., 1994).  In diabetic rat, levels of ACE in retinal vessels are elevated 
compared with non-diabetic controls (Okada et al., 2001).  
The EUCLID study, investigated the use of lisinopril, an ACE inhibitor in 
patients with type I diabetes, who were predominantly normotensive (1997b).  
At 2 years of follow-up, the ACE inhibitor group had a 50% reduction in the 
progression of retinopathy compared to placebo (Chaturvedi et al., 1998).  
However, the findings of this study were weakened owing to differences in 
initial and final glycated haemoglobin levels favouring lisinopril.
The Heart Outcomes Protection Evaluation Study (HOPE Study), which was 
a multicentre study of ramipril versus placebo of patients at high risk of 
cardiovascular disease (2000), has supported the specific effect of ACE 
inhibition. Although this study was not designed to show an effect on diabetic 
retinopathy, a reduction in need for laser treatment in the ramipril group was 
observed.  Additionally the DIRECT studies, showed that candesartan 
reduced the incidence of DR by 25% compared to placebo.  However there 
was no change in progression of retinopathy in those patients with 
established DR (Chaturvedi et al., 2008).  
Data from the ETDRS (Chew et al., 1996) and more recent studies (Sen et 
al., 2002;Chowdhury et al., 2002) suggest that lipid lowering drugs may 
decrease the risk of hard exudate formation and associated vision loss in Diabetic Macular Oedema:  The role of steroids and VEGF
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patients with diabetic retinopathy.  The mechanisms by which lipid-lowering 
agents might improve exudative diabetic retinopathy are not yet established.  
Basic research has suggested that oxidised LDL cholesterol is toxic to retinal 
endothelial cells, and that statins may improve endothelial function, platelet 
aggregation, and reduces growth factor-induced DNA synthesis.  
More recently the Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study (Keech et al., 2007) found a reduction in progression of 
established DMO in the fenofibrate group compared with the placebo group.  
The mechanism of action does not seem to be related to plasma 
concentrations of lipids.  
Based on these and similar findings, guidelines on the optimal control for 
diabetics have been adopted.  HbA1c should be 6.5% or less, blood 
pressure 140/80 or under and total cholesterol less than 4mmol/l or low-
density lipoprotein (LDL) cholesterol level below 2.0 mmol/l (National 
Institute for Health and Clinical Excellence, 2008).  However despite optimal 
blood glucose control, complications still occur and 20 yearsafter the onset 
of diabetes, almost all patients with diabetes will have some degreeof 
retinopathy.  Even at the time of diagnosis of type 2 diabetes,about a quarter 
of patients have established background retinopathy (British Medical 
Association, 2004).  Diabetic Macular Oedema:  The role of steroids and VEGF
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1.7.2 Regular screening and early detection
It has been shown that early detection of sight-threatening diabetic 
retinopathy and timely treatment halves the risk of MVL (1985).  DR 
conforms well to the principles of screening; it is an important health problem 
with a recognisable presymptomatic state, the screening procedure is 
acceptable to the public, there is an appropriate treatment and it is cost 
effective.  
In 2001, the National Service Framework Diabetes Standards were 
published for England and Wales (National Institute for Health and Clinical 
Excellence, 2008).  These included the targets and standards for diabetic 
retinopathy screening, stating that by 2007, 100% of patients diagnosed with 
diabetes should be screened on an annual basis.  The standards included 
that the screening test must be performed by digital photography, screening 
staff must be adequately trained and have a clinical lead and programme 
manager and there must be good links between the hospital and primary 
care.  
The strength of screening is illustrated in Iceland.  In 1980 Iceland started its 
screening program. All diabetics were screened and laser treatments carried 
out when needed.  In 1980 the prevalence of legal blindness in the type 1 
diabetes population was 2.4% (Danielsen et al., 1982) but by 1994 it had 
decreased to 0.5% for type 1 diabetes (Kristinsson et al., 1994b) and 1.6% 
for type 2 diabetes (Kristinsson et al., 1994a).  
.Diabetic Macular Oedema:  The role of steroids and VEGF
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1.7.3 Current treatments
To date, conventional macular laser therapy is the only proven effective 
treatment for CSMO (1985).  The principal aim of laser photocoagulation is 
to prevent visual loss.  The ETDRS assessed the effect of laser 
photocoagulation versus observation and found that at 3 years the risk of 
MVL was reduced by 50% (from 24% to 12%) in the laser group.  Visual 
acuity improved in only 3% of patients (1987).  Therefore despite all these 
current interventions, visual loss due to DMO still occurs and in some 
patients even the most aggressive treatment cannot prevent vision loss 
(Frank, 2002). Therefore, there is a desperate need for further treatment 
options to reduce visual impairment due to DMO.
A number of pharmacological agents for DR and DMO are currently being 
investigated.  These include PKC beta inhibitors (2007) , angiotensin 
converting enzyme (ACE) inhibitors  (Sjolie and Chaturvedi, 2002) and anti-
VEGF agents (Chun et al., 2006). 
1.7.3.1 Protein Kinase C inhibitors 
As previously discussed (section 1.2), protein kinase C (PKC) has been 
shown to be involved in the pathogenesis of DMO.  Ruboxistaurin, is an 
orally active PKC β inhibitor which was developed to reduce the permeability 
of the BRB (Jirousek et al., 1996).  In the retina of diabetic animals, 
ruboxistaurin has been shown to decrease retinal PKC activity, normalize 
retinal blood flow (Jirousek et al., 1996), reduce Na+/-K+ ATPase activity 
(Kowluru et al., 1998) and reduce VEGF-induced angiogenesis and VEGF-
induced permeability (Aiello et al., 1997).  Diabetic Macular Oedema:  The role of steroids and VEGF
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The Protein kinase C diabetic macular oedema study group (PKC-DMES)
was designed to investigate the effect of ruboxistaurin on DMO (2007).  This 
multicentered, randomized, controlled study assessed patients with oedema 
further than 300 µm from the center of the macula, without prior 
photocoagulation.  Over 30 months, 686 patients received placebo or 
ruboxistaurin orally (4, 16, or 32 mg/day).  The primary outcome was 
progression to sight-threatening DMO or application of focal/grid 
photocoagulation for DMO.  There were no statistical differences between 
the groups.  However secondary analysis show that 32 mg ruboxistaurin 
significantly reduced the occurrence of MVL and reduced the encroachment 
of CSMO to the centre of the macula in patients with moderate to severe 
NPDR (Aiello et al., 2006).  
1.7.3.2 .Anti-VEGF agents
As previously discussed VEGF has been implicated as an important factor in 
vascular permeability and DR.  There are several different anti-VEGF drugs 
which have been used in the management of DMO, including pegaptanib 
(Macugen), bevacizumab (Avastin), and ranibizumab (Lucentis).  Pegaptanb 
is an aptamer, which binds to and thus neutralises VEGF165, whereas 
ranibizumab, an antibody fragment and bevacizumab, a whole antibody, bind 
to all isoforms of VEGF.
VEGF undoubtedly plays a central role in the development of DR.  However, 
apart from its pro-angiogenic role its pleiotropic functions range from 
inducing survival of endothelial cells to potent vasodilation (Ferrara and 
Gerber, 2001;Pandya et al., 2006).  Consequently, although VEGF blockade 
may be useful in arresting DR, it is predicted to result in additional unwanted 
side effects. Indeed, hypertension (due to the increased vasoconstriction) 
and proteinuria (due to glomerular dysfunction) are the most frequent Diabetic Macular Oedema:  The role of steroids and VEGF
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adverse effects of systemic VEGF blockade and are particularly worrying in 
the diabetic population (Simo and Hernandez, 2008).  
Although systemic absorption is minimized by intravitreal injection, concern 
is raised as VEGF maintains fenestrations in the choriocapillaris (Peters et 
al., 2007) and is important  for retinal ganglion cells survival (Nishijima et al., 
2007). This adverse effects on the local oxygen supply in ischaemic tissue 
have to be considered.  
Pegaptanib sodium
A multicentred randomized, controlled, phase II trial evaluated the efficacy of 
pegaptanib versus sham injection in patients with centre-involving DMO 
(Cunningham, Jr. et al., 2005).  At 36 weeks, 0.3 mg pegaptanib led to an 
increase in median visual acuity (20/50 versus 20/63 (sham)) and the mean 
central retinal thickness decreased by 68 µm versus an increase of 4 µm 
with sham.  34% versus 10% of the study group experienced a gain visual 
acuity (10 or more ETDRS letters) and laser photocoagulation was 
necessary in fewer patients in the study group. 
Bevacizumab and Ranibizumab
Initial pilot studies have shown that bevacizumab and ranibizumab reduce 
macular thickness improve visual acuity in the short-term in patients with 
DMO (Haritoglou et al., 2006;Arevalo et al., 2007;Chun et al., 2006;Nguyen 
et al., 2006).  However all studies to date are non-comparative case studies 
in small numbers of patients.    Diabetic Macular Oedema:  The role of steroids and VEGF
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1.7.3.3 Growth Hormone inhibitors
Prior to the publication of the ETDRS, pituitary ablation was a treatment 
option for PDR.  Improvement in the degree of retinopathy was found to 
correlate with the postablation level of growth hormone (GH).  Since then it 
has been established that Insulin-like growth factor (IGF-1) a downstream 
product of GH is elevated in the vitreous of patients with PDR (Grant et al., 
1986) and that IGF-1 along with VEGF induce retinal neovascularizations. 
(Frystyk et al., 2003;Schultz and Grant, 1991).  Experimental inhibition of the 
GH-IGF-1 axis in a model of acute proliferative retinopathy prevented new 
vessel formation, and small clinical trials indicate that the administration of 
the GH inhibitor, octreotide maybe beneficial.  
A recent multicentred trial in United States, Canada, and Brazil, found that 
30 mg octreotide in a long-acting release injection once per month lead to a 
delay in the progression of retinopathy but no effect was observed for visual 
acuity and progression of DMO (Grant M, 2008). The most frequent side 
effects being diarrhoea, development of cholelithiasis, and mild 
hypoglycemia.  A similar European study however failed to confirm these 
results. When comparing serum IGF-1 it was suggested that the American-
based study had better patient compliance and study monitoring than the 
European study.
1.7.4 Vitrectomy
The vitreous is the transparent gelatinous mass that fills the space between 
the lens and the retina.  It is mostly composed of water (98%) with salts, 
sugars, collagen type 2 and 9,  and glycosaminoglycans.  The vitreous is 
loosely adherent to the anterior body of the retina, the macula and the optic Diabetic Macular Oedema:  The role of steroids and VEGF
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nerve.  If the vitreous pulls away from the retina, as is more common with 
age, it is known as a vitreous detachment.  
The vitreous has implicated in the production of DMO.  Eyes with diabetic 
retinopathy are much more likely to develop macular oedema if the vitreous 
is still attached.  A retrospective study by Nasrallah et al compared the 
prevalence of posterior vitreous detachment (PVD) in 125 eyes of elderly 
diabetic patients with and without CSMO.  They observed a PVD in 20% of 
the CSMO group and a PVD in 55% of the non-CSMO group (Nasrallah et 
al., 1988).  It is postulated that an attached posterior hyaloid may cause 
tangential macular traction leading to macular oedema; a theory that is 
supported by the fact that both spontaneous vitreous separation and 
vitrectomy can result in improvement of CSMO (Hikichi et al., 1997)
Vitrectomy may be useful in the absence of obvious traction (Tachi and 
Ogino, 1996;Ikeda et al., 1999;Ikeda et al., 2000;La Heij et al., 2001).  
Several explanations have been suggested as a mechanism of action in this 
instance, such as the vitreous may act as a potential reservoir of 
inflammatory molecules or growth factors such as vascular endothelial 
growth factor, which promotes vascular permeability (Aiello, 1997).  Another 
possible explanation is that vitrectomy may improve oxygenation of the 
retina (Stefansson et al., 1990a).  
1.7.5 Intravitreal Triamcinolone
The use of intravitreal corticosteroids (GCs) was first suggested over 30 
years ago with dexamethasone as an adjunctive treatment for inflammation 
in endophthalmitis and triamcinolone acetonide as a possible treatment for 
proliferative vitreoretinopathy (PVR) (Stefansson et al., 1990b;Graham and Diabetic Macular Oedema:  The role of steroids and VEGF
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Peyman, 1974). Attention was directed towards triamcinolone acetonide (TA) 
because of its long duration of action owing to its relative insolubility and its 
lack of intraocular toxicity (Tano et al., 1980).
Like other GCs, TA suppresses inflammation and reduces extravasation 
from leaking blood vessels (Floman and Zor, 1977), however the complete 
understanding of its mechanism of action are not fully elucidated. Their anti-
inflammatory activity appears to involve inhibition of the phospholipase A2 
pathway and the production of prostaglandins and leukotrienes (Abelson 
MB, 1994).  GCs also interfere with the release of inflammatory cell 
mediators such as ICAM-1 (Penfold et al., 2000) which promote leukocyte 
adhesion and extravasation (Penfold et al., 2002) and inhibit leukocyte 
chemotaxis (Abelson MB, 1994).  Additionally GCs may have a positive 
response due to the downregulation of retinal VEGF expression (Nauck et 
al., 1998;Horiuchi and Weller, 1997).  
Intravitreal TA has been shown experimentally to reduce BRB breakdown 
induced by pan retinal photocoagulation in rabbits eyes (Wilson et al., 1992).  
Initial pilot studies in humans show that a single 4 mg IVTA injection has a 
rapid effect in patients with diffuse DMO that have been both resistant to 
laser treatment and in those with no previous treatment (Patelli et al., 
2005;Bonini-Filho et al., 2005;Cardillo et al., 2005) and suggest that 
intravitreal TA can improve the visual acuity by around 30% (Martidis et al., 
2002) (Jonas et al., 2003).  
A 4 mg intravitreal TA dose provides continual treatment for approximately 3 
months before some eyes begin to have recurrent macular thickening (Beer 
et al., 2003).  At 6 months, it has been shown that up to 90% of eyes may 
have recurrent macular thickening (Patelli et al., 2005;Bonini-Filho et al., Diabetic Macular Oedema:  The role of steroids and VEGF
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2005;Cardillo et al., 2005) and retreatment is as effective as the initial 
injection (Ozdemir et al., 2005b).  However long-term evidence of efficacy 
and prospective data of intravitreal triamcinolone in the treatment of DMO is 
limited.  
Recruiting for our trial began in 2002.  Since this time, there have been 
numerous reports of the use of intravitreal TA for DMO.  In particular there 
are three prospective randomised controlled trials using intravitreal TA for 
more than 6 months.  Avitabile et al had the shortest follow up with a mean 
of only 9 months comparing eyes with DMO treated with intravitreal TA, 
macular laser or both.  In this study, the groups receiving TA had better VA 
at all time points.  
Similarly, in the study by Gillies et al. (Gillies et al., 2006), eyes with 
persistent DMO had a better visual outcome than the placebo group 
(subconjunctival saline) if they received 4 mg intravitreal TA at 2 years.  Both 
groups received additional laser treatment if clinically indicated.  The primary 
outcome measure of an improvement of ≥5 letters after 2 years was 
achieved in 19 of 34 (56%) eyes treated with intravitreal TA, compared with 
9 of 35 (26%) eyes treated with the placebo (P = 0.006). It is significant to 
note that 15 of 28 (54%) treated versus 0 of 21 (0%) untreated eyes 
(P<0.0001) required cataract surgery. 
In contrast, intravitreal TA did not have such positive results in the largest of 
these three trials (Beck et al., 2009;2008).  Eight hundred forty study eyes of 
693 subjects with DMO were entered into this study.  Ar 2 and 3 years, laser 
photocoagulation proved more effective than either 1-mg or 4-mg doses of 
intravitreal TA for most patients with DMO.  Diabetic Macular Oedema:  The role of steroids and VEGF
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 1.8 Aims of thesis
1. To create and characterise an in vitro model of the blood-retinal barrier 
(and blood-brain barrier) by isolating microvascular endothelial cells from rat 
retinal (and cerebral) capillaries.  Due to time limitations, the scope of this 
thesis was limited to isolated microvascular endothelial cells.
2. To investigate the effect of VEGF on the permeability across 
microvascular endothelial cells and on the spatial localisation of proteins that 
comprise the junctional complexes. 
3. To investigate the effect of steroids on the permeability across 
microvascular endothelial cells and on the spatial localization of junction 
proteins.
4. To determine if repeated intravitreal injections of triamcinolone, improves 
BCVA at 1 year compared to conventional laser therapy and whether if this 
treatment has a role in the long-term management of patients with DMO.
5.  To investigate the significance of the morphological characteristics of 
diabetic macular oedema as demonstrated by optical coherence tomography 
and to assess if they are predictive of outcome of the treatment.  
6.  To evaluate the safety and long term efficacy of combined vitrectomy and 
intraocular triamcinolone in patients with diabetic macular oedema without 
the need for re-injections.Diabetic Macular Oedema:  The role of steroids and VEGF
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7.  To assay the concentration of VEGF in the ocular fluids in patients with 
DMO both before and after treatment for DMO and to assess if the 
concentration of vitreous VEGF is predictive of outcome of such treatment.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 2.1:  
Laboratory MethodsDiabetic Macular Oedema:  The role of steroids and VEGF
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All laboratory work was carried out by the study investigator under the 
supervision of Dr Patric Turowski and with help in basic methodology from 
other members of the labarotory (see acknowledgements).  
2.1.1 Materials
All reagents used throughout were purchased from Sigma-Aldrich Company 
Ltd. (Poole, Dorset, UK) with the exceptions mentioned below.
2.1.1.1 Cell culture
All tissue culture plastic ware was purchased from Gibco Life Technologies 
Ltd (Paisley, UK).  Polycarbonate transwell filters (6.5 mm diameter, 0.4 m 
pore size) were obtained from Corning Costar Corporation (Corning, NY, 
USA).
Hanks’ buffered salt solution (HBSS) with and without Ca
2+ and Mg
2+, 10x 
HBSS with Ca
2+/Mg
2+, phosphate buffered saline (PBS),  Hams’ F-10 
medium with glutamax, penicillin-streptomycin and heat-inactivated 
European foetal calf serum (FCS) were all purchased from Gibco Life 
Technologies Ltd (Paisley, UK).  Bovine serum albumin 0.5% and 22%, and 
bovine plasma-derived serum (PDS) were purchased from First Link.  
Collagenase /dispase was purchased form Roche and and collagen IV was 
purchased from BD biosciences.  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.1.2 Cell and Molecular Biology
Methanol was purchased from BDH Laboratory Supplies (Poole, UK) and 
sterile distilled water (dH2O) was obtained from Braun (Melsungen, 
Germany). Bio-Rad Laboratories Ltd (Hemel Hempstead, Herts, UK) 
supplied Bradford reagent.  30% weight per volume (w/v) acrylamide, 0.8% 
w/v bisacrylamide stock solution and 10x sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) running buffer were both 
purchased from National Diagnostics (Atlanta, Georgia, USA).  Molecular 
weight rainbow markers, enhanced chemiluminescence (ECL) hyperfilm, and 
calf intestinal alkaline phosphatase with buffer were purchased from 
Amersham Pharmacia Biotech International (Little Chalfont, UK).  Protran
nitrocellulose membrane was obtained from Schleicher and Schuell (Dassel, 
Germany) and blotting paper was purchased from Whatman International Ltd 
(Maidstone, UK).  Bovine serum albumin (BSA) used for Bradford assays 
was obtained from Pierce (Chester, UK).  ECL lumi-light reagents were from 
Roche (Mannheim, Germany).  BD Biosciences (Oxford, UK) supplied 26G 
syringes.  Mowiol 4-88, for mounting cells, was purchased from calbiochem 
and recombinant rat VEGF was supplied by R&D systems.  
2.1.2 Collagen coating of plasticware
Calf skin collagen type I (0.005 %) in HBSS was added to all cell culture 
plastic surfaces for coating for at least 1 hour at room temperature.  The 
collagen solution was removed and the residual collagen was polymerised 
by placing in ammonia vapour for 15 to 30 min.  Following this the plastic 
ware was extensively washed with HBSS to neutralize the pH.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Polyester filters were coated with human collagen IV (0.01 %) and 
fibronectin (0.005 %) for 2 hours at 37° C.  They were washed in PBS before 
use.
2.1.3 Retinal endothelial cells
2.1.3.1 Isolation of retinal endothelial cells
2.1.3.1.1 Retrieval of eyes
All animals used for the cell cultures were maintained and treated in 
accordance with the ARVO resolution on the use of animals in research.  
Lewis rats, each weighing 150 – 170g were used for the isolation of tissues.  
The periorbital area of each freshly killed rat was cleaned with 70% ethanol.  
A medial and lateral cantholysis of each eye was performed.  The insertion 
of the muscles to the globe was cut and the eye enucleated by cutting 
through the optic nerve.  The whole eyes were immediately transferred to 
ice-cold working buffer (Ca
2+/Mg
2+- free HBSS, 10 mM Hepes, 100 i.u 
penicillin, 100µg/ml streptomycin, 0.5% Bovine serum albumin (BSA), pH 
7.4)
2.1.3.1.2 Isolation of the retina
Using a dissecting microscope under aseptic conditions, each eye was 
placed on a gauze swab soaked in working buffer.  An incision was made 
just posterior to the limbus and using a pair of Vannas scissors each eye 
was hemisected and the anterior segment and vitreous removed.  A 360
o
retinal detachment was created and the retina cut at its insertion to the optic 
nerve.  The retinae were transferred to a fresh container of working buffer 
and kept in ice. Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.3.2 Digestion of the retina 1
The retinae were centrifuged for 5 minutes at 4
oC at 600g and the 
supernantant removed.  The pellet was resuspended in 5 ml of digest 
medium (Ca
2+/Mg
2+-free HBSS,  1mg/ml collagenase /dispase, 10mM 
Hepes, 20 units/ml DNAse, 0.147µg/ml Tosyl-lysine-choromethylketone 
(TLCK), 100 i.u. penicillin, 100µg/ml streptomycin.).  The retinae were 
digested for 1 hour at 37
oC, agitating every 15 minutes.
At the end of the one-hour digest, the sample was centrifuged for 5 minutes 
at 4
oC at 600g, resuspended in 20 ml of 22% BSA and further centrifuged for 
20 minutes at 4
oC at 1000g.  The supernatant was poured off and the tube 
inverted to drain off residual material.  The pellet was resuspended in 1 ml of 
working buffer, transferred into a fresh container and topped up with 9 ml of 
working buffer and then centrifuged for 5 minutes at 4
oC at 600g.  
2.1.3.3 Digestion of the retina 2
The retinae were digested in a further 5 ml of digest medium for 1 hour at 
37
oC.  Afterwards the tissue fragments were centrifuged for 5 minutes at 4
oC 
at 600g and then resuspended into 1ml of working buffer.  Capillary vessels 
were then further processed or cultured as detailed in paragraphs 2.1.5–
2.1.7.Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.4 Brain endothelial cells
2.1.4.1 Isolation of brain endothelial cells
2.1.4.1.1 Retrieval of the Brains
The head and neck region of each freshly killed animal was sprayed with 
10% ethanol.  The head was removed from the body and any remaining 
vertebrae removed.  A midline incision was made over the vertex of the skull 
and 2 lateral incisions opened the occipital bones so that the bone and dura 
matter could be peeled back and the brain exposed and removed.  The 
brains were transferred in to a container of working buffer and kept on ice. 
2.1.4.1.2 Isolation of the Cerebral cortex
Isolation of the cerebral cortex was performed under aseptic conditions.  
Each brain was placed on a sterile gauze swab soaked in working buffer.  
The cerebellum was removed and the hemispheres separated.  The 
remaining meninges and the choroidal plexus were removed along with as 
much of the white matter as possible.  The residual grey matter was 
transferred into a fresh container of working buffer and chopped into 1-2
mm
3 pieces with a scalpel.  
2.1.4.2 Digestion of neural tissue 1
The neural tissue was centrifuged and digested in 15 ml of digest buffer as 
described for the retina.  At the end of the first digestion, the tip of a Pasteur 
pipette was gently flamed to remove any sharp edges, and used to triturate 
the neural material.  A second pipette was gently narrowed over the flame 
and used to further break up the neural tissue.  The suspension was Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 77
centrifuged for 5 minutes at 4
oC at 600g, and the pellet resuspended in 20 ml 
of 22% BSA.  This was then centrifuged for 20 minutes at 4
oC at 1000g.  A 
myelin plug was formed on the top of the suspension and a pellet of 
microvessels at the bottom.  The myelin plug was rolled away from the sides 
of the tube and disguarded.  The supernatant poured off and kept.  The tube 
was then inverted to drain off any residual material.  The pellet was 
resuspended in 1 ml of working buffer, transferred into a fresh container and 
topped up with 9 ml of working buffer and centrifuged for 5 minutes at 4
oC at 
600g.  The tituration process was then repeated on the residual supernatant.   
2.1.4.3 Digestion of neural tissue 2
The neural tissue was further digested in 5 ml of digest media for 2 - 3 hours 
at 37
oC.  As for the retina, the brain microvessels were centrifuged to 
remove the digest media and resuspended in working buffer.  
2.1.5 Purification of microvessels
One problem encountered during the isolation and culture of primary 
endothelial cells is the growth of contaminating cells.  2 methods were used 
to reduce the overgrowth of vessels.  The first was the use of a percoll 
density gradient and the second was the use of puromycin in the media to 
selectively kill non-endothelial cells.  Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 78
2.1.5.1 Percoll density gradient
The gradient was pre-formed, in 10 ml sterile Du Pont centrifuge tubes.  The 
tubes were coated with working buffer for 1 hour to prevent the microvessels 
sticking to the tube walls.  The gradient was preformed by centrifuging 7 ml 
of percoll solution (50 ml percoll, 5 ml 10x HBSS with Ca
2+/Mg
2+ and 45 ml 
1x HBSS with Ca
2+/Mg
2+), in a Heraeus centrifuge for 1 hour at 4
oC at 
25,000g.
The microvessels, resuspended in 1 ml of working buffer, were gently 
layered onto the preformed percoll density gradient and centrifuged for 20 
minutes at 4
oC at 1000g. The capillary fragments from brain isolations were 
seen as hazy layer approximately two thirds down the tube.  These were 
removed placed into a fresh tube and washed in working buffer.  In the 
retinal extract the capillary fragments were more difficult to detect with the 
naked eye and therefore, a layer equidistant to the one seen in the brain 
isolates was taken.  The washed microvessels pellets were resuspended 
onto growth media (Hams F-10 containing 16% bovine cell free plasma-
derived serum (PDS), 2mM L-glutamine, 100 i.u. penicillin/100µg/ml 
streptomycin, 80µg/ml heparin (Grade I) and 75µg/ml endothelial cell growth 
supplement (ECGS)) ready for cell culture.
2.1.5.2 Puromycin
The use of puromycin to purify endothelial microvessels was first described 
by Perrière et al (Perriere et al., 2005).  P-glycoprotein (P-gp) is a multidrug 
resistance-associated protein that is found on the plasma membrane of Diabetic Macular Oedema:  The role of steroids and VEGF
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endothelial cells in particular of the BBB and BRB (Beaulieu et al., 1997).  
Endothelial cells that express P-gp can survive treatments that target cells 
that lack P-gp (Jette et al., 1993).  This characteristic can be used to select 
endothelial cells in culture as contaminating cells lacking P-gp are unable to 
survive (Chen et al., 1998).  
Puromycin is an aminoacylnucleoside antibiotic produced by Streptomyces 
alboniger.  Puromycin is cytotoxic to the cells lacking P-gp when it is 
metabolized in the cells into puromycin aminonucleoside, which goes on to 
produce reactive oxygen species, thus producing its toxicity (Zent et al., 
1995;Gwinner et al., 1997).
Retinal and brain endothelial cells were seeding onto collagen coated tissue 
culture plates and incubated at 37
oC in a 5% CO
2 / 95% air in humidified 
atmosphere.  Cells were cultured in Hams F10 medium containing 16% 
bovine cell free plasma-derived serum (PDS), 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 80 µg/ml heparin (Grade I), 75 µg/ml 
endothelial cell growth supplement.  
Following the 24 hour attachment period, the cell medium was changed and 
supplemented with 5 ng/ml puromycin.  The medium containing puromycin 
was renewed every 24 hours for three days. Subsequently the cells were
extensively washed and placed in normal growth medium.Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.6 Culture of retinal and brain endothelial cells
Cells were cultured / subcultured for up to 3 weeks at 37
oC in 5% CO
2 and 
the growth medium was replaced every 2-3 days.  During their growth, 
cultures were frequently inspected by inverse phase contrast microscopy to 
record their growth and morphology and to observe for an overgrowth of 
contaminating cells.  
2.1.7 Trypsination and cell passage
After 7 - 8 days, cells were passaged.  The cells were first washed with 
Ca
2+/Mg
2-free phosphate buffered solution (PBS).  0.025% trysin in 
Ca
2+/Mg
2+ free PBS was added to the cells for 10-20 seconds and then 
aspirated.  Under a microscope, the detachment of the cells could be 
observed.  When 50% of the cells detached the cells were washed off with 
growth medium, triturated with a 5 ml pipette and plated onto collagen-
coated plastic ware for experiments.Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.8 Cell fixation 
2.1.8.1 Methanol fixation
The culture media was removed and immediately replaced with -20
oC 
methanol for 5 minutes at room temperature.  The methanol was diluted out 
and the dishes rinsed three times with phosphate–buffered saline (PBS).  
2.1.8.2 Formaldehyde / formalin fixation 
The culture media was removed and the cells immediately fixed with freshly 
prepared 3.7% formaldehyde in PBS for 15 minutes at room temperature.  
The cells were washed with PBS and the cells permeabilised by adding        
-20
oC acetone (propanone) to the dish for 3 minutes.  The acetone was then 
diluted out with PBS.  
2.1.9 Immunofluorescence
Retinal and brain microvascular endothelial cells were passaged onto 
collagen coated dishes and grown to confluence.  The cells were washed 
with PBS and fixed with either methanol or formaldehyde as described 
above.  Samples were blocked with PBS, 0.5% BSA and 0.02% Azide. 
(PBS/BSA/azide).  The primary antibody at the desired dilution (table 2.1.1) 
was centrifuged at 6000g for 5 minutes to remove any particulates.  This was 
added onto the monolayer of cells and incubated at 37
oC for 1 hour. 
Samples were again blocked with PBS/BSA/Azide and incubated at 37
oC
with the centrifuged secondary antibodiy at the desired dilution (table 2.1.1).Diabetic Macular Oedema:  The role of steroids and VEGF
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Hoechst stain (bis-benzamide) was added along with the secondary 
antibody.  This stain binds double-stranded DNA and therefore permits 
visualisation of cell nuclei.  
Cells were then washed with PBS/BSA/Azide, followed by PBS and then 
water and mounted in 10% Mowiol 4-88.  Omission of the primary antibody 
served as a negative control.  Cells were initially viewed with a fluorescent 
microscope (Axiophot) and thoroughly imaged on a confocal scanning 
microscope as detailed in the next paragraph.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 2.1.1:  Details of primary antibodies used for immunofluoresence 
and immunoblotting
Primary antibodies
Dilutions
Antigen Host 
species Clone
IF IB
Source
ZO-1 rabbit polyclonal 1:50 1:1000 Zymed
Occludin mouse monoclonal 1:50 Zymed
Cl-5 mouse monoclonal 1:100 1:500 Zymed
VEC goat polyclonal 1:20 1:1000 Santa cruz
a catenin rabbit polyclonal 1:50 1:1000 Sigma-Aldrich
b catenin rabbit polyclonal 1:50 1:4000 Sigma Aldrich
g catenin mouse monoclonal 1:50 BD biosciences
P120 mouse monoclonal 1:50 BD biosciences
ZO-1, zonular occludens-1; Cl-5, claudin-5; VEC, vascular endothelial 
cadherin / VE cadherin; a catenin, alpha catenin; b catenin, beta catenin; g 
catenin, gamma catenin. Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 2.1.2:  Details of secondary antibodies and stains used for 
immunofluoresence and immunoblotting
Secondary antibodies for immunofluorescence
Antigen
Host 
species Clone Dilutions Source
anti rabbit FITC 
conjugated goat polyclonal 1:50 ICN/Cappel
anti rabbit rhodamine 
conjugated goat polyclonal 1:50 ICN/Cappel
anti goat FITC 
conjugated rabbit polyclonal 1:50 ICN/Cappel
Secondary antibodies for immunoblotting 
Antigen
Host 
species Clone Dilutions Source
anti rabbit HRP  goat polyclonal 1:10,000 Southernbiotech
anti mouse HRP goat polyclonal 1:10,000 Imgenex
anti goat HRP Rabbit polyclonal 1:5,000 Southernbiotech
Secondary stains for immunofluorescence
Antigen Dilutions Source
Phalloidin FITC 1:50 Biotium
Phalloidin rhodamine 1:50 Biotium
Hoechst  1:100 Sigma
FITC, Fluorescein isothiocyanateDiabetic Macular Oedema:  The role of steroids and VEGF
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2.2.10 Confocal laser scanning microscopy
Confocal laser scanning microscopy was carried out on a CLSM 510 (Zeiss, 
Welwyn Garden City) equipped with UV, argon and helium-neon lasers. 
Standard settings were used to visualize Hoechst, fluorescein and 
rhodamine staining.  FITC and rhodamine were excited at 488 nm and 543 
nm and visualized with 540 +/- 25 and 608 +/- 32 nm bandpass filter 
respectively, where the levels of interchannel cross talk were insignificant. 
The pinhole was set to 1 Airy unit.  Images were acquired through a x40 or 
x60 oil immersion lens. Series of overlapping 0.8 µm sectionsspanning the 
entire cell thickness (ca. 4 µm) were recorded and projectionsgenerated as 
detailed in the figure legends.
2.1.11 Analysis of images
A change in the mean pixel intensity of the immunofluorescent images, 
captured by confocal, were quantified using ImageJ software package 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2006.).  Similarly this 
programme was used to quantify the change in the mean pixel intensity 
visualized on immunoblotting.   Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.12 Transendothelial permeability assay
The passage of FITC-dextran through confluent cell monolayers was 
measured using transwell cell culture chambers (Polyester filter of 6.5 mm 
diameter, 0.4 um pore size, Costar). The wells were each coated with 150 µl 
collagen IV and fibronectin (both at 50 µg/ml) for 2 hours at 37
oC.  Brain 
endothelial cells were seeded at a density of 40 000 to 100 000 per well and 
grown until confluent.  
The volume of the apical and basolateral chambers were 500 µl and 1500 µl 
respectively.  24 hours before experimentation, the medium (from both 
chambers) was diluted 1:2 with serum free medium.  Each experiment 
included at least three wells per group.  The principal findings were 
confirmed in at least two duplicate experiments.  
Sodium fluorescence (FITC) of molecular weight 376 Da or fluorescein 
isothiocynate-labeled dextrans (FITC-dextran) of variable molecular weight 
were added to the top well (final concentration 1 mg/ml) and further 
incubated a 37
oC.  At desired time points 50 µl was sampled from the basal 
chamber and the volume replaced with 50µl of the serum free medium in 
order to maintain hydrostatic pressure throughout the experiment.  
Each sample was diluted and then analysed in triplicate, along with 
reference samples from the apical chamber at time 0, were analysed on a 
plate reader spectrophotometer (Safire version 4.20) using an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm.  The 
permeability coefficient (Pe) was according to the following formula,
1/PEcell =1/PEall -1/PEfilterDiabetic Macular Oedema:  The role of steroids and VEGF
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For calculating the Pe, slope of clearance versus time was determined by 
linear regression analysis and multiplied the surface area of the filter 
(0.65 cm
2).  Finally, the reciprocal value of the permeability coefficient 
without cell layer (PEfilter) is substracted of the permeability coefficient of the 
experiment with cell layer (PEall) to gain the reciprocal value only for the cell 
layer.  
2.1.13 Transendothelial electrical resistance
Transendothelial electrical resistance (TER) was measured through 
confluent monolayers using transwell cell culture chambers.  Chambers were 
coated and seeded as above.
  
Subsequently changes in TER across the monolayers were monitored over a 
2-week period using STX-2 chopstick electrodes connected to an EVOM 
epithelial voltohmmeter (World Precision Instruments, Herts, UK).  Net TER 
values were calculated by subtracting the mean resistance determined for 2 
filters in the absence of cells (prepared and treated as the experimental 
samples), from the value recorded for each monolayer grown on transwell 
cell culture chambers.  Final resistance-area products (in ohms * cm
2) were 
obtained by multiplication with the effective growth area.
Each experiment included at least four wells per group.  The principal 
findings were confirmed in at least two duplicate experiments.  A resistance 
of over 100 ( *cm
2) was deemed significant.  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.14 Cell extraction 
2.1.14.1 Total cells extracts
Cells were placed on ice and washed with ice cold PBS.  Protein fractions 
were prepared from cultured cells by solubilisation in boiling SDS sample 
buffer (4% SDS, 20 mM tris buffer (pH 6.8), 20% glycerol, 0.005% 
bromophenol blue and 100 mM dithiothreitol (DTT)).  Following lysis, the 
cells were scraped off the dishes using a rubber cell scraper and the cell 
lysates were syringed through a 26 G needle to shear genomic DNA, heated 
to 100
oC for 5 minutes and then kept at -20
 oC until required.  
2.1.14.2 Cell fractionation
Cells were placed on ice and washed with ice cold PBS.  Subcellular protein 
fractions were prepared by solubilisation in lysis buffer (10 mM Hepes/ 
sodium hydroxide (pH 7.5 containing 1 mM DTT, 1.5 mM Magnesium 
choride, 5 mM EDTA, 100 nM calcyculin A, 1 mM pervanadate and a mix of 
protease inhibitors (E64, TPCK, pepstatin A, PMSF) . Subsequently, the 
cells were scraped off the dishes using a rubber cell scraper and then lysed 
by syringing through an 18 G needle and a 23 G needle.  Cells were 
inspected under a microscope to ensure completion of lysis (i.e. that nuclei 
had been released).  Nuclei, polymerized cytoskeleton and large organelles 
were collected by centrifugation at 1000g for 5 minutes at 4
oC.  The 
supernatant was respun in an ultracentrifuge at 100 000g for 30 minutes at 
4
oC resulting in a high speed (membrane) pellet and a high speed (cytosolic)
supernatant.  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.15 Protein concentration Determination (Bradford Assay)
The protein concentration of the cell extracts were determined by the method 
of Bradford (Bradford, 1976). Duplicate solutions containing 1l, 2l and 5l 
aliquots were taken from each sample and each added to 995 l of 1:50 
Bradford reagent (Bio Rad protein assay).  The absorption spectrum was 
measured at 595 nm and the protein concentration calculated by comparing 
to a standards curve produced from bovine serum albumin (BSA) standard.  
2.1.16 Sodium Dodecylsulphate Polyacrylamide Gel 
electrophoresis (SDS-PAGE)
Tris-glycine slab gels were cast using the Biorad Mini-protein II system.  All 
apparatus was thoroughly washed and rinsed before use.  Separating gel 
mix contained 10% polyacrylamide, 375 mM Tris/CL pH 8.8, 0.1 % SDS,  
0.08 % APS and 0.0004 % TEMED.   This was poured in between the gel 
plates and left to polymerise.  A stacking gel (4.5% acrylamide, 125 mM 
Tris/Cl pH 6.8, 0.1% SDS, 0.15% APS and 0.002% TEMED) was cast on 
top.  
50 l of each sample was loaded per well.   To visualize the migration of 
proteins and give an indication of the molecular weight of the detected 
proteins, 8 µl of markers were loaded into each gel along side samples.  The 
standard molecular weight of the markers were 220, 97.4, 66, 46, 30, 21.5 
and 14.3 kDa.  Gels were typically run at 100 V for approximately 90 minutes 
or until the sample front had reached the end of the gel.    Diabetic Macular Oedema:  The role of steroids and VEGF
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2.1.17 Electrotransfer
A Biorad wet-transfer gel tank was used to electrotransfer proteins to 
nitrocellulose membranes (Hybond ECL, Amersham).  The components for 
the transfer were first equilibrated in the transfer buffer (25mM Tris, 192 mM 
glycine, 0.1 % SDS and 20% methanol).  A stack of the components 
consisting of a pad, blotting paper, the gel, nitrocellulose membrane blotting 
paper and further pad were arranged and compressed to remove air 
bubbles.  Electrotransfer of proteins was done at 12 V for approximately 75–
90 minutes.  
After transfer, the positions of the standard molecular weight proteins were 
located by soaking the membrane in 0.1% Ponceau red stain for 5 minutes.  
The blot was washed to remove the Ponceau Red and then blocked with 
TBS containing 0.1% Tween, 1% BSA and 0.2% triton X 100 for 1 hour at 
room temperature.
2.1.18 Immunoblotting
Proteins on blots were detected by probing the nitrocellulose membrane with 
primary antibodies diluted in TBS containing 1% BSA, 0.05% Tween-20 and 
Triton X 100 at room temperature for 1.5 hours (see Table 2.1.1).   After 
extensive washing with TBS/BSA/Tween/ Triton X100, the membrane was 
incubated for 45 minutes at room temperature with HRP-conjugated 
secondary antibodies of the appropriate species, diluted in PBS/ 
BSA/Tween/Triton X100.  The membrane was again extensively washed 
using PBS/ BSA/Tween/Triton X100, then PBS/Tween/Triton X100 and 
finally with PBS alone.    Diabetic Macular Oedema:  The role of steroids and VEGF
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Immunodecorated proteins were visualized by immersion of the blots into 
enhanced chemiluminescence detection reagent (ECL, Amersham, Bucks,
UK) for 5 minutes.  Membranes were then wrapped in transparent layer and 
exposed to light sensitive film (Hyperfilm, Amersham). 
Membranes could be ‘stripped’ of bound antibodies and re-probed by 
incubating in stripping buffer (200 mM glycine / HCL ph 2., 1% v/v NP-40, 
500 mM NaCL) for 20 minutes at room temperature.  Membranes were then 
washed 3 times with Tween 20 /TBS, then reblocked and immunoblotted as 
before.  
2.1.19 Statistical analysis 
For all quantitative experiments, data was compared using a Student's t-test 
using a two-tailed P-value with a significance set at 0.05. Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 2.2:
Clinical studiesDiabetic Macular Oedema:  The role of steroids and VEGF
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2.2.1 Patient Enrolment
All studies were conducted in accordance with the ethical standards of the 
Declaration of Helsinki and were approved by the local Research and Ethics 
Committees at Moorfields Eye Hospital.  Patients were recruited via the 
Medical Retinal Service at Moorfields Eye Hospital between February 2003 
and June 2005.  Written informed consent was obtained from all patients 
before details of medical and ophthalmic examinations were recorded.  
If both eyes were eligible for inclusion into the randomized controlled trial 
(RCT) or combined pars plana vitrectomy with intraocular triamcinolone 
(PPV + TA), the eye with the worst BCVA was included and the fellow eye 
followed standard treatment.
Study assessments are carried out by the study investigator.  All information 
was stored in an anonymous fashion on an access database.  Each patient 
was identified by their unit number and a unique study number.  
2.2.2 Inclusion and exclusion criteria
Inclusion and exclusion criteria for all studies is shown in table 2.2.1.  CSMO 
as defined by the ETDRS (1985) was diagnosed by slit lamp biomicroscopy 
and confirmed both angiographically and tomographically.
In addition any patient with a pre-existing PVD was excluded from the pars 
plana vitrectomy studies.    Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 2.2.1:  Study inclusion and exclusion criteria. 
Inclusion criteria Exclusion criteria
CSMO persisting 4 or more 
months
at least 1 prior laser treatment
BCVA between 6/12 – 3/60 
Significant macular ischaemia 
(foveal avascular zone of greater 
than 1000m or severe perifoveal 
capillary dropout as compared with 
ETDRS standard photograph) 
(1991a)
visual acuity in fellow eye ≥ 3/60. baseline IOP greater than 23 mmHg
duration visual loss < 24 months glaucoma
co-existent retinal disease
loss of visual acuity as a result of 
other causes
previous vitrectomy
intraocular surgery or laser within 3 
months of study entry
previous inclusion in other clinical 
trials for DR
inability to return for follow up
inability to give informed consent
CSMO, clinically significant macular oedema; BCVA, best corrected visual 
acuity; ETDRS, early treatment of diabetic retinopathy study; IOP, intraocular 
pressure; DR, diabetic retinopathyDiabetic Macular Oedema:  The role of steroids and VEGF
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2.2.3 Sample size Calculation for RCT
The principal outcome measure was the proportion of patients who improved 
by 15 or more ETDRS letters at 12 months.  Based on the original pilot 
studies, (Jonas et al., 2003;Martidis et al., 2002) the estimated frequency for 
this outcome measure in the TA arm would be approximately 20% and from 
the ETDRS the in laser arm approximately 3%.  The study was powered at 
80%, with a significance level of 0.05.  Therefore for a ratio of study patients 
to control patients of 1:1, the calculated sample size was 41 patients in each 
arm.  Adjusting for an estimated loss to follow up of 8% of eyes, we aimed to 
recruit 44 patients into each group. 
2.2.4 Data collection 
Best corrected visual acuity (BCVA) was measured by a trained optometrist, 
masked to treatment arm, using an ETDRS chart to record distance vision, a 
Bailey-Lovie chart at 25 cm to record near vision and a Pelli-Robson chart at 
1 metre to record contrast sensitivity.  Intraocular pressure (IOP) was 
measured using Goldman applanation tonometry.  Fundoscopy was 
performed by slit-lamp biomicroscopy using a 66D lens.  The degree of lens 
opacity was graded using the Wisconsin system for classifying cataracts
(Klein BEK, 2007).  Diabetic control was assessed by measuring 
Glycosylated Haemaglobin (HbA1c).  
At 4, 8 and 12 months, follow up visits included BCVA, IOP and central 
retinal thickness.  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.5 Fundus Fluorescein Angiogram (FFA)
A FFA was performed at baseline to assess the degree of macular 
ischaemia and at 12 months to determine any change in the degree of 
macular ischaemia.  
Macular ischaemia was graded based on the ETDRS grading system.  The 
maximal linear diameter of the foveal avascular zone (FAZ) was measured 
using the measuring tool on the Topcon imaging system and amount of 
capillary drop out assessed against ETDRS standard photograph (fig 2.2.1).Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 2.2.1:  Examples of levels of capillary drop out.  Copy of Standard 
photograph 2 representing severe capillary dropout from ETDRS report 11.
(1991a).  Any patient considered to have equal or worse perifoveal dropout 
when compared to standard photo 2 was excluded from study (a).  This 
patient was considered to have moderate capillary dropout and was 
therefore included in the study (b) while this patient was considered to have 
severe capillary dropout and was excluded from study (c).  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.6 Optical Coherence Tomography (OCT)
OCT was performed by a certified research technician, masked to the 
treatment arm.  The macula was scanned using the six x 6mm radial line 
scan protocol on the Stratus OCT model 3000 scanner (Zeiss Humphrey 
Instruments, Dublin, CA).  All computer generated measurements were 
visually inspected by the study investigator to exclude computerised 
artefacts.  If no artifacts were observed, the foveal minimum was selected to 
represent the central macular thickness from the computer generated retinal 
thickness analysis program.  In the case of computerised artifacts, the retinal 
thickness was calculated manually using the calipers available on the 
software.  Macular volume, where possible, was calculated using the 
computer algorithm.  
2.2.7 Randomisation for RCT
Patients were allocated to 4 mg of TA or further ETDRS laser 
photocoagulation using a centralised computer-generated randomisation 
program (based on the weighted coin method) in operation at the Clinical 
Trials Unit.  Patients were retreated at 4 and 8 months if they had persistent 
CSMO on clinical examination with final review at 12 months. Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.8 Treatments
2.2.8.1 Intravitreal triamcinolone
Intravitreal TA was performed by the study investigator in a treatment in the 
outpatient clinic under sterile conditions.  The eyes were prepared with 1% 
amethocaine followed by 5% povidone-iodine.   A subconjunctival injection of
2% lignocaine was given using a 27-gauge needle, sufficient to raise a small 
bleb over the site of intravitreal injection.  Then, using a sterile 27-gauge 
needle, 4 mg /0.1 ml of triamcinolone acetonide (Kenalog, Bristol Myers 
Squibb) was injected through the pars plana into the mid-vitreous without 
removing the vehicle.  Following injection, indirect ophthalmoscopy was used 
to check the patency of the central retinal artery and if occluded a 
paracentesis was performed.  Following the procedure 0.5% 
chloramphenicol was instilled and eyes were checked at the slit lamp, to look 
for triamcinolone crystals in the anterior chamber, to measure the IOP and to 
examine the fundus.  Patients were discharged with 0.5% chloramphenicol 
four times a day for four days.  A further post operative check was repeated 
after 1 week and 1 month.  
2.2.8.2 Laser photocoagulation
Conventional macular laser was performed by the study investigator based
to ETDRS guidelines (1985).  A pre-treatment FFA was used to identify 
areas of leakage.  Areas were treated with 100 micron argon green-only 
burns of 0.1s duration, with adequate power to obtain light grey burns in 
areas of leakage.  Care was taken to avoid the foveal avascular zone (FAZ).  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.8.3 Pars plana vitrecotomy with intraocular triamcinolone 
All operations were performed by 2 surgeons.  A standard 3-port pars plana 
vitrectomy was performed on all patients.  The posterior hyaloid was 
detached from the posterior pole by using high suction power with the 
vitrectomy instrument at the optic disc.  Further separation of the posterior 
hyaloid towards the peripheral retina was achieved with the vitrectomy 
instrument using a combination of suction and cutting.  For patients with 
proliferative diabetic retinopathy the new vessels were delaminated with 
horizontal scissors and additional endolaser photocoagulation was applied.  
The internal limiting membrane was not peeled.  At the end of surgery 4 mg 
/0.1 ml of intravitreal triamcinolone (Kenalog, Bristol Myers Squibb) was 
injected into the vitreous cavity via one of the vitrectomy ports.   Patients 
were postured in the upright position for 8 hours.  No further injections of 
triamcinolone were performed during follow up.  
2.2.9 Collection of vitreous and aqueous samples 
Undiluted vitreous fluid samples were harvested from the mid-vitreous at the 
start of vitrectomy.  The aqueous fluid was acquired at the end of the 
operation before the injection of TA.  Further aqueous samples were 
collected at 1 week and 4 months.  All samples were frozen at -80
oC until 
required.  Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.10 VEGF Assay
The samples were defrosted and centrifuged to remove particulate material.  
VEGF levels were quantified by enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems, Minneapolis, MN).  Each assay was performed 
according to the manufacturer’s instructions.    
In summary, the seven standards and one zero were run in duplicate along 
with the unknown samples which were run in triplicate.  Where stated, plates 
were washed 3 times with the wash buffer supplied by the kit.  All 
incubations were performed at room temperature.
50 μl of the standard solution and samples were added to the wells of a 96-
well plate, which was pre-coated with an anti-human VEGF antibody and 
incubated for 1 hour at room temperature.  After incubation, the plate was 
washed, and 100 μl biotinylated antibody was added to each well and 
incubated for 1 hour.  After the second incubation, the plate was washed and 
100 µl strepatavidin-HRP reagent was added to each well and incubated for 
30 minutes.  The plate was then washed and 100 μl of TMB substrate 
solution was added to each well. The enzymatic colour reaction was allowed 
to occur in the dark at room temperature. 
After 30 minutes, the reaction was stopped by adding 100 ul of stop solution 
to each well and the optical density was determined at 450 and 550 nm 
using an absorption spectrophotometer (Safire multiscan 12901300013, 
firmware V 2 00 03/02 Safire; XFLUOR4 version: V 4.20).  Reading at dual 
wavelengths corrected for optical imperfections within the microtitre plate.Diabetic Macular Oedema:  The role of steroids and VEGF
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A standard curve was plotted from measurements made with the standard 
solution (from 0 to 1000 pg/ml).  A curve-fitting statistical software package 
was used to plot a four parameter logistic curve fit and this formula was in 
turn used to interpolate the VEGF concentration in the unknown sample.  
The minimum detectable concentration was 14.7 pg/ml.  
2.2.11 Grading of OCTs 
This was a retrospective review of all baseline OCTs.  2 radial line scans 
were selected by the study investigator, from the original 6 scans captured at 
the baseline visit.  Where possible the 2 scans were orientated at 90 
degrees to each other. 
Based on the classification system by Panozzo (Panozzo et al., 2004), the 
morphology of each OCT was classified by two independent masked 
graders.  If there was any disagreement in categorization, a third investigator 
was asked reclassification the scans in question.  The 2 OCT scans were 
graded for the present of the following morphological patterns; cystoid 
macular oedema (CME), neurosensory detachment (NSD), posterior hyaloid 
traction (PHT) and abnormal macular profile (AMP).  
CME was defined as the localization of circular or ovoid areas of reduced 
reflectivity.  (fig 2.2.2a,b).  NSD was defined as a well delineated non-
reflective intraretinal space adjacent to the hyper-reflective line of the 
pigment epithelium (fig 2.2.2b).  PHT was defined as a continuous hyper-
reflecting line over the inner retinal surface with at least one point of 
adhesion with the retina (fig 2.2.2a) and AMP was defined as the absence of 
the normal foveal depression (fig 2.2.2a,b)  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 2.2.2:  OCT images illustrating morphological subtypes.  CME and 
AMP (a) NSD with a normal macular profile (b).  PHT, CME and AMP (c).
CME, cystoid macular oedema; AMP, abnormal macular profile; NSD, 
neurosensory detachment; AMP, abnormal macular profile.   Diabetic Macular Oedema:  The role of steroids and VEGF
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2.2.12 Outcome measures 
2.2.12.1 RCT
The primary outcome measure was the proportion of patients who improved 
by 15 or more ETDRS letters at 12 months.  Secondary endpoints mean 
ETDRS letter score, mean central retinal thickness and mean macular 
volume at 12 months and adverse event reporting.  Adverse event reporting 
included a change in IOP measurements, and a significant change in the 
size of the FAZ.  
2.2.12.2 PPV + TA
The outcome measures were the change in visual acuity letter scores, 
median best corrected visual acuity (BCVA) and central macular thickness at 
12 months and adverse event reporting.  Adverse event reporting included a 
change in IOP measurements, and a significant change in the size of the 
FAZ.  
2.2.12.3 Predictive value of OCTs
To outcome measure was determine the relationship between the OCT 
morphology and the baseline characteristics and the outcome of 
intervention.     Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 105
2.2.12.4 Predictive value of VEGF
The outcome measures were the change in aqueous VEGF concentration
before and after combined PPV with intravitreal TA and to assess whether 
the vitreous VEGF level was predictive of outcome at 4 and 12 months.  
2.2.13 Statistical analysis
2.2.13.1 RCT
We analysed the data according to the intent to treat principle.  However, 
data for 5 (5.7%) of the patients (4 of whom were on laser treatment) was 
not available on the primary outcome measure at one year.  We did not 
consider it valid to carry forward data from earlier visits and thus adopted the 
available case analysis approach.  Baseline characteristics of the patients 
were studied in order to assess the adequacy of randomisation.  Fisher’s 
exact test was used to assess the statistical significance of the difference in 
the proportion of patients in each group who improved by 15 or more ETDRS 
letters.  Analysis of covariance was used to assess secondary outcome 
variables. 
2.2.13.2 PPV + TA
Since this was an exploratory study on a small number of patients 
descriptive methods only were employed.  Summary statistics (medians and Diabetic Macular Oedema:  The role of steroids and VEGF
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interquartile ranges) were computed, and box and whisker plots constructed 
to show the change in outcomes over time.
2.2.13.3 Predictive value of OCTs
The inter-grader and intra-grader reliability was calculated as a kappa value.  
The strength of agreement was based on table 2.2.2 as described by Landis 
and Koch (Landis and Koch, 1977).  When there was a discrepancy in 
grading, a third observer was asked to grade the questionable OCTs.  The 
OCT morphological subtypes were assessed to see if they had any influence 
over visual outcome using a 2-sample student t-test.  P < 0.05 was 
considered statistically significant.  
2.2.13.4 Predictive value of VEGF
Since this was an exploratory study on a small number of patients, 
descriptive methods only were employed.  Summary statistics (medians and 
interquartile ranges) were computed and box and whisker plots constructed, 
to show the change in outcomes over time.  Scatterplots and spearman rank 
sum correlations were used to assess relationships between VEGF levels 
and visual acuity at 4 and 12 months.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 2.2.2  Strength of agreement based on Kappa 
values
Kappa Strength of agreement
0.00 poor
0.01-0.20 slight
0.21-0.40 fair
0.41-0.60 moderate
0.61-0.80 substantial
0.81-1.00 almost perfectDiabetic Macular Oedema:  The role of steroids and VEGF
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3. ResultsDiabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.1
Characterisation of primary retinal and 
brain microvascular endothelial cell 
cultures. Diabetic Macular Oedema:  The role of steroids and VEGF
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3.1.1 Introduction
Breakdown of the inner BRB (iBRB) has been proposed as one of the 
earliest retinal changes in diabetic retinopathy (Cunha-Vaz et al., 1975).  
However, the molecular mechanisms involved with disruption of the barrier 
are not completely understood.  Both steroids and VEGF have been shown 
to modulate vascular permeability but their underlying mechanisms still await 
full characterisation.  
The best index of physiological barrier function is the in vivo measurement of 
microvascular permeability.  However this is a complex procedure requiring 
elaborate surgical techniques (Cunha-Vaz et al., 1975;Tornquist et al., 
1990).  In addition, in vivo quantification of permeability can be difficult and is 
prone to artefact such as from hydrostatic pressure.  In contrast, in vitro
methods allow the environment of cells to be precisely controlled and the 
molecular mechanisms in an individual cell type can be studied.  Additionally 
they avoid the complexities of studies on living animals.  
The aim of this thesis was to assess the effects of corticosteroids and VEGF 
on an in vitro model of the BRB and in particular the junctional proteins.  
Therefore an in vitro model of the BRB was required.  An immortalised 
endothelial cell line generated from rat retinal microvascular endothelial cells 
was available (SV40 large T), however we were unable to detect any 
junctional proteins (data not shown). Therefore we sought to isolate primary 
cells from rat retinal capillary microvessels.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.1.2 Rat retinal microvascular endothelial cells in vitro 
maintain endothelial cell characteristics
12 retinae were harvested form the eyes of 6 Lewis rats.  Retinal 
microvascular endothelial cells (RMEC) were isolated from the retinae, by 
digesting the tissue with collagenase /dispase and DNAse, by physically 
separating cell types on a percoll gradient and by the selective growth of 
endothelial cells using puromycin which is toxic to contaminating cells that 
do not express P-glycoprotein.  
At the end of the isolation period, small vessel fragments were identified on 
light microscopy (fig 3.1.1a,b).  Single cells and small microvessel fragments 
of less than 10 µm diameter attached to the collagen-coated surface within 
12 hours.  After attachment, cells could be seen spreading out from the 
microvessels and cell division was noted by day 6.  
RMEC grew to form elongated spindle-shaped cells, of average dimensions 
of 30 µm x 10 µm.  Cells grew in a typical swirl-like configuration (fig 3.1.1c).  
Confluent monolayers exhibited characteristic density-dependent inhibition of 
growth.  The isolated RMEC were 20% confluent by day 7.  One isolation of 
RMEC from six animals yielded approximately 500 000 primary cells at day 
14 and consisted of 96-98% pure endothelial cells.  On day 7 -8, the RMEC 
were passaged by trypsinisation, to separate the cells and encourage cell 
division.  
Weibel-Palade bodies are secretory organelles which are highly specific to 
endothelial cells (Elgjo et al., 1975).  One of their main constituent proteins is 
von Willebrand Factor (vWF).  Its expression is considered to be a faithful 
marker of endothelial cells.  Indirect immunocytochemistry of our RMEC cell Diabetic Macular Oedema:  The role of steroids and VEGF
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cultures with anti-vWF antibodies revealed staining of cigar-shaped 
organelles distributed throughout the cytoplasm of all RMEC (fig 3.1.1d).  
This distribution was reminiscent of Weibel-Palade bodies and similar to that 
reported for many other endothelial cells including HUVEC (Elgjo et al., 
1975).Diabetic Macular Oedema:  The role of steroids and VEGF
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Fig 3.1.1: Retinal microvacular endothelial (RMEC) cell isolation.  Phase 
contrast images of RMEC at 1 day (a,b) and at 1 week (c).  RMEC at one 
week were fixed using formaldehyde and stained for von Willebrand factor 
(d).
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Endothelial cells contain functional tight junctions (TJ) (Karnovsky, 1967)
and we therefore characterized TJ in RMEC.  The expression and 
distribution of occludin, zonula occludens -1 (ZO-1) and Claudin-5 (Cl-5) was 
analysed by indirect immunocytochemistry (see appendix for negative 
control staining).  Staining of occludin was mostly restricted to junctional 
areas at cell-cell contacts (fig 3.1.2,a).  ZO-1 was also primarily localised to 
the junctional areas of cells but additional diffuse intracellular localisation in 
the perinuclear cytoplasm and in the nucleus was detected (fig 3.1.2,b).  Cl-5 
staining delimited the cell boundary but diffuse staining was observed in the 
area of the main cell body of 1 -5 % of cells (fig 3.1.2,c-f).  When assessed in 
more detail this diffuse stain appeared to be present mostly in apical 
sections of the preparations (fig 3.1.2,d,e) suggesting that membrane-
inserted Cl-5 had not segregated to cell-cell contact areas in all cells.  In 
addition vesicular Cl-5 staining was seen in most cells with increased density 
in the perinuclear area (fig 3.1.2,f).  This vesicular Cl-5 staining was 
interpreted to represent newly synthesised protein present in endoplasmic 
reticulum, golgi or transport vesicles.  All three proteins could be detected 
immediately after isolation but occludin and Cl-5 expression started to 
declined within 8 days of in vitro culturing (results not shown).  RMEC 
cultured and passaged for 2-3 times over a period of 3-4 weeks were devoid 
of occludin or Cl-5 staining similarly that observed in immortalised cell lines 
(data not shown).
Because actin filaments play an importantrole in the organization of 
adherens junctions (AJ) and TJ, RMEC were analysed using rhodamine-
phalloidin.  Filamentous actin (F-actin) was identified as filaments through-
out the whole cell with the main strands confined to the cortical / junctional 
area (fig 3.1.3).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Next, the distribution of AJ proteins, VE cadherin (VEC), and associated 
catenins, p120, alpha-, beta- and gamma-catenins, was analyzed by indirect 
immunocytochemistry (fig 3.1.4).  All AJ proteins were localised in at the 
junctional area of RMEC.  As expected, catenins showed some degree of 
non-junctional staining.  Alpha-catenin showed strong cytoplasmic and 
nuclear staining, while weak nuclear staining was also observed for gamma-
catenin.Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.1.2:  Tight junction protein distribution in RMEC.  Cells were 
grown to confluence and then fixed using methanol.  Subsequently cells 
were stained for occludin (a), ZO-1 (b) and Cl-5 (c-f).  The staining of 
occludin was mostly restricted to junctional areas at cell-cell contacts (a).  
ZO-1 was also primarily localised to the junctional areas of cells but 
additional diffuse intracellular localisation in the perinuclear cytoplasm and 
the nucleus was detected (b,arrow). 
Cl-5 staining delimited the cell boundary but diffuse staining was observed 
(c).  Images are projections of all confocal sections spanning the entire cell.  
Shown in panels d,e,f are selected sections from the top (d), bottom (e) or 
middle (e) of the RMEC monolayer.  Cells were stained for Cl-5 and confocal 
images were taken as 0.8µm slices through the cells.  Diffuse stain appeared 
to be present mostly in apical sections of the preparations (d, arrow).  In 
addition vesicular Cl-5 staining was seen in most cells with an increased 
density in the perinuclear area (f, arrowhead).  
ZO-1, Zonula occludens-1; Cl-5, claudin-5  
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Figure 3.1.3:  F-actin distribution in RMEC. Cells were grown to 
confluence, fixed using 3.7% formaldehyde extracted using acetone and 
then stained using phalloidin-rhodamine.  F-actin was identified as filaments 
through-out the whole cell with the main strands confined to the cortical / 
junctional area.
Image is a projection of all confocal sections spanning the entire cell.
F-actin, filamentous actin.
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Figure 3.1.4:  Adherens junction protein distribution in RMEC.  Cells 
were grown to confluence and then fixed using 3.7% formaldehyde and 
permeabilised with acetone.  Subsequently cells were stained for VEC (a), 
alpha-catenin (b) and beta-catenin (c), gamma-catenin (d) and p120 (e).  All 
AJ proteins were located at the junction area of RMEC.  All catenins showed 
some degree of non-junctional staining in particular alpha-catenin showed
strong perinuclear staining (arrows), while gamma catenin showed weak 
nuclear staining (d, arrowheads).  
Images are projections of all confocal sections spanning the whole cell.
VEC, vascular endothelial cadherin / VE cadherin
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3.1.3 Characterisation of junctional proteins by subcellular 
fractionation
Immunofluorence staining is notoriously prone to artefacts and quantification 
is difficult.  Since we wanted to assess changes in the level of junction 
proteins, we further analysed them by subcellular fractionation and 
subsequent Western blotting.
RMEC were grown to confluence and then mechanically lysed in a buffer 
without detergents.  Subsequently, lysates were fractionated by 
centrifugation.  We recovered a low spin pellet containing mainly nuclei, 
large membrane fragments/compartments and F-actin and a high spin pellet 
containing the remaining membranes and cytoskeleton.  The supernatant of 
the high spin pellet was considered to be the soluble cytosol.  Protein 
extracts were quantified using a Bradford assay and equivalent amounts of 
cell extract were loaded for each lane.  
VEC, Cl-5 and ZO-1 were primarily detected in the low and also high spin 
pellets (fig 3.1.5). This indicated that LSP was the main biochemical fraction 
to contain cell-cell junction structures.  A small fraction of Cl-5 and ZO-1 was 
detected in the cytosol.  Catenins were found in all fractions.Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.1.5:  Localisation of junctional proteins in RMEC.  RMEC were 
grown to confluence and then mechanically lysed in a buffer without 
detergents. Subsequently lysates were fractionated by centrifugation.  This 
yielded a low spin pellet, a high spin pellet and a supernatant.  All were 
analyzed along with whole cell lysates by Western blotting for the expression 
of junction proteins.  Protein extracts were quantified using a Bradford assay 
and equal amounts of cell extract were loaded for each lane.  Western blots 
show typical examples obtained for different proteins.  
VEC, Cl-5 and ZO-1 were primarily detected in the low and also high spin 
pellets.  A small fraction of Cl-5 and ZO-1 was detected in the cytosol.  
Catenins were found in all fractions.
HSP, high spin pellet; LSP, low spin pellet; SN, supernatant after high spin; 
total, total cell lysates. 
Cl-5
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VEC
alpha catenin
beta catenin
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3.1.4 Isolation and characterization of brain MEC.  
One disadvantage of using RMEC was the low yield of cells and this limited 
further experimentation.  Based on the common assumption that the BRB 
and the BBB are similar in physiology and molecular composition, we also 
isolated brain microvascular endothelial cells (BMEC) from the rat BBB and 
then compared these with our in vitro RMEC.  
BMEC were essentially isolated as detailed above for RMEC.  At the end of 
the isolation period, small vessel fragments were identified by light 
microscopy.  Single cells and small microvessel fragments of less than 10 
µm diameter attached to the collagen-coated surface within 12 hours.  After 
attachment, cells could be seen spreading out from the microvessels and 
cell division was noted by day 6 (fig 3.1.6a,b).  
BMEC were indistinguishable from RMEC.  They grew to form elongated 
spindle-shaped cells, of average dimensions of 30 µm x 10 µm.  Cells grew 
in a typical swirl-like configuration (fig 3.1.6c).  Confluent monolayers 
exhibited characteristic density-dependent inhibition of growth.  The isolated 
BMEC were 95-100% confluent by day 7.  One isolation of BMEC from six 
animals yielded approximately 1 x 10
6 primary cells at day 7 and consisted of 
95% pure endothelial cells.   On day 7 -8, the BMEC were passaged by 
trypsination at a dilution of 1:2.  
Indirect immunocytochemistry of our BMEC cell cultures with anti-vWF 
antibodies revealed its staining in all cells (fig 3.1.6d).  Staining was 
exclusively seen on cigar-shaped organelles which were distributed 
throughout the cytoplasm of BMEC.   Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.1.6:  Brain microvacular endothelial cell isolation (BMEC).   
Phase contrast images of BMEC at 3 day (a,b) and at 1 week (c).  BMEC at 
one week were fixed using formaldehyde and stained for von Willebrand 
factor (d).
10µm
a b
d c
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The distribution of the TJ proteins occludin, ZO-1 and Cl-5, was analysed by 
indirect immunohistochemistry.  Occludin was mostly restricted to junctional 
areas at cell-cell contacts (fig 3.1.7a).  ZO-1 was also primarily localised to 
the junctional areas of cells but additional diffuse intracellular localisation in 
the perinuclear cytoplasm and the nucleus was detected (fig 3.1.7b).  Similar 
to RMECs, Cl-5 staining delimited the cell boundary and diffuse staining was 
observed in 40-50 % of cells.  In addition vesicular Cl-5 staining was seen in 
some cells (fig 3.1.7c).  All three proteins could be detected immediately 
after isolation but occludin and Cl-5 expression declined gradually after ca. 
day 8 of in vitro culturing (results not shown).  
F-actin was identified as overlapping filaments throughout the whole cell.  
There was a concentration of the strands towards the cortical / junctional 
area of the cell (fig 3.1.8).  
The distribution of AJ proteins, VEC, alpha and beta catenins, was analyzed 
by indirect immunocytochemistry (fig 3.1.9).  All AJ proteins were mostly 
restricted to the junction area of BMEC.  Beta catenin showed some 
perinuclear staining.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.1.7:  Tight junction protein distribution in BMEC.  Cells were 
grown to confluence and then fixed using methanol.  Subsequently cells 
were stained for occludin (a), ZO-1 (b) and Cl-5 (c).  Occludin was mostly 
restricted to junctional areas at cell-cell contacts (a).  ZO-1 was also 
primarily localised to the junctional areas of cells but additional diffuse 
intracellular localisation in the perinuclear cytoplasm and the nucleus was 
detected (b, arrows).  Cl-5 staining delimited the cell boundary and diffuse 
staining was observed in 40-50% of cells.  In addition vesicular Cl-5 staining 
was seen in some cells (c, arrowheads).  
Images are projections of all confocal sections spanning the entire cell.
ZO-1, zonula occludens-1; Cl-5, claudin-5
20µm
b a
10µm
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Figure 3.1.8: F-actin distribution in BMEC.  Cells were grown to 
confluence, fixed using 3.7% formaldehyde and then stained using 
phalloidin-rhodamine.  F-actin was identified as overlapping filaments 
through-out the whole cell.  Strands concentrated in cortical / junctional 
areas of the cell.
Image is a projection of all confocal sections spanning the entire cell.
F-actin, filamentous actin.  
10µmDiabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.1.9:  Confocal images of adherens junction proteins in BMEC.  
Cells were grown to confluence and then fixed using 3.7% formaldehyde and 
permeabilised with acetone.  Subsequently cells were stained for VEC (a), 
alpha catenin (b) and beta catenin (c).  All AJ proteins were mostly restricted 
to the junctional areas of BMEC.  Beta catenin showed some perinuclear 
staining (c, arrows).  
Images are full projections of confocal sections spanning the whole cell.
VEC, vascular endothelial cadherin / VE cadherin.  
10µm
a
10µm
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3.1.5 Permeability of MEC. 
RMEC and BMEC form the main barrier in-vivo to solutes at the level of the 
BRB and the BBB respectively (Gardner et al., 1999).  In order to correlate 
changes in the spatial localisation of the junctional proteins with changes in 
the permeability of MEC, we had to establish methods for testing 
permeability of our cells in vitro.   
MEC were cultured on transwell cell culture chambers, which contain 2 
wells.  The base of the apical well comprises of a semi-permeable 
membrane onto which cells can be seeded to form a monolayer and 
subsequently the exchange of solutes or electrical charge across the 
monolayer can be measured.  However the first challenge encountered was 
adherence of the cells to the membrane.  Based on the results by Tiling et. 
al. (Tilling et al., 1998), we precoated the membrane with different 
extracellular matices and found that the combination of collagen IV and 
fibronectin allowed our cells to form a visually complete monolayer (results 
not shown).  
In addition, the medium was supplemented with 550 nM hydrocortisone (HC) 
and 100 µM ascorbic acid in order to maintain adherence with the 
extracellular matrix.  HC has been shown to increase in the barrier function 
of MEC (Antonetti et al., 2002).  Ascorbic acid induces endothelial cells to 
synthesis their own basement membrane (Utoguchi et al., 1995).
Prior to experimentation we diluted our enhanced medium with serum- and 
hydrocortisone-free medium in order to strike the balance between unduly 
influencing the results of our experiments with growth factors and the risk of 
the MECs detaching from the filter.Diabetic Macular Oedema:  The role of steroids and VEGF
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Permeability was assessed either by measuring the transendothlelial 
electrical resistance (TER) or transendothelial flux.  TER depends on areas 
with the lowest electrical resistance between single cells (Madara, 1998).  
Transendothelial flux is the passage of detectable molecules for example 
FITC-conjugated dextrans through the monolayer which depends on the sum 
of transport across all cellular transport pathways.
3.1.5.1 Transendothelial electrical resistance of BMEC
BMEC were grown to confluence and then passaged onto transwell cell 
culture chambers at a density of 40 000 to 100 000 cells per well into culture 
medium containing 550 nM HC and 100 µM ascorbic acid until confluent.  24 
hours prior to experimentation, the medium was diluted 1:2 with serum free 
medium containing HC only.  Net transendothelial electrical resistance (TER) 
was measured at intervals until day 13.  TER was calculated by subtracting 
the mean resistance determined fro 2 filters in the absence of cells (table 
3.1.1).  The mean TER was 6.8  *cm
2.  
3.1.5.2 Transendothelial permeability assay
BMEC were grown to confluence and passaged onto transwell cell culture 
chambers at a density of 40 000 to 100 000 cells per well into culture 
medium containing 550 nM hydrocortisone and 100 µM ascorbic acid until 
confluent.  24 hours prior to experimentation, the medium was diluted 1:2 
with serum free serum free medium containing HC only.  Transendothelial 
permeability was measured by calculating the clearance of fluorescein 
isothiocyanate (FITC) or FITC-conjugated with 40kDa dextran from the 
apical to the basolateral aspect of the membrane.  The clearance of FITC / 
FITC-dextran was measured on a plate reader spectrophotometer and the Diabetic Macular Oedema:  The role of steroids and VEGF
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permeability coefficient (Pe) was calculated (fig 3.1.10).  The Pe for FITC 
was 2.16 x 10
-3 +/- 5.63 x 10
-5 cm/min and for 40 kDa FITC-dextran, 2.32 x 
10
-4 +/- 1.83 x 10
-5 cm/min.Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.1.1:  Mean transendothelial electrical resistance measured 
from BMEC over time. Values are a mean over 4 wells.  Control wells 
which consisted of
Time (days) 5 7 12 13
TER ( *cm
2 ) 3.9 9.75 2.6 7.8
TER, trans-endothelial electrical resistance 
Figure 3.1.10:  The flux of FITC and 40kDA FITC-dextran with time.  
BMEC were grown to confluence on transwell chambers.  FITC or FITC-
conjugated dextran (40kDA) was added to the apical chamber.  The 
clearance of FITC (a) or FITC-dextran (b) was measured at intervals by 
spectrophotometry.  The diffusive flux (Pe) for FITC was 2.16 x 10
-3 +/- 5.63 
x 10
-5 cm/min and for 40 kDa FITC-dextran, 2.32 x 10
-4 +/- 1.83 x 10
-5 
cm/min.
FITC, fluorescein isothiocyanate. 
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3.1.6 Discussion
3.1.6.1 Isolation of RMEC
In order to investigate the effects of steroids and VEGF on the barrier 
properties and on the junctional proteins of the BRB / BBB an in-vitro model 
of the blood-retinal barrier (BRB) was required.   Isolation of primary cultures 
of microvascular endothelial cells has been established in numerous animal 
models most commonly from bovine and rat retinae and each has been 
shown to form a barrier to tracer molecules (Harhaj et al., 2006;Oshitari et 
al., 2006).  Recently the bovine spongiform encephalopathy has presented a 
serious social problem (Giles, 2001) and therefore our initial study was to 
create a reproducible model of the BRB and we chose the rat model.  One 
advantage of using the rat species is that future work in this lab may involve 
in vivo work on established models of experimental induced diabetic rats 
which could easily be compared to our in vitro model.  
We describe a method to isolate retinal (and brain) endothelial cells adapted 
from the method of Abbott et al. (Abbott et al., 1992).  Our isolated retinal 
microvascular endothelial cells (RMEC) grew in a typical swirls and exhibited 
density-dependent inhibition consistent with their endothelial cell lineage.  
The cells also expressed Weibel-Palade bodies in the cytoplasm of the cell 
and Cl-5 around the cell periphery, both important endothelial cells markers.  
The isolation of RMEC was easily accomplished but the maintenance of 
these populations with time was more difficult.  A major problem associated 
with primary cultures is the difficulty in achieving 100% purity.  In order to 
minimise the growth of other cell types, the microvessels isolation and 
culture procedure, in particular the use of the percoll gradient, was designed Diabetic Macular Oedema:  The role of steroids and VEGF
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to restrict the number of non-endothelial cells plated out.  The growth of 
contaminating cells in cultures is inhibited firstly by selecting a medium 
containing plasma-derived serum to promote the growth of endothelium and 
not contaminants such as pericytes (Greenwood, 1992) and secondly by 
using the puromycin (Perriere et al., 2005).  By combining the above 
techniques a culture purity of 96 -98% and 95% was obtained for the RMEC 
and BMEC respectively.  
3.1.6.2 Spatial localisation of TJ and AJ 
We characterized the TJ in RMEC by determining the distribution of Cl-5, 
occludin, and ZO-1.  Staining for all three proteins was mostly restricted to 
junctional areas at cell-cell contacts and was similar to previous studies 
(Antonetti et al., 2002;Deissler et al., 2008).  However, we also observed 
diffuse cytoplasmic staining for Cl-5 as well as vesicular cytoplasmic 
staining.  The diffuse stain appears to be present mostly in the apical 
sections of the preparations, suggesting that membrane-inserted Cl-5 had 
not segregated to cell-cell contact areas in all cells.  In addition vesicular Cl-
5 staining was seen in most cells and interpreted to represent newly 
synthesised protein present in endoplasmic reticulum, golgi body or transport 
vesicles, which is supported by the increased density of these vesicles in the 
perinuclear area.  It is possible that they are due to artefact, however the 
antibody was centrifuged to remove particulates and this staining pattern 
was not observed with our negative control (results not shown) and therefore 
we conclude that they are real observations.  Although neither of these 
cytoplasmic stains have been previously reported, they can be observed in 
MEC images of other researchers (Weidenfeller et al., 2005;Calabria et al., 
2006). Diabetic Macular Oedema:  The role of steroids and VEGF
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ZO-1 was also primarily localised to the junction areas of cells, but additional 
diffuse intracellular localisation in the perinuclear cytoplasm and the nucleus 
was detected.  Membrane-associated proteins including ZO-1 are known for 
their role in intracellular signalling and the cellular location is related to the 
cell activity.  During remodelling of cell-cell contacts, ZO-1 can be detected 
in the nucleus (Gottardi et al., 1996).  
Similarly we observed the junctional staining for the AJ proteins, VEC, alpha-
, beta- and gamma-catenin and p120, with some additional nuclear/ 
perinuclear staining for alpha- and gamma-catenin, which again concurs with 
previous observations (Deissler et al., 2008;Russ et al., 1998;Herrenknecht 
et al., 1991;Hegland et al., 1999;Romero et al., 2003).  Like ZO-1, the 
membrane-associated proteins of the AJ also have a role in intracellular
signalling (Novak and Dedhar, 1999) and therefore the cytoplasmic and 
nuclear locations are linked to the cellular activity.  
We further analysed ZO-1, Cl-5, VEC, alpha and beta-catenin by Western 
blotting.  We combined this with subcellular fractionation in order to 
corroborate our immunocytochemistry data.  Detergent-free cell lysates were 
centrifuged twice, initially at a low speed and then the supernatant was 
centrifuged a second time at a high speed.  We predicted that junction 
proteins would be found in either or both pellets. Indeed the majority of the 
junctional proteins were found in the low spin fraction and the remainder in 
the high spin fraction.  This suggested that junction proteins were highly 
insoluble and primarily associated with bulky membrane and cytoskeletal 
components.
The soluble portion should contain only proteins from the cell cytoplasm.  
ZO-1, alpha- and beta-catenin are junctional-associated proteins and in Diabetic Macular Oedema:  The role of steroids and VEGF
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accordance detected to varying degrees the soluble portion, corresponding 
to the cytoplasmic / perinuclear staining observed on immunohistochemistry.  
Unexpectedly traces of Cl-5 were also detected in the soluble cytosolic 
fraction.  Cl-5 is a known transmembrane protein and should only been 
found in association with membranes.  In contrast VEC, the other 
transmembrane protein analysed biochemically, was exclusively restricted to 
membrane pellets demonstrating that cross-contamination of fractions did 
not occur.  Cl-5 may associate with very small membrane compartments 
which were not separated from the cytosol by our centrifugation.  As 
discussed above we also noted speckled cytoplasmic immunostaining and 
assumed that this was vesicular.
3.1.6.3 Comparison of RMEC / BMEC 
We were able to passage the cells and increase the amount of material but 
passaging the cells also increased the amount of contaminating cells and 
over the course of time the cells showed a decline in the expression of 
various junctional proteins especially Cl-5 and occludin.  
This limited the amount of material we were able to generate and it was 
difficult to consistently produce enough tissue to look at permeability.  
However it is recognized that endothelial cells of the cerebral and retinal 
capillaries have similar characteristics.  Both form a non-fenestrated, single 
layer that possess TJ and AJ with a similar composition of proteins (Harhaj 
and Antonetti, 2004;Russ et al., 1998;Ueno, 2007).  Both sets of endothelial 
cells are surrounded and supported by pericytes and glial cells (Farrell et al., 
1987;Martin et al., 2000;Newman and Reichenbach, 1996;Brightman et al., 
1983), are rich in mitochondria and possess specific carrier-mediated 
transport proteins for example GLUT1 and GLUT3 (Badr et al., 1999).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Additionally autoregulation of blood flow is a property of both the inner retinal 
and cerebral circulations (LASSEN, 1964;Bill and Sperber, 1990) and they 
both undergo similar changes in response to aging, diabetes and 
hypertension (see review patton et. al. (Patton et al., 2005).  
Therefore based on the assumption that the BRB and the BBB are similar in
physiology and molecular composition, and that undoubtedly more cells 
could be generated from the BBB we also isolated brain microvascular 
endothelial cells (BMEC) and compared the endothelial cultures from the two 
tissues. 
Our results showed that the two tissues models were very similar, in 
particular terms of the spatial localisation of the junction proteins.  There 
were some subtle differences in terms of the catenins.  In RMEC alpha-
catenin showed some perinuclear staining however this was not evident in 
the BMEC.  Similarly beta-catenin was isolated to the junctional area for 
RMEC but in BMEC there was some additional perinuclear staining.  As 
previously discussed, not only are these junctional proteins but they are also 
nuclear signalling proteins and therefore their expression depends on the 
cellular activity and therefore we predict that the difference observed 
between the cell types reflect differing intracellular signalling.  
3.1.6.4 Permeability of MEC
Our monolayer had a tendency to detach from the fitler and therefore out 
initial challenge was to grow the cells on the membrane.  Detachment from 
the filter could be limited (although not entirely eliminated) if we grew the 
cells on an extracellular matrix of collagen IV and fibronectin.  In addition, we 
seeded cells of low passage (P1) and enhanced the medium with Diabetic Macular Oedema:  The role of steroids and VEGF
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hydrocortisone and ascorbic acid to encourage the cells to remain attached 
to the filter.  Previous investigators have found a TER with bovine endothelial 
cells between 11.7 – 170 ohm cm
2 (Wang et al., 2001;Tretiach et al., 
2004;Guo et al., 2008;Gardner et al., 1997;Yaccino et al., 1997;Gillies et al., 
1995).  Most notably the studies of higher resistance are either unpassaged 
cells or cells of low passage (P1 or 2).  In comparison, cultured retinal 
pigment epithelial cells have a TER of around 50 – 100 ohm cm
2 (Zech et al., 
1998;Ablonczy and Crosson, 2007) however TER of around 500 ohm cm
2 for 
RPE cells can be achieved after culture for 1 month (Geisen et al., 2006).  
We used cells of low passage, however our TER was still very small 
suggesting that our cells were unable to form a good barrier.  Due to the 
problem of growing and maintaining our MEC on the filters, measuring the 
TER in the long-term was not an option.  However we demonstrated that our 
cells formed a good barrier to the passage of FITC / FITC-dextran.  
TER depends on areas with the lowest electrical resistance between single 
cells (Madara, 1998).  Before experimentation, our filters were ispected 
microscopically and any wells with visible gaps were discarded, however our 
low TERs suggest that microscopic gaps were present, either as occult 
gaps, at the edges of the monolayer or due to the presence of a 
contaminating cell.  In contrast, transendothelial permeability is the passage 
of molecules through the monolayer which depends on the sum of transport 
across all junctional pathways and therefore would be assumed to be much 
more forgiving towards gaps.
3.1.6.5 Conclusion
Our in-vitro culture of the RMEC and BMEC were morphologically very 
similar and demonstrate a phenotype that suggests aspects of the BRB are 
maintained (e.g. TJ and AJ expression, barrier to FITC-dextran).  We also Diabetic Macular Oedema:  The role of steroids and VEGF
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conclude that BMEC are a reasonable model system to dissect aspects of 
the BRB.  Unfortunately due to the time limitation, we were unable to repeat 
the studies of permeability on RMEC.   Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.2
The effects of VEGF on the barrier function 
of blood-retinal and blood-brain 
microvascular endothelial cells.Diabetic Macular Oedema:  The role of steroids and VEGF
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3.2.1 Introduction
Apart from its angiogenic activity, VEGF displays potent vasoactivity.  It 
induces increased vessel permeability (Senger et al., 1983) and induces 
microvascular barrier breakdown in a number of in vitro systems (Antonetti et 
al., 1999;Lakshminarayanan et al., 2000;Behzadian et al., 2003).  However, 
the mechanism by which VEGF induces vascular permeability remains 
unclear.  Activation by VEGF of its receptors leads to a multifaceted 
activation of downstream signalling pathways some of which are proposed to 
play an important role inducing microvascular permeability, presumably 
through changes in the endothelial cell-to-cell junctions.  Antonetti et.al. 
show that VEGF treatment leads to a down regulation in the junctional 
expression of occludin in bovine retinal endothelial cells in vitro and this 
correlates to an decrease in barrier function (Antonetti et al., 1998).  
We used our RMEC and BMEC cultures to further characterise the role of 
VEGF at blood-retinal barrier (BRB) and blood-brain barrier (BBB).     Diabetic Macular Oedema:  The role of steroids and VEGF
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3.2.2 VEGF induces permeability of BMECs 
In order to investigate the effect of VEGF on the permeability of our 
endothelial cell monolayer, BMEC were grown to confluence and then 
passaged onto transwell cell culture chambers at a density of 40 000 to 100 
000 cells per well.  They were cultured until confluent and two days prior to 
experimentation the medium was diluted 1:2 with serum-free medium with 
hydrocortisone (HC).  Due to the difficulties of maintaining a complete 
monolayer on the membrane, there were considerable variations between 
the monolayers and therefore we used each individual filter as its own 
control.  
1 mg/ml 40kDa FITC-dextran was added to the apical chamber and the 
transendothelial permeability was measured by determining its flux from the 
apical to the basolateral chamber over 180 minutes.  Then 50 ng/ml VEGF 
was added to the apical well and the change in transendothelial permeability
of the 40kDa FITC-dextran was determined over the next 180 minutes.  
VEGF lead to a significant increase in permeability of the BMEC monolayer.    
Increased permeability was observed as early as 30 minutes after the 
addition of VEGF and persisted for at least three hours (fig 3.2.1).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.1:  VEGF induces enhanced flux across BMEC.  (a) BMEC 
were grown to confluence on transwell chambers.  1mg/ml 40kDa FITC 
dextran was added to the apical chamber.  50 ng/ml VEGF was added to the 
apical chamber at 180 minutes (arrow) and the change in the permeability of 
the monolayer was assessed by measuring the clearance of FITC-dextran 
(40 kDa).  30 minutes following the addition of VEGF, an increase in the 
clearance of FITC- dextran was observed (error bars = standard deviation).  
(b)  Overall there was nearly a 2 fold (x1.8) increase in permeability with 
following the addition of VEGF.    
FITC, fluorescein isothiocyanate; VEGF, vascular endothelial growth factor.   
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3.2.3 VEGF leads to an alteration in the spatial localisation of 
junctional proteins
Paracellular permeability has been proposed to be influenced by the level 
and localisation of junctional proteins.  In order to investigate if VEGF leads 
to changes in the spatial localization of junctional proteins, RMEC were 
grown to confluence and passaged onto the centre of collagen coated plastic 
and cultured in primary medium.  Cells were serum starved for 24 hours and 
then treated with 50ng VEGF for up to 24 hours, fixed and then the junctional 
proteins were identified by immunohistochemistry.  
Firstly, we verified that RMEC responded to VEGF under these conditions.  
Cells were stained for filamentous action (F-actin) using phallodin.  Changes 
in the spatial localisation of F-actin occurred very rapidly.  Indicative of 
growth factor activation and in agreement with published date we observed 
stress fibre formation in response to VEGF (Cullen et al., 2000).  This was 
seen as early as 5 minutes and the response was transient since by 60 
minutes, F-actin distribution returned to the pretreatment appearance (fig 
3.2.2).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.2:  Confocal images showing the spatial localization of F-
actin in RMEC following treatment with VEGF.  RMEC were treated with 
50 ng/ml VEGF for up to 60 minutes and then fixed with methanol.  
Subsequently cells were stained for F-actin.  The addition of VEGF led to a 
rapid increase in the stress fibre formation as early as 5 min.  By 60 minutes 
the stress fibre formation was nearly back to control levels.  
Images are full projections of confocal sections spanning the whole cell
F-actin, filamentous actin; VEGF, vascular endothelial growth factor.  
F-actin
Untreated  5 minutes 60 minutes
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Next, we analysed the distribution of junctional proteins following VEGF 
treatment and observed both early and late changes of junction protein in 
response to VEGF.  After 1 hour, VEGF led to a reduction in the amount of 
junctional staining for ZO-1, alpha-catenin and gamma-catenin (fig 3.2.3-4).  
In contrast the spatial localisation of beta-catenin was unaffected by VEGF 
(fig 3.2.4a).  The reduction in the junctional staining of ZO-1 and alpha-
catenin was transient and by 24 hours the junctional staining for these 
proteins resembled untreated cell (fig 3.2.3), however gamma-catenin loss 
extended over the whole 24 hour observation period (fig .3.2.4b).  
In contrast to the relatively rapid changes seen for the junction-associated 
proteins, changes to the transmembrane proteins in response to VEGF were 
much slower to occur.  Occludin and VEC levels were unaffected within the 
first hour of treatment but significantly reduced after 24 h.  Cl-5 showed an 
early response at 1 hour with a reduction of the cytoplasmic speckles, 
indicating that Cl-5 synthesis and export was inhibited (fig 3.2.5a).  However, 
a strong reduction in the staining at the cell boundary took 24 h to manifest 
(fig 3.2.5b,c).   Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.3:  Confocal images showing the spatial localization of ZO-1 
and alpha-catenin in RMEC following treatment with VEGF.  Cells were 
grown to confluence, starved for 24 hours, treated with 50 ng/ml VEGF for 
up to 24 hours and then fixed with methanol (ZO-1) or 3.7% formaldehyde 
(alpha-catenin). Subsequently cells were stained for ZO-1 (a) or alpha-
catenin (b).  The addition of VEGF leads to a reduction in the junction 
expression of ZO-1 and alpha-catenin at 1 hour.  By 24 hours the staining 
patterns for both ZO-1 and alpha-catenin reverted to control levels.  
Images are full projections of confocal sections spanning the whole cell.
RMEC, retinal microvascular endothelial cells; ZO-1, zonula occludens-1; 
VEGF, vascular endothelial growth factor.
20µm
b
20µm
Untreated  1 hour 24 hours
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Figure 3.2.4:  Confocal images showing the spatial localization of beta 
and gamma catenin in RMEC following treatment with VEGF.  Cells were 
grown to confluence, starved for 24 hours, treated with 50 ng/ml VEGF for 
up to 24 hours and then fixed with 3.7% formaldehyde.  Subsequently cells 
were stained for beta-catenin (a) and gamma-catenin (b).  After 1 hour, 
VEGF led to a reduction in the amount of junctional staining for gamma-
catenin which extended over the whole 24 hours observation period.  In 
contrast the staining for beta-catenin was not affected by VEGF treatment.  
Images are full projections of confocal sections spanning the whole cell 
RMEC, retinal microvascular endothelial cells; VEGF, vascular endothelial 
growth factor.
b
20µm
a
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`
Figure 3.2.5:  Confocal images showing the spatial localization of the 
transmembrane proteins in RMEC following treatment with VEGF.  Cells 
were grown to confluence, starved for 24 hours, treated with 50 ng/ml VEGF 
for up to 24 hours and then fixed with methanol (Cl-5 and occludin) or 3.7% 
formaldehyde (VEC).  Subsequently cells were stained for Cl-5 (a), occludin 
(b) or VEC (c).  The addition of VEGF leads to a reduction of junctional 
expression of all three transmembrane proteins at 24 hours.  Images are full 
projections of confocal sections spanning the whole cell.  RMEC, retinal 
microvascular endothelial cells; VEGF, vascular endothelial growth factor; 
Cl-5, claudin-5; VEC, vascular endothelial cadherin / VE cadherin.
Untreated  1 hour 24 hours
a
c
20µm
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3.2.4 VEGF leads to a 30% reduction in ZO-1
As shown above, we observed a decrease in junctional ZO-1 staining in 
response to VEGF (fig 3.2.3 and 3.2.6) that coincided with increased 
permeability (fig 3.2.1).  This has been noted before: For instance increased 
expression of ZO-1 is observed in parallel with increased electrical 
resistance in cultured rat brain capillary endothelial cells (Krause et al., 
1991). Additionally, ZO-1 levels are reduced in the presence of elevated 
glucose concentrations (Gardner, 1995).
Taken together this suggested that ZO-1 may act as a critical down-stream 
effector of VEGF signalling possibly directly involved in barrier breakdown 
and in permeability.  To test the hypothesis we tried to correlate VEGF-
induced ZO-1 loss to VEGF-induced permeability more closely through the 
signalling pathways used.  
Changes in detection of immunofluorescent staining may reflect actual 
reduction in protein levels but may also be due to reduced epitope 
accessibility.  Western blot is usually considered more reliable to detect 
actual protein levels.  Therefore to confirm that loss of ZO-1 immunostaining 
represented actual protein loss, RMEC were grown to confluence on 
collagen coated dishes and then serum starved for 24 hours.  Cells were 
treated with 50ng/ml VEGF for 1 hour, lysates were prepared and analysed 
by Western blot for the expression of ZO-1.  
Following 1 hour treatment with VEGF, there was a clear reduction of ZO-1 
protein (fig 3.2.6a).  Indeed quantification of three independent experiments 
revealed that reduction after one hour was 34%, n=3, P=0.04 (fig 3.2.6b).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Importantly, the reduction of ZO-1 observed by immunocytochemistry was 
very similar (30%, n=4, P=0.008) (fig 3.2.6d).  
From these results, we concluded that we were able to obtain similar results 
if we analysed the change in intensity of ZO-1 stain, by 
immunocytochemistry or by biochemistry.  Analysis of the cells by 
immunocytochemistry took much less material and therefore we compared 
effect of inhibitors of the signal transduction pathway to 
immunocytochemstry only.   Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.6:  Quantification of VEGF-induced ZO-1 loss.  RMEC were 
grown to confluence and treated with 50ng/ml VEGF for 1 hour.  Changes in 
ZO-1 were visualized by both Western blotting (a) or immunohistochemistry 
(c).   Quantification of VEGF-induced ZO-1 loss showed a 30% reduction in 
the mean intensity of ZO-1 in both instances. n=3, P=0.04 (b), n=4, 
P=0.008(d).
VEGF, vascular endothelial growth factor; ZO-1, zonula occludens-1.  
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3.2.5 VEGF-induced loss of ZO-1 via PKC, PI3K AND ENOS
We next wanted to test whether VEGF-induced ZO-1 loss was a critical 
downstream endpoint for VEGF-induced permeability.  Consequently, we 
compared the intracellular signalling pathway of VEGF-induced ZO-1 loss 
with the described pathway for VEGF-induced permeability.  
VEGF binds several transmembrane tyrosine kinase receptors (VEGF-R) 
which induce intracellular signals and endothelial permeability (fig 3.2.7).  
VEGF-R2 activates membrane-associated kinases such as Src and 
phosphatidylinositol 3-kinases (PI3K) (Waltenberger et al., 1994;Guo et al., 
1995).  These along with Src kinase has been implicated in VEGF-induced 
permeability (Suarez and Ballmer-Hofer, 2001) (fig 3.2.7).  In the following 
experiment we have used PP2 (3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine) as a selective inhibitor or Src-family 
tyrosine kinases (Hanke et al., 1996) and wortmannin and LY294002 to 
inhibit PI3K (Cross et al., 1995;Vlahos et al., 1994).  
A variety of other signalling components may also contribute to vascular leak 
such as endothelial nitric oxide synthase (eNOS) and protein kinase C (PKC) 
(Wu et al., 1999) (Radomski et al., 1990). We utilised L-NAME (NG-nitro-L-
arginine methyl ester) and overnight treatment with phorbol ester PMA to 
prevent activation of eNOS and PKC respectively.
Increases in intracellular calcium have been shown to be induced by VEGF 
in vivo (Wu et al., 1999) and as in vitro (Brock et al., 1991) to increase 
permeability. We used BAPTA-AM (1,2 bis-(-o-aminophenoxy) ethane 
tetraacetoxymethyl ester) to chelate Ca
2+ (Harrison and Bers, 1987).Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.7:  Schematic diagram illustrating the signal transduction pathway 
of VEGF-induced permeability.  
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The actin cytoskeleton is known to interact with junctional proteins and 
VEGF led to an increase in actin stress fibre formation (fig 3.2.2) and this 
may regulate permeability (Sun et al., 2006).  We used cytochalazin D to 
disrupt actin filaments and inhibit actin polymerization (Mortensen and 
Larsson, 2003).
A summary of the inhibitors of the signal transduction pathway are shown in 
table 3.2.1.
Confluent RMECs were serum starved and then pretreatedwith PMA (160 
nM,18hr), wortmannin (300 nM, 1hr), LY294002 (15 µM, 1hr), PP2 (20 µM, 
30min), BAPTA-AM (20 µM, 1hr), cytochalazin D (2 µM, 30min), or L-NAME 
(1 mM, 1hr).  Cells were then treated with 50 ng/ml VEGF for 1 hour, fixed 
with methanol and stained for ZO-1.  Staining intensity was quantified using 
the image analysis programme, ImageJ. 
In untreated cells, VEGF led to the 30% reduction in the ZO-1 described 
above. Our data showed that inhibitors of PKC, PI3K and eNOS prevented 
the VEGF-induced ZO-1 loss (fig 3.2.8).  In contrast, pre-treatment with PP2, 
cytochalazin D or BAPTA-AM was mostly ineffective in preventing VEGF-
induced ZO-1 loss suggesting that Src protein kinases, the actin 
cytoskeleton and Ca2+ transients were not involved in ZO-1 downregulation.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.2.1:  Summary of the action of the inhibitors of signal transduction 
pathway used to investigate VEGF-induced ZO-1 loss
Name of Inhibitor action on signal transduction 
pathway 
abbreviation
PP2 inhibits Src-family tyrosine kinases Src
wortmanin inhibits phosphatidylinositol 3-kinase PI3K
LY294002 inhibits phosphatidylinositol 3-kinase PI3K
L-NAME inhibits nitric oxide synthase (but only 
eNOS is expressed)
eNOS
PMA stimulates and downregulates protein 
kinase C following prolonged exposure
PKC
BAPTA-AM calcium chelator Ca2+
cytochalazin D prevents actin polymerization actinDiabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.2.8:  VEGF-induced ZO-1 loss was blocked by PMA, 
wortmannin and LY294002 and L-NAME.  Confluent RMECs were 
pretreatedwith PMA (160nM, 18hr), wortmannin (300nM, 1hr), LY294002 
(15 µM, 1hr), PP2 (20µM, 30min), BAPTA-AM (20µM, 1hr), cytochalazin D 
(2µM, 30min), and L-NAME (1mM, 1hr) and then stimulated with 50 ng/ml 
VEGF for 1 hour.  RMEC were fixed and stained for ZO-1.  In untreated 
cells, VEGF led to the expected 30% reduction in the ZO-1 stain.  
Pretreatment with PMA, wortmannin, LY294002, and L-NAME all led to a 
complete inhibition of VEGF-induced ZO-1 loss.  In contrast, pre-treatment 
with PP2, cytochalazin D or BAPTA-AM was mostly ineffective in preventing 
VEGF-induced ZO-1 loss Results show the median value of 3 experiments 
plus interquartile range. 
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3.2.6 Discussion
VEGF led to an increase in permeability which was discernible within 30 min 
of treatment.  Such a relatively rapid response has also been noted by other 
investigators (Bates et al., 1999;Esser et al., 1998;Feng et al., 1996).  In 
addition Behzadian et. al. (Behzadian et al., 2003),  found that VEGF 
induced a rapid and transient phase of permeability (1-2hr) followed by a 
delayed and sustained phase (6-24hr).  Our data did not give any clear 
indication of a biphasic response to VEGF.  However, our analyses were 
undoubtedly inappropriate to monitor such changes: flux rates at many more 
closely spaced time points would be required.  Continuous measurements of 
hydraulic conductivity (Lakshminarayanan et al., 2000) or impedance (Nitz et 
al., 2003) would be more appropriate  to resolve time-resolved changes of 
VEGF-induced permeability.
Significantly, we observed two clearly distinguishable phases of junctional 
rearrangements in response to VEGF, which may illustrate a biphasic 
response of endothelial cells.  We found an initial rapid but transient loss in 
the junction-associated proteins, followed by a delayed but sustained loss in 
the transmembrane junction proteins.  The membrane-associated proteins 
form reversible bounds with the transmembrane proteins, allowing signalling 
between the transmembrane proteins and the rest of the cell especially the 
nucleus.  Therefore it makes sense that the loss of junction-associated 
proteins occurred rapidly.  In contrast, the transmembrane proteins are 
hydrophobic proteins that form an integral part of the cell membrane and 
protein loss may require the turnover of the membrane and hence occurs 
more slowly.Diabetic Macular Oedema:  The role of steroids and VEGF
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To our knowledge, this is the first report of the VEGF-induced changes of 
alpha- and gamma-catenin.  We showed a rapid but transient change in both 
of these proteins.  There was no change in the spatial localisation of p120 or 
beta-catenin in accordance with previous results (Wong et al., 2000).  One 
report describes a transient increase in cytosolic beta catenin but no 
correlative change in the junctional-associated pool is shown (Behzadian et 
al., 2003).  
VEGF treatment also led to a reduction of ZO-1 within 1 hour.  This was 
observed by immunocytochemistry and by Western blotting, clearly 
indicating that total intracellular levels of this protein were reduced which 
concomitantly affected its junction association.  By 24 hours the staining 
pattern of ZO-1 on immunohistochemistry reverted to the appearance of 
untreated cells.  Other investigators have looked at VEGF-induced ZO-1 loss 
and did not find a significant change in the level of its expression on Western 
blotting.  However all of these investigators looked at ZO-1 after 24 hours 
and this may account for the difference (Brankin et al., 2005;Wang et al., 
2001;Deissler et al., 2008).  
Furthermore, we found changes in the spatial localisation of occludin and 
VEC that have also been noted by previous investigators (Behzadian et al., 
2003;Wang et al., 2001;Antonetti et al., 1998;Nakamura et al., 2008;Esser et 
al., 1998).  We also observed a significant reduction in Cl-5 after 24 hours of 
VEGF treatment.  The loss of Cl-5 may well contribute to enhanced 
endothelial permeability as suggested by results obtained with Cl-5 knock 
out mice (Nitta et al., 2003).  Rodewald noted that VEGF induced a reduction 
in Cl-5 staining in the ovaries (Rodewald et al., 2007).  However a study by 
Deissler et al. found no change in Cl-5 expression in bovine retinal 
endothelial cell following VEGF treatment for 24 hours (Deissler et al., 2008). 
Clearly further investigations are required to explain these discrepancies.  Diabetic Macular Oedema:  The role of steroids and VEGF
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We have shown that VEGF leads to rapid increase in permeability (within 30 
minutes) and is associated with a reduction in the junctional localisation of 
ZO-1.  Previous investigators have shown that during hypoxia there is 
reduction in the localization and expression of ZO-1 and hypoxia –induced 
ZO-1 loss is attenuated by neutralising antibodies to VEGF, making it a 
possible critical downstream-effector of VEGF-induced permeability (Fischer 
et al., 2002).  In order to test this theory, we compared the signal 
transduction pathway of VEGF-induced ZO-1 loss to the established of the 
signal transduction pathway for VEGF-induced permeability.  
Our data showed that PKC, PI3K, eNOS were involved in mediating the 
VEGF-induced ZO-1 loss.  In contrast, inhibition of calcium transients, the 
actin cytoskeleton or Src protein kinases did not prevent VEGF-induced loss 
of ZO-1.  All three signalling components have been unambiguously 
implicated in mediating endothelial permeability.  In particular Src protein 
kinase has a clearly demonstrated role in mediating VEGF-induced 
endothelial permeability both in vitro and in vivo (Suarez and Ballmer-Hofer, 
2001;Weis et al., 2004a).  We therefore conclude that the level of 
intracellular (and junctional) ZO-1 is not a critical mediator of VEGF 
vasoactivity in BMEC or RMEC.  Of course formal proof would require 
studying the permeability response to VEGF in the absence or presence of 
the same pharmacological inhibitors.  Such studies have not yet been 
performed.Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.3
The effects of steroids on the barrier 
function of blood-retinal and blood-brain 
microvascular endothelial cells.Diabetic Macular Oedema:  The role of steroids and VEGF
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3.3.1 Introduction
Breakdown of the blood-retinal barrier and the resultant vascular 
permeability remains one of the first observable alterations in diabetic 
retinopathy and strongly correlates with vision loss.
Initial pilot studies suggest that steroids such as intravitreal triamcinolone 
reduce the amount of DMO (Jonas et al., 2003;Martidis et al., 2002), 
however the mechanism of action that leads to the reduction in oedema 
remains poorly understood.  They may act by suppressing inflammation and 
thus reducing microvascular endothelial permeability or they may have a 
direct role in the organization of cell-to-cell junctional complexes (which may 
in turn affect barrier function).  
The aim of this particular study was to assess the role of corticosteroids, 
namely hydrocortisone and triamcinolone on the in vitro model of the blood-
retinal barrier (BRB) and or the blood-brain barrier (BBB) as described in 
chapter 1.     Diabetic Macular Oedema:  The role of steroids and VEGF
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3.3.2 Glucocorticoids led to an improvement of MEC barrier 
function to low and high molecular weight solutes
To compare the effect of steroids on the barrier function of MEC, the flux of 
FITC or FITC-conjugated protein across monolayers of BMEC was 
assessed.  BMEC were grown to confluence and then passaged onto 
transwell cell culture chambers at a density of 40 000 to 100 000 cells per 
well.  Cells were grown to confluence and two days prior to experimentation 
the medium was diluted 1:2 with serum free medium (plus or minus 
hydrocortisone).  The transendothelial permeability was then measured by 
measuring the flux of FITC (389 Da), 40kDa FITC-coupled dextran or 70kDa 
FITC-coupled dextran.  
In the presence of hydrocortisone, the cells formed a much tighter barrier to 
FITC (fig 3.3.1a).  This barrier effect was enhanced when repeated with 40 
kDa FITC-dextran.  Indeed calculation of the diffusive flux revealed that 
hydrocortisone improved the barrier to function around two-fold for FITC and 
around a hundred-fold for 40 kDa FITC-dextran, indicating that 
hydrocortisone affected barrier in a size-dependent manner.  
Similar experiments were performed to compare the effects of 
hydrocortisone (HC) and triamcinolone (TA) using 70kDa FITC.  Both 
compounds enhanced barrier function of BMEC.  In fact barrier improvement 
by TA was even greater than that achieved by HC (fig 3.3.1b). 
When we assessed the vasoactive responsiveness of BMEC using the 
vasoactive compounds VEGF and lysophosphatidic acid (LPA) as inducers 
of permeability, we realized that both HC and TA were able to protect BMEC 
against VEGF-induced permeability but not against LPA induced Diabetic Macular Oedema:  The role of steroids and VEGF
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permeability (fig 3.2.2), suggesting that glucorticoids may be able avoid 
barrier breakdown secondary to VEGF but they may be unable to inhibit 
other types of vasoactive stimulation.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.3.1:  Comparison of diffusive flux of FITC and FITC-conjugated 
dextran in the presence and absence of steroids.  Primary cerebral 
microvascular endothelial cells (BMEC) were isolated and grown to 
confluence and passaged onto transwell cell culture chambers.  Cells were 
grown to confluence and 2 days prior to experimentation the medium was 
diluted 1:2 with serum free medium (plus or minus 550nM hydrocortisone).  
The transendothelial permeability was then measured by measuring the flux 
of FITC (389 Da) or 40kDa FITC-coupled dextran (a). In the presence of 
hydrocortisone, the cells formed a much greater barrier to FITC (left).  The 
effect was even greater when repeated with FITC-dextran (right).   When 
similar experiments were performed using a similar concentration of 
triamcinolone we also observed greater barrier function than that achieved 
with hydrocortisone.  Results show a change in the permeability of BMEC to 
70kDa FITC-dextran (b).  P< 0.005.
FITC, fluorescein isothiocyanate; HC, hydrocortisone; TA, triamcinolone
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Figure 3.3.2: Effect of steroids at reducing permeability secondary to 
the vascoactive compounds, VEGF and lysophosphatidic acid (LPA).  
Primary cerebral microvascular endothelial cells (BMEC) were isolated and 
grown in normal growth medium or medium supplemented with 550 nM 
hydrocortisone or 550 nM triamcinolone.  Cells were passaged onto 
permeable transwell cell culture chambers and then exposed to 50ng /ml 
VEGF or 5 µM LPA for 1 hour.  The permeability of 70 kDa FITC dextran 
measured over 4 h.
HC and TA were able to prevent VEGF-induced permeability but were 
unable to prevent LPA induced permeability.  
Note: Within the time limitations of this thesis this experiment could only be 
independently performed twice. Therefore statistical analysis cannot be 
provided
VAC, vasoactive compounds; HC, hydrocortisone, TA, triamcinolone; VEGF, 
vascular endothelial growth factor; LPA, lysophosphatidic acid.  
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3.3.3 The presence of hydrocortisone led to enhancement in 
the spatial localization of the junctional proteins
To compare the effect of steroid on the spatial localisation of junctional 
proteins, BMEC were cultured in the presence or absence of 550 nM 
hydrocortisone for up to 4 weeks.  Cells were then fixed and stained to 
detect changes in the organisation of the junctional proteins.  
Four-week BMEC cultures in the absence of hydrocortisone contained little 
or no Cl-5 or occludin (fig 3.2.3a,b).  In clear contrast, the expression and 
junctional localisation of Cl-5 and occludin was preserved when cells were 
cultured with HC (fig 3.2.3d,e).  Similarly in the presence of HC, junctional 
ZO-1 was also significantly enhanced (fig 3.2.3c,f).  
In contrast we found minimal change in the expression of the AJ proteins (fig 
3.2.4). The only change in the AJ proteins observed was that the junctional 
staining for VEC was more discretely concentrated in junctional areas 
suggesting a qualitative improvement of AJ.  In contrast beta-catenin 
staining was unchanged by the presence of hydrocortisone.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.3.3:  Confocal images of TJ protein in the presence and 
absence of hydrocortisone.  BMEC were grown in culture medium in the 
presence of absence or 550 µM hydrocortisone: –HC or +HC for 4 weeks 
and then fixed with methanol.  Subsequently cells were stained for Cl-5, 
occludin and ZO-1.  In the absence of HC many of the cells expressed little 
or no Cl-5 or occludin.  In contrast, the expression and junctional localisation 
of Cl-5 and occludin was preserved in cells cultured + HC.  Similarly in the 
presence of HC, junctional ZO-1 was significantly enhanced.
Images are full projections of confocal sections spanning the whole cell.
TJ, tight junctions; HC, hydrocortisone; Cl-5, claudin-5; ZO-1, zonula 
occludens -1
20µm
20µm
CL-5 Occludin ZO-1
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Figure 3.2.4:  Confocal images of AJ proteins in the presence and 
absence of hydrocortisone.  BMEC were grown in the absence or 
presence of 550 nM hydrocortisone for 4 weeks and then fixed using 3.7% 
formaldehyde. Subsequently cells were stained for VEC or beta catenin.  
There was little change in the expression of the both VEC and beta catenin 
although for VEC the staining was more discretely concentrated in junctional 
areas suggesting a qualitative improvement of AJ. 
Images are full projections of confocal sections spanning the whole cell.
10µm 10µm
10µm
10µm
+HC
-HC
VEC Beta cateninDiabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 168
3.3.4 Discussion
In our study, we showed that glucocortocoids led to increased barrier 
function and enhanced tight junction protein expression.  TA enhanced 
barrier function more effectively than HC.  Additionally both HC and TA 
inhibited VEGF- but not LPA-induced permeability.   
It has been known for a long time that glucocorticoids can increase the 
barrier properties endothelial cells (INGRAHAM et al., 1952;Long et al., 
1966).  In most of the Transwell experiments we used an HC-supplemented 
medium to allow the formation of a suitable barrier.  However, 48 hours prior 
to experimentation we diluted down the medium 1:2 thus reducing the effect 
of the remaining HC on the control cells.  Additionally our results show a 
significant change in the barrier function of MEC in response to fresh HC and 
therefore we were confident that the residual HC did not exert a significant 
effect on our MEC.  
Hydrocortisone is a naturally occurring glucocorticoid.  The physiological 
range of hydrocortisone is 70 – 550 nM (Karlson P and Doenecke, 1994).  
We chose a dose to mimic the physiological range and has been used by 
other investigators.  In contrast, triamcinolone is a synthetic steroid which 
has been engineered to reduce the mineralocorticoids (salt-retaining) activity 
and thus its side-effect profile.  In injectable form, it is licensed for intra-
articular / intramuscular use.  It has gained popularity for intravitreal injection 
as it forms a depot in the eye which remains in the vitreous for up to 3 
months (Beer et al., 2003).  Additionally, its safety has been well 
documented (Martidis et al., 2002;McCuen et al., 1981).  Diabetic Macular Oedema:  The role of steroids and VEGF
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At the same dose, TA was more effective at increasing the barrier function of 
the cells to 70 KDa dextran, which suggests that it might enhance the barrier 
function in vivo,  even in the presence of high endogenous HC.  Other have 
also shown the increased barrier function of MECs following treatment with 
HC (Hoheisel et al., 1998;Antonetti et al., 2002) but we believe that our 
report is the first to illustrate a beneficial effect of TA on the in vitro barrier 
function of MEC.  
Our BMEC showed an increase in the junctional staining of predominately TJ 
proteins following treatment with HC.  These results corroborate findings of 
others in BMEC (Weidenfeller et al., 2005;Calabria et al., 2006;Romero et 
al., 2003).  Additionally Antonetti and co-workers showed that 103 nM HC 
increases occludin and ZO-1 staining at the cell border of bovine retinal 
endothelial cells (Antonetti et al., 2002).  
Edelman et al (Edelman et al., 2005) showed that corticosteroids inhibit 
VEGF-induced vascular leakage in a rabbit model of BRB breakdown.  Our 
results confirmed that whilst HC and TA clearly attenuated the vasoactive 
response of VEGF they were both unable to inhibit LPA-induced 
permeability.  It is possible that our system does not reflect the true ratio of 
physiological doses of all drugs.  However we used LPA at 5 µM which is 
with-in the physiological range (Baker et al., 2001).  Lysophosphatidic acid 
(LPA) is generated by platelets during blood coagulation for example 
following a cerebral vascular occlusion.  Endothelial cells cultured in vitro
express LPA receptors and its stimulation leads to strong activation of Rho 
and Rho kinase (Hu et al., 2001).  Consequently increases in permeability by 
actin stress fiber formation, contraction of endothelial cells and intercellular 
gap formation have been described (Hu et al., 2001).  We have not observed 
any gap formation between BMEC or RMEC following VEGF treatment 
suggesting that this may be a prerogative of LPA.  Clearly and intuitively the Diabetic Macular Oedema:  The role of steroids and VEGF
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mechanism of vasoactive stimulation is entirely dependent on the stimulus 
used and therefore it is not surprising that GC did not have a universal effect 
in preserving endothelial barriers.  
It is likely that our results demonstrate that corticosteroids exert their effect 
via a specific intracellular pathway such as the downregulation of matrix 
metalloproteinases (MMPs) (Lohmann et al., 2004).  These enzymes play an 
important role in the degradation of occludin (Lohmann et al., 2004).  
Taken together, the opposing effects of VEGF and hydrocortisone on 
permeability and on TJ assembly provide compelling evidence that VEGF 
and hydrocortisone exert their effects at least in part, through specific 
changes in the junctional proteins.  Our results also suggest that 
glucocorticoid may constitute a useful therapeutic option in treating diseases 
that have an underlying VEGF-induced vasoactive complication.Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.4
Randomised controlled trial of intravitreal 
triamcinlone versus laser 
photocoagulation for diabetic macular 
oedemaDiabetic Macular Oedema:  The role of steroids and VEGF
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3.4.1 Introduction
Diabetes Mellitus is the commonest cause of blindness in the working 
population in England and Wales with over 80% due to diabetic maculopathy 
(Evans J, 1995;McMeel et al., 1977).  The prevalence of diabetic 
maculopathy is directly related to the duration of diabetes, with 
approximately 30% of diabetic patients affected after 25-30 years of disease 
(Klein et al., 1984).  As the incidence of diabetes increases, the rate of 
diabetic complications including diabetic macular oedema (DMO) and visual 
loss are set to increase (Amos et al., 1997).
The only proven effective treatment for DMO is laser photocoagulation 
(1985).  However this treatment only reduces the chance of moderate visual 
loss by 50% and is unlikely to improve visual acuity.  As a result, better 
treatments are being sought. 
Initial pilot studies using intravitreal triamcinolone (TA) suggest that it can 
improve visual acuity in patients with DMO in approximately 30% in the 
short-term (Jonas et al., 2003;Martidis et al., 2002).  However long-term 
evidence of efficacy from prospective data is limited.  The aim of this study 
was to determine if repeated TA improves ETDRS best corrected visual 
acuity (BCVA) letter score at 1 year compared to conventional laser therapy 
and whether this treatment has a role to play in the long-term care of 
patients with DMO.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.4.2 Patient enrollment 
A total of 88 eyes from 88 patients were included, of which 43 eyes were 
randomised to receive TA and 45 eyes to receive laser photocoagulation.  
One-year data were available for 83 patients (94%).  5 patients did not 
complete a follow-up.  2 patients died, 1 patient moved away from the area, 
1 patient was unable to travel to the hospital and 1 patient (who received TA) 
refused follow up (fig 3.4.1).  
3.4.3 Baseline characteristics
The baseline characteristics of the patients in each group are shown in 
Tables 3.4.1 and 3.4.2, which show that the groups were comparable with 
regards to all characteristics assessed.Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.4.1:  Consort figure for randomised controlled trial of intravitreal 
triamcinolone verses lasers photocoagulation for diabetic macular oedema.  
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Table 3.4.1:  Baseline characteristics of eyes in randomized 
controlled trial of triamcinolone versus laser treatment.
Triamcinolone (N=43)        Laser (N=45)
Characteristic
Number (%) n* Number (%) n*
male 28 (65.1) 32 (71.1)
left eye 22 (51.2) 29 (64.4)
type II diabetes 43 (100.0) 44 (97.8)
western european 17 (39.5) 22 (48.9)
PDR 8 (19.5) 2 8 (17.8)
hypertensive 40 (93.0) 36 (80)
current smoker 1 (2.4) 1 4 (8.9)
PVD 6 (15) 4 8 (17.8) 7
pseudophakia 8 (18.6) 6 (13.3)
Mean (SD) Mean (SD) 
age 62.3 (7.5) 64.8 (10.1)
Median (IQR) Median (IQR)
previous laser 3 (2-4) 2 (2-4)
duration diabetes (yrs) 15 (10-21) 13 (8-20)
duration CSMO (mths) 27 (15-48) 23.5 (12-31)
duration VL (mths) 12.5 (10-22) 18.5 (9-24)
HbA1c  7.8 (7-8.7) 7 (6.5-8.1)
* n = number of cases data missing on particular characteristic.
PDR, proliferative diabetic retinopathy; PVD, posterior vitreous detachment; 
IQR, interquartile range; CSMO, clinically significant macular oedema; mths; 
months; HbA1c, glycosylated haemoglobin; VL, visual loss.Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.4.2:  Baseline characteristic of eyes in triamcinolone and 
laser groups.
Characteristic (mean) Triamcinolone (SD*) Laser (SD*)
distance visual acuity 54.6 (13.3) 53.0 (14.2)
near visual acuity 0.83 (0.33) 0.82 (0.30)
contrast sensitivity 1.01 (0.32) 1.05 (0.29)
retinal thickness (µm) 413.4 (127.8) 410.4 (134.1)
macular volume (mm
3) 9.74 (2.41) 9.42 (2.02)
IOP (mmHg) 15.9 (2.7) 15.5 (3.1)
Size FAZ 732.0 (182.5) 667.4 (213.6)
SD, standard deviation; IOP, intraocular pressure; FAZ, foveal avascular 
zoneDiabetic Macular Oedema:  The role of steroids and VEGF
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81 injections were performed over the 12 months (mean = 1.9 treatments per 
eye).  In the same period, 73 laser treatments were performed (mean = 1.6 
treatments per eye).  
An outline of the injection profile for the patients undergoing intravitreal TA is 
summarised in table 3.4.3.  10 of 43 patients received all 3 injections.  22 
injections (17%) were not performed due to a resolution of the CSMO on 
clinical examination.  6 injections (5%) were not performed as treatment was 
refused (2 treatments) or the patient failed to attend (4 treatments).  18 
injections (14%) were not performed due to protocol exclusions which 
included:  (i) A rise in the IOP (13 treatments (10%)); (ii) dense cataracts 
obscuring the fundal view (2 patients); (iii) medically unfit. 1 patient (2 
treatments) was deemed unfit for further injections following a myocardial 
infarction just prior to the 2nd injection and 1 patient had a sterile 
endophthalmitis following the 2nd injection.    Diabetic Macular Oedema:  The role of steroids and VEGF
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CSMO, clinically significant macular oedema; DNA, did not attend; IOP, 
intraocular pressure.
Table 3.4.3:  Treatment profile for patients randomised to 
triamcinolone
Reason for missed treatment Number
resolution of CSMO 22
refused treatment / DNA 6   
protocol exclusion – (e.g. raised IOP, 
endophthalmitis, no fundal view)
18
Total  46 / 129Diabetic Macular Oedema:  The role of steroids and VEGF
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3.4.4 Visual acuity
A change in the visual acuity letter score at 12 months is presented in fig 
3.4.2.  Improvement in 15 or more ETDRS letters was seen in 2 of 42 
patients in the TA group (4.8%) and in 5 of 41 (12.2%) patients in the laser 
group (P = 0.265).  
At baseline the mean ETDRS letter scores were 54.6 in the triamcinolone 
group and 53.0 in the laser group.  At 12 months they were 54.4 and 54.7 
respectively and analysis of covariance indicated that there was no evidence 
of a difference between the 2 therapies (P = 0.44) (table 3.4.4).  
Similarly we found little evidence of any differences in the mean near acuity 
(Bailey-Lovie scores) or contrast sensitivity (Pelli-Robson scores). Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.4.2:  Change in the ETDRS letter score in triamcinolone and laser 
eyes at 12 months. 
ETDRS, early treatment of diabetic retinopathy study.Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.4.4:  Comparison of mean visual acuity scores (distance & 
near visual acuity and contrast sensitivity) for study and control eyes 
(standard deviation)
ETDRS letter 
scores Triamcinolone Laser    P value 
(ANOVA)
baseline 54.6 (13.3) 53.0 (14.2)
4 months 55.9 (14.0) 54.7 (18.7)
8 months 53.5 (12.3) 53.4 (19.7)
12 months 54.5 (13.6) 54.7 (17.7)
P = 0.44
Bailey-Lovie
scores Triamcinolone Laser P value 
(ANOVA)
baseline 0.83 (0.33) 0.83 (0.30)
4 months 0.78 (0.29) 0.80 (0.30)
8 months 0.84 (0.34) 0.74 (0.30)
12 months 0.87 (0.33) 0.83 (0.29)
P = 0.64
Pelli-Robson 
scores Triamcinolone Laser P value 
(ANOVA) 
baseline 1.01 (0.32) 1.04 (0.29)
12 months 0.96 (0.36) 0.93 (0.36)
P = 0.95
ETDRS, early treatment diabetic retinopathy study; ANOVA, one-way 
analysis of varianceDiabetic Macular Oedema:  The role of steroids and VEGF
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3.4.5 Retinal thickness and macular volume
At baseline the mean retinal thickness (RT) was 413.4 µm in the study group 
and 410.4 µm in the comparison group (fig 3.4.3).  At 4 months the mean RT 
had fallen to 325.6 µm in the study group and 374.2 µm in the comparison 
group.  At 12 months the mean RT was 322.1 µm in study group and the 
laser group had fallen to 346.7 µm.  Even the largest difference observed 
(i.e. at 4 months) was not statistically significant in these data (P = 0.19) and 
analysis by ANOVA revealed no evidence of a significant difference (P = 
0.738)
At baseline the mean macular volume was 9.74 mm
3 in the triamcinolone 
group and 9.42 mm
3 in the laser group (fig 3.4.4).  At 4 months the mean 
macular volume had fallen to 8.45 mm
3 in the triamcinolone group and 9.08 
mm
3 in the laser group.  At 12 months the mean macular volume was 8.41 
mm
3 in triamcinolone group and the laser group had reduced to 8.66 mm
3.  
Again analysis by ANOVA revealed no significant difference (P = 0.65)  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.4.3:  Change in the mean retinal thickness in study and control 
eyes with time
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Figure 3.4.4:  Change in the mean macular volume in study and control 
eyes with time.  
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3.4.6 Adverse Events
We observed one case of sterile endophthalmitis. (1 case in 78 injections, 
1.3 % of injections, 2.3% of patients). The patient presented at the 1 week 
review, following the third intravitreal injection, with a drop in visual acuity.  
The eye was white, with +1 of cells in the anterior chamber, and a hazy 
vitreous.  A vitreous biopsy was negative and despite intravitreal antibiotics 
there was little change in the appearance of the vitreous 12 months after 
antibiotics administration.
There were 3 cases in 2 eyes of triamcinolone crystals in the anterior 
chamber. All cases were detected immediately following injection and settled 
spontaneously within 2 weeks of injection.  The IOP remained within normal 
limits.  
There was little change in the mean size of the foveal avascalar zone either 
group from baseline to 12 months (study = 758 to 759 µm, control = 682 to 
762 µm).
3.4.6.1 Intraocular pressure
The most common adverse event was a rise in intraocular pressure (table 
3.5.5).  There was a rise in the mean intraocular pressure in the study group 
from 15.9 mmHg to 20.3 mmHg at 4 months.  Furthermore, 22 out of 43 
patients required ocular antihypertensives at some point during follow up.  
However all rises in intraocular pressure were easily managed with one or 
more ocular antihypertensives and further intervention such as vitrectomy to Diabetic Macular Oedema:  The role of steroids and VEGF
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remove the TA crystals or glaucoma filtration procedures were unnecessary.  
There were no cases of glaucoma following TA. Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.4.5.  Changes in the mean intraocular pressure (IOP) in study 
and control groups. (range)
IOP 
measurements 
(mmHg)
Triamcinolone Laser P value
baseline 15.9 (8-20) 15.5 (10 -21) 0.5
4 months 20.3 (12-32) 15.0 (10-23) <0.01
8 months 20.1 (12-48) 15.0 (8-22) <0.01
12 months 18.2 (12-26) 14.6 (11-21) <0.01
IOP, intraocular pressureDiabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 188
3.4.6.2 Cataract progression
The only statistically significant change was in the degree of posterior 
subcapsular lens opacity (PSCLO) in the TA group compared with the laser 
group (fig 3.4.5).  The degree of lens PSCLO changed in the TA eyes from a 
mean of 1.1 to 1.9, while the laser eyes changed for a mean of 1.1 to 1.3.  
2 eyes in the TA group and 1 eye in the laser group underwent additional 
cataract surgery during the follow up for visually significant lens opacity. Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.4.5:  Mean change in the degree of lens opacity from baseline to 
12 months in triamcinolone and laser eyes. 
PSCLO, posterior subcapsular lens opacity.Diabetic Macular Oedema:  The role of steroids and VEGF
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3.4.7 Discussion
Our study directly compared intravitreal TA injection with argon laser 
photocoagulation for patients with persistent CSMO.  TA is unlikely to gain 
acceptance in clinical practice unless it confers a significant advantage over 
conventional laser photocoagulation and consequently the primary endpoint 
was the proportion of patient in each group with improved visual acuity.  The 
sample size calculations were based on a 17% difference which was 
calculated from the original 2 pilot studies.  
This study did not achieve the primary endpoint of an improvement of 15 
ETDRS letters at 12 months in the TA compared to the laser group.  
Preliminary studies had shown an improvement in VA and a reduction in 
central retinal thickness in CSMO (Jonas et al., 2003;Martidis et al., 2002).  
However these studies were typically uncontrolled. There was a small 
reduction in macular thickness in the short-term following TA in this study, 
although this was not statistically significant from the laser group.  It is 
possible that our study was underpowered to show a significant difference. 
This seems unlikely as no difference was noted from the controls at any time 
point with respect to visual acuity and retinal thickness.  In addition the visual 
outcome was better in the control group than in the TA group.  
The Diabetic Retinopathy Clinical Research Network (DRCRN) evaluated 
the efficacy of 1mg and 4 mg doses of preservative free TA with laser 
photocoagulation (2008).  This was a large multi-centred randomised 
controlled trial of similar design to our own, comparing 1 mg and 4 mg TA 
with macular laser photocoagulation with a primary outcome measure was at 
2 years.  The only difference in the baseline characteristics of this study 
compared to our study was a better baseline VA.  This probably reflects the Diabetic Macular Oedema:  The role of steroids and VEGF
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fact that 40% of patients had no prior intervention for DMO and therefore it is 
likely that they had a shorter duration of CSMO.   Both at 1 and 2 years there 
was no significant differences in visual acuity among the groups.  
The DRCRN suggested that TA had a better outcome over the natural 
history of DMO.  The best estimate of the natural history in eyes with DMO 
comes from the treatment group in the ETDRS in which focal/grid 
photocoagulation was deferred.  The incidence of MVL,(defined as a loss of 
15 letters on the ETDRS chart ) if treatment was deferred was 8% at 1 year.  
Our study was not powered to look at the risk of MVL however the incidence 
of MVL in the control group was comparable to the ETDRS (7%) whereas 
the incidence of MVL was in the study group was 12% (5 of 42 eyes).  This 
suggests that the results of TA are worse than the natural history for DMO, 
however our patients had persistent DMO and therefore are not directly 
comparable.  Furthermore, there was no change in the size of foveal 
avascular zone was seen form baseline to 12 months in the TA group.  In 
particular the sudden increase in IOP associated with injection did not 
increase non perfusion of the macular and therefore it is unlikely that TA is 
worse than the natural history of DMO.  However further studies are required 
to further investigate the effects on MVL.
Gillies and co-workers published a study suggesting benefits of 
triamcinolone for visual acuity after 2 years (Gillies et al., 2006).  This was a 
prospective randomised study in which the primary endpoint was a 5 letter 
gain compared to 15 letter gain in this study.  Furthermore 50% of their 
patients had cataract surgery in the 2nd year of study and these 2 factors 
may explain, at least in part, the different study outcomes.  Interestingly, this 
study showed slight progression of posterior subcapsular cataract in the TA
group.  Although this change was statistically significant, we did not feel that Diabetic Macular Oedema:  The role of steroids and VEGF
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it was clinically significant there was no reduction in the retinal thickness in 
the patients with an increase in lens opacity.  
Similarly, Avitabile and colleagues found a positive effect on both visual 
acuity and central retinal thickness in eyes treated with TA and TA combined 
with laser (Avitabile et al., 2005b).  Despite the effect of the TA regressing at 
6 months and some patients requiring a second injection, the results of TA 
were in marked contrast to laser.  Eyes treated with laser alone had no 
change in either visual acuity or central retinal thickness.  
The most significant difference between this study and our own is the 
duration of macular oedema.  Our aim was to include patients with reversible 
macular oedema, however in reality our study population included patients 
with a long duration of macular oedema (median duration 27 months, IQR 
15-48 months).  In comparison, the duration of macular oedema was 6-12 
months (mean 9 months) for the study by Avitabile and colleagues (Avitabile 
et al., 2005b).  Additionally the inclusion criteria for this trial were a visual 
acuity between 6/12 to 3/60.  Patients were excluded if they had severe 
macular ischaemia but patients with a moderate amount of ischaemia were 
included.  The estimate of macular ischaemia was made by the study 
investigators and not by independent graders.  Therefore this study was 
biased towards patients with chronic macular oedema and included patients 
with quite advanced ischaemia.  Although the population of patients selected 
for this trial is likely representative of patients that undergo intravitreal TA in 
clinical practice and suggests that patients with DMO should be treated early 
before irreversible changes occur.  Perhaps if we had excluded patients with 
chronic macular oedema, we would have found a significant improvement in 
visual acuity.Diabetic Macular Oedema:  The role of steroids and VEGF
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The study was designed to give repeated intravitreal injections to determine 
whether prolonged intravitreal TA improves visual acuity long-term compared 
to a single injection which may have only a transient effect.  It is notable that 
46/129 injections were not performed (28 of the 46 were the third injection).  
It could be postulated that the significant number of 3rd injections not 
performed may have adversely effect on outcome; if for instance, the first 2 
injections had led to a significant improvement in visual acuity and reduction 
in central macular thickness.  However, this is unlikely as at no study time-
point there was a significant improvement in visual acuity or a decrease in 
central macular thickness or macular volume.  It may be possible to have 
given final injections by raising the intraocular pressure threshold to exclude 
fewer patients.  However, by choosing a threshold of 30 mmHg, there were 
no serious cases of persistent raised intraocular pressure requiring filtration 
surgery.  
Additionally, based on the recommended guideline for macular laser, 
retreatment was performed every 4 months.  A 4 mg intravitreal TA dose 
provides continual treatment for approximately 3 months before some eyes 
begin to have recurrent macular thickening (Beer et al., 2003).  Perhaps, if 
we had chosen a retreatment time of 3 month, more patients would have 
reached our primary outcome measure.  
At 1 month, a reduction in retinal thickness was detected (results not shown), 
which concurs with the results for initial pilot studies.  Based on these results 
and the results of other investigators, TA maybe utilised as an adjunctive 
therapy to first reduce retinal thickness before applying macular laser 
photocoagulation.  This combined treatment may prove more effective at 
reducing the risk of moderate visual loss associated with DMO and the 
DRCRN is currently recruiting for patients in a trial to assess the efficacy of 
this treatment.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Similarly, intravitreal TA may have a role in treating DMO (in the absence of 
significant ischaemia) in patients where laser treatment had failed.  
Additionally, it may have a role in macular oedema associated with other 
disease processes such as branch retinal vein occlusions and pseudophakic 
macular oedema
In conclusion, this study was relatively small, with limited follow up.  It 
directly compared TA to conventional macular laser therapy, which is the 
only recognised standard treatment for CSMO.  However, the patient 
population tended to have chronic CSMO.   There were few side effects with 
only one case of sterile endophthalmitis and no cases of retinal detachment 
or glaucoma.  However, neither TA nor laser treatment led to an 
improvement in visual acuity nor a reduction in central retinal thickness at 
any time point.  Therefore we did not find evidence to support the use of 
triamcinolone as a routine treatment for chronic CSMO.  Since other studies 
suggest a role for intravitreal triamcinolone early in the treatment for CSMO 
aggressive treatment for CSMO should be undertaken as early as possible 
in order to avoid permanent structural changes.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.5
Do the morphological characteristics 
demonstrated by optical coherence 
tomography predict the outcome of 
treatment for persistent diabetic macular 
oedema?Diabetic Macular Oedema:  The role of steroids and VEGF
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3.5.1 Introduction
Optical coherence tomography (OCT) is a quick, non-invasive and 
reproducible method of producing high-resolution, cross-sectional images of 
the retina (Massin et al., 2001).  It is based on the principle of low-coherence 
interferometry, which measures the time of flight delay of light reflected from 
ocular structures (Baumal, 1999) analogous to the ultrasound B-scan (Hee 
et al., 1998).  Low-coherence infrared light is produced by a continuous-
wave, superluminescent diode source, which is coupled into a fibre optic 
Michelson interferometer (Baumal, 1999).  The echo delay and intensity of 
reflected light from internal tissue structures can be measured to produce 2-
and 3D-images of the retina (Drexler et al., 2003). 
A number of studies have been undertaken to correlate OCT images with 
histology.  It is well established that the internal boundary corresponds to the 
internal limiting membrane and is well defined because of the contrast 
between the non-reflective vitreous and the highly reflective retina, while the 
external boundary represents the internal edge of the retinal pigment 
epithelium.  However, there appears to be some debate between the 
relationship between OCT banding and specific retinal layers.  While Toth et. 
al. consider that the retinal morphology obtained by OCT correlates with 
those obtained by light microscopy, Chauhan & Marshall argue that OCT 
bands do not represent specific retinal layers (Toth et al., 1997;Chauhan and 
Marshall, 1999).  Ultra-high resolution OCT images (not yet commercially 
available) have now been compared with histology with a high degree of 
concordance (Drexler et al., 2003).  
However the retinal thickness measured by OCT has been shown to 
correlate with the thickness of retina in histological specimens (Chauhan and Diabetic Macular Oedema:  The role of steroids and VEGF
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Marshall, 1999) and although these data do not replace visual acuity (VA), it 
is a useful adjunct and studies shown that retinal thickness broadly 
correlates with VA (Hee et al., 1998;Otani and Kishi, 2007;Yang et al., 2001).  
Recently a classification of different morphological OCT appearances in 
DME has been reported but their clinical significance remains unclear 
(Panozzo et al., 2004).  This study aimed to describe the various 
morphologic OCT appearances seen in DME, to correlate them with the 
baseline visual acuity and to determine if any morphological subtype was 
predictive of the response to intervention.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.5.2 Baseline characteristics and visual acuity
88 eyes of 88 patients were included in the original randomised controlled 
study.  87 (99%) baseline OCTs were available for analysis of OCT 
morphologic characteristics. Only one radial line scan was available for 
grading in 1 eye (1.1%). 
Baseline demographics included 37 right eyes, a male to female ratio of 2:1, 
a mean (SD) patient age of 63.7 (+/-9.0) years and a mean duration of 
diabetes of 15.5 (+/-9.9) years.  Prior focal laser photocoagulation had been 
performed a mean 3.1(+/-1.5) times.  14 eyes (11.5%) were pseudophakic. 
An average of 1.7 treatments (laser or TA) were performed during follow up.  
The mean visual acuity (SD) was 53.8 letters (+/-13.7) at baseline and 55.3 
letters (+/-14.5) at 12 months.  Improvement of ≥15 ETDRS letters occurred 
in 7 (8%) patients and a decline of ≥15 ETDRS letters occurred in 7 (8%) 
patients.  Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 199
3.5.3 Morphological characteristics 
Eyes were graded according the presence or absence of cystoid macular 
oedema (CME), neurosensory detachment (NSD), posterior hyaloid traction 
(PHT) and abnormal macular profile (AMP).  2 OCT scan were ungradable 
with respect to CME and 1 was ungradable for NSD.  There was a moderate 
to good degree of interobserver and intraobserver agreement (table 3.5.1).
The most frequent characteristic was the presence of CME (85%) (fig 3.5.1)  
1 eye (1%) had an increased retinal thickness without any of the 4 key 
subtypes.  68 of 74 eyes (91.9%) with CME had other features.  20 of 21 
eyes with NSD had CME but only 8 of the 21 eyes with NSD had PHT.  PHT 
was always seen in association with CME.  NSD and traction were never 
seen concurrently without other features.  Only 1 eye had a NSD with an 
apparently normal overlying retina.  
A subset of eyes with DME had NSD (21/87, 24%), which was only 
correlated with PHT in 9/24 eyes, had a shorter natural history of DME (19 
vs 37 months, P=0.005) and of reduced visual acuity (14 vs 19 months, 
P=0.05) than eyes without NSD (table 3.5.2).Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 200
  
CME, cystoid macular oedema; NSD, neurosensory detachment; PHT, 
posterior hyaloidal traction, AMP, abnormal macular profile.  
Figure 3.5.1:  Venn diagram illustrating the number of eyes that fall into 
each morphological subtype (percentage).  
CME = cystoid macular oedema, NSD = neurosensory detachment; PHT, 
posterior hyaloidal traction, AMP, abnormal macular profile.  
Table 3.5.1:  Interobserver and intraobserver agreement 
between graders
Kappa value Morphological 
subtype Interobserver Intraobserver
CME 0.447 0.392
NSD 0.638 0.718
PHT 0.713 0.598
AMP 0.546 0.738
AMP, n=66 (76%)
NSD,   
n=21 (24%)
PHT, n=28 
(32%)
CME,n=74 (85%)
7
6
7
1
5
30
2 5
6 14
No subtype 
1 (1%)Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 201
  
Table 3.5.2: Comparison of baseline characteristics in each of the 
morphological subtypes.   
Morphological 
subtype n CSMO 
(mths) P value Visual loss 
(mths) P value
present 75 28.2 29.7
CME absent 10 33.6 0.5 16.1 0.09
present 21 19 13.6 NSD absent 65 37.3 0.003 19.3 0.05
present 8 26.5 15.9
PHT absent 59 35.4 0.2 21.5 0.2
present 66 30.8 20.6
AMP absent 21 37.8 0.6 17.5 0.4
CSMO, clinically significant macular oedema; mths, months; CME, cystoid 
macular oedema; NSD, neurosensory detachment; PHT, posterior hyaloidal 
traction; AMP, abnormal macular profile.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.5.4 Comparison of visual acuity and retinal thickness for 
each of the four morphological subtypes.
The presence of a NSD, PHT or AMP did not correlate with the BCVA, (fig 
3.5.2, top).  In contrast, eyes with CME had a statistically significantly lower 
BCVA than eyes without CME (CME, 53 letters; no CME, 61 letters, P=0.05).  
Similarly, eyes with CME had a statistically significant increase in retinal 
thickness compared to eyes without CME (CME, 418µm; no CME, 354µm; 
P=0.04), as did eyes with an abnormal macular profile.  (abnormal profile, 
436µm; normal profile 314µm; P=0.0005) (fig 2, bottom).  There was no 
difference in the central retinal thickness in eyes with or without traction or a 
NSD.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.5.2:  Differences in the baseline BCVA (top) and retinal thickness 
(bottom) with respect to the different morphological subtypes.  
BCVA, best corrected visual acuity; ETDRS, early treatment diabetic 
retinopathy study; CME, cystoid macular oedema; NSD, neurosensory 
detachment, PHT, Posterior hyaloidal traction; AMP, abnormal macular 
profile.  
P=0.05
P=0.1
P=0.9
P=0.2
25
30
35
40
45
50
55
60
65
70
75
CME NSD PHT AMP
B
C
V
A
 
(
E
T
D
R
S
 
l
e
t
t
e
r
s
)
present
absent
P=0.0005
P=0.2
P=0.07
P=0.04
200
250
300
350
400
450
500
CME NSD PHT AMP
R
e
t
i
n
a
l
 
t
h
i
c
k
n
e
s
s
 
(
µ
m
)
present
absentDiabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 204
3.5.5 Change in mean visual acuity and retinal thickness 
from baseline to 12 months for each of the four OCT 
characteristics.   
None of the morphological subtypes was predictive of the change in VA nor 
retinal thickness from baseline to 12 months following treatment (laser or 
triamcinolone) (figure 3.5.3).  Additionally, none of the morphological 
subtypes was predictive of final VA for laser and triamcinolone alone (results 
not shown).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.5.3:  Comparison of the mean change in BCVA (top) and retinal 
thickness (RT) (bottom) from baseline to 12 months for each of the four 
morphological subtypes distinguished by OCT.  
BCVA, best corrected visual acuity; ETDRS, early treatment of diabetic 
retinopathy study; CME, cystoid macular oedema; NSD, neurosensory 
detachment; CRT, central retinal thickness; PHT, posterior hyaloidal traction; 
AMP, abnormal macular profile.  
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3.5.6 Discussion
Fundus fluorescein angiogram is clinically the most widely available and 
useful clinical test to assess vascular hyperpermeability.  It permits study of 
the circulation of the retina and choroid in normal and diseased states (Jaffe 
et al., 1981).  In recent years, the availability of optical coherence 
tomography (OCT) has changed the clinical management of many eye 
conditions.  
Optical coherence tomography is a non-invasive device that obtains cross-
sectional, high-resolution images of the retina that provides repeatable 
values of retinal thickness (Huang et al., 1991).  Additionally, images can 
also be used to determine microstructural features and investigators have 
debated whether this is can be correlated with histological features.  During 
DMO, fluid first accumulates within the Muller cells, which may correspond to 
the OCT appearance of sponge-like swelling, namely increased retinal 
thickness in the absence of cystic spaces.  Later, with cellular death, 
extracellular fluid arises in the inner and outer plexiform layers and this has 
been correlated to the cystic spaces observed on OCT. 
Previous reports have evaluated the incidence of various patterns of DME on 
OCT; diffuse retinal thickening (DRT) that is increased retinal thickness with 
areas of reduced intraretinal reflectivity, CME, NSD and PHT (Otani and 
Kishi, 2007;Panozzo et al., 2003;Brasil et al., 2007;Ozdemir et al., 
2005a;Catier et al., 2005).  In our study, the incidence of DRT correlated with
the absence of CME, and therefore we did not report this as a separate 
subtype.  In addition, we also evaluated our OCTs with respect to the 
presence or absence of normal concave macular profile.  Diabetic Macular Oedema:  The role of steroids and VEGF
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The presence of each subtype has been reported at 40 -85% for CME (Brasil 
et al., 2007;Otani and Kishi, 2007;Yamamoto et al., 2001;Panozzo et al., 
2003;Kim et al., 2006), 15 – 37% for NSD (Otani and Kishi, 2007;Panozzo et 
al., 2003;Ozdemir et al., 2005a;Brasil et al., 2007;Catier et al., 2005) and 16 
– 28% for PHT (Brasil et al., 2007;Kim et al., 2006).  Despite being reported 
separately each subtype may also occur concurrently.  Our data were
collected using an OCT 3000 which is a scanner of higher resolution than 
that used to generate some of the earlier data.  This may partially explain our 
high prevalence of all 3 subtypes.  Additionally, the study investigator 
selected 2 perpendicular line scans to try the capture the maximum amount 
of pathology for each eye.  
There are obvious limitations of this study.  The most obvious is that this is a 
small retrospective case series with limited follow up.  The patients were 
randomized to one of 2 interventions – laser or intravitreal triamcinolone and 
here we report the 2 treatments as one larger group.  When analysed as 2 
separate groups, there were no differences but the number of patients in 
each was small.  Finally, our patients had persistent DMO despite previous 
laser treatment and this chronicity of the disease undoubtedly has an 
influence on the impact of treatment.  Therefore, it would be interesting the 
repeat this study on eyes with CME prior to initial treatment.   
NSD is seen on OCT as a triangular or dome shaped non-reflective
intraretinal space with its greatest height at the central foveal.  It is seen 
adjacent to the hyper-reflective line of the pigment epithelium, with a well-
defined inner border and is of similar appearance during other disease 
processes such as branch retinal vein occlusion or following retinal 
detachment repair (Yamaguchi et al., 2006;Schocket et al., 2006). It is 
exclusively observed topographically and not clinically or with FFA.  As a 
result, it has only recently been described.  Therefore the significance of a Diabetic Macular Oedema:  The role of steroids and VEGF
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NSD is not yet apparent.  We observed that NSD was present when the 
macular oedema was of shorter duration than in eyes without NSD.  These 
data correspond to that of Gaucher et. al., who reported that an NSD occurs 
in 20% of cases when the overlying neuroretina is of a normal thickness 
(Gaucher et al., 2008).  They and others found no relationship between NSD 
and VA  (Catier et al., 2005;Massin et al., 2001) as it was in our study.  Otani 
et al observed that during the treatment of DMO, the NSD transiently 
enlarged in 3 eyes and developed transiently in another 3 eyes and they 
interpreted this as the movement of fluid from the retina to the subretinal 
space during the process of macular oedema absorption (Otani and Kishi, 
2000).  Another study describes it later in the disease evolution (Soliman et 
al., 2008), 
The relevance of NSD is yet to be determined.  More information, perhaps in 
the form of a large longitudinal study, is required to determine the 
significance of this feature and to understand if it truly represents the efflux 
of fluid through the RPE.  Additionally it maybe associated with a drop in 
visual acuity and therefore the patient presents to the ophthalmologist 
sooner than if it were not to form.  
In contrast, the presence of CME was associated with a worse VA which 
was comparable to that reported by Kim et al (Kim et al., 2006).  Due to 
distortion of the normal anatomy and the loss of the foveal pit it becomes 
increasingly difficult to determine the exact position of the CME and to 
assess the thickness of the surrounding retina.  Therefore, it was difficult to 
conclude from OCT if there was intraretinal or extracellular oedema and 
reflects our lack of true understanding about exact correlation between the 
morphological characteristics on OCT and the histological appearance.  Diabetic Macular Oedema:  The role of steroids and VEGF
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With more recent advances in OCT technology the resolution of the images 
has increased from 10 µm to 3 µm and it will be interesting to observe if high 
resolution OCT improves correlations with histopathological changes.  
Perhaps, then we will be able to identify morphological patterns that identify 
intracellular oedema and extracellular oedema that is reversible from 
irreversible changes.  
It has been suggested that CME and PHT are predictive of a poor outcome 
following intervention (Brasil et al., 2007).  In contrast, the presence of a 
NSD does not necessarily correlate with the visual outcome following laser 
or intravitreal TA (Brasil et al., 2007;Gaucher et al., 2008).  However, its 
presence predicted a poorer visual outcome following vitrectomy and inner 
limiting membrane peel (Shah et al., 2006) and following laser for branch 
vein occlusion (Ohashi et al., 2004).  In our study, none of the OCT subtypes 
were predictive of the outcome of intervention. 
In conclusion, CME was associated with poor baseline but not final visual 
acuity suggesting that CME cases should be treated.  Some patients with 
DME develop a NSD, apparently unrelated to traction, with a more rapid 
onset of visual loss and should be considered for early treatment.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.6
Combined vitrectomy and intraocular 
triamcinolone for diabetic macular oedemaDiabetic Macular Oedema:  The role of steroids and VEGF
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3.6.1 Introduction
Initial pilot studies using intravitreal triamcinolone (TA) suggested it can 
improve visual acuity (VA) in patients with diabetic macular oedema (DMO) 
in the short-term (Massin et al., 2004;Jonas and Sofker, 2001;Martidis et al., 
2002).  However repeated injections are often necessary due to a recurrence 
of the macular oedema.  The vitreous has implicated in the production of 
DMO.  Eyes with diabetic retinopathy are much more likely to develop 
macular oedema if the vitreous is still attached (Nasrallah et al., 1988).  It is 
postulated that an attached posterior hyaloid may cause tangential macular 
traction leading to macular oedema.  Additionally vitrectomy may be useful in 
the absence of obvious traction (Tachi and Ogino, 1996;Ikeda et al., 
1999;Ikeda et al., 2000;La Heij et al., 2001).  
By combining these two novel therapies there may be some benefit from 
approaching the disease process using two different strategies.  The aim of 
this exploratory study was to evaluate the safety and long-term efficacy of 
combined PPV and intraocular TA in patients with persistent DMO and if this 
intervention reduced the need for reinjections of TA.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.6.2 Baseline characteristics
This study was conducted in accordance with the ethical standards of the 
Declaration of Helsinki and were approved by the local Research and Ethics 
Committees at Moorfields Eye Hospital.  Patients were recruited via the 
Medical Retinal Service at Moorfields Eye Hospital between February 2003 
and May 2004.  Written informed consent was obtained from all patients 
before details of medical and ophthalmic examinations were recorded.  
16 patients were eligible for the study.  3 patients declined entry into the 
study and 1 patient was excluded from the study due to minimal DMO.  A 
total of 12 eyes from 12 patients were recruited for this study.  All the 
patients underwent a standard 20 G 3 port PPV with 4 mg in 0.1 ml TA 
injected into the vitreous cavity at the end of the operation.  All patients
completed all the follow up visits.  The baseline characteristics of the 
patients are shown in the table 3.6.1.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.6.1:  Baseline characteristics of patients undergoing PPV 
with TA
Variable Number (%)
male 9 (75 %)
left eye 4 (33 %)
type 2 diabetes 9 (75 %)
systemic hypertensive 10 (83 %)
pseudophakia 1 ( 8 %)
proliferative diabetic retinopathy 7 (58 %)
Variable  Median (IQR) n*
age 61.5 (52.5-66.5)
HbA1c 7.1 (6.6-7.6)
duration diabetes (years) 15.5 (13.5-21)
duration of oedema (months) 49 (24-54) 1
duration of visual loss (months) 24.5 (20.5-40.5)
Number previous macular laser 
treatments Number (%) n* = 4
3 2 (17 %)
4 3 (25 %)
5 1 (8 %)
7 2 (17 %)
Variable Median (IQR)
distance visual acuity (ETDRSletters) 53.5 (50-58.5)
central macular thickness (µm) 409.5 (312.5-508)
IOP (mmHg) 16 (15.5-18)
*n = number of cases data missing on particular characteristic.
PPV, pars plana vitrectomy; TA, triamcinolone; IQR, interquartile range; 
HbA1c, glycoslylated haemaglobin; ETDRS, early treatment of diabetic 
macular oedema; IOP, intraocular pressure, mmHg, millimeters mercury.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.6.3 Distance visual acuity
4 of 12 eyes showed an improvement of 10 or more ETDRS letters (2 lines 
Snellen acuity) at four months and 2 of 12 eyes showed an improvement of 
10 or more letters at 12 months (fig 3.6.1).  Both patients were relatively 
young (24 and 35 yrs), had type 1 diabetes with treated proliferative diabetic 
retinopathy.  4 of 12 eyes lost 10 or more letters at 12months.  
The median letter score at baseline was 53.5 letters (fig 3.6.2).  The median 
letter score was 59.5 letters at four months and 51 letters at twelve months.  
3.6.4 Median central retinal thickness
The median retinal thickness was 409.5 µm at baseline (fig 3.6.3).  The 
retinal thickness had fallen to 289.5 µm at 4 months and 387 µm at 12 
months.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.6.1:  Changes in the BCVA letter scores following combined 
vitrectomy with triamcinolone. 
BCVA, visual acuity; ETDRS, early treatment of diabetic retinopathy study.   Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.6.2:  Change in the median BCVA letter scores over time in 
patients undergoing combined vitrectomy with triamcinolone.  Central line 
illustrates the median value, the boxes illustrate the interquartile range and 
the extremes illustrate the minimum and maximum values.  
ETDRS, early treatment of diabetic retinopathy study.  
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Figure 3.6.3:  Change in median retinal thickness over time in patients 
undergoing combined vitrectomy with triamcinolone.  Central line illustrates 
the median value, the boxes illustrate the interquartile range and the 
extremes illustrate the minimum and maximum values. Diabetic Macular Oedema:  The role of steroids and VEGF
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3.6.5 Safety
One patient was noted to have an entry site break at the time of surgery 
which required laser retinopexy and a C3F8 gas tamponade.  A second 
patient had a pneumatic retinopexy for a small superior retinal detachment.  
The retinae in both patients remained attached throughout follow up.  One 
patient had a vitreous haemorrhage immediately following surgery which 
cleared spontaneously within 4 weeks.
A change in the median intraocular pressure (IOP) is shown in fig 3.6.4.  4 of 
12 eyes required topical antihypertensive treatment because of an increased 
IOP of more than 30 mmHg following the combination therapy.  All rises in 
IOP were transient and ocular antihypertensives were stopped within 1 
month of the surgery.   
There was an overall increase in the amount of nuclear sclerotic lens opacity 
from baseline to 12 months (baseline, 0.5; 12 months, 1.875) and two 
patients required a cataract extraction during the 12 month follow up period.  
Finally, there was no change in the size of the foveal avascular zone from 
baseline (baseline median 643 µm; 12 months, median 652 µm).Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.6.4:   Change in median intraocular pressure over time in patients 
undergoing combined vitrectomy with triamcinolone.  Central line illustrates 
the median value, the boxes illustrate the interquartile range and the 
extremes illustrate the minimum and maximum values. 
mmHg, millimeters of mercury. Diabetic Macular Oedema:  The role of steroids and VEGF
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3.6.6. Discussion
The results of this exploratory study indicated that there was a short term 
improvement in visual acuity and a reduction in macular thickness following 
PPV and intraocular TA for patients with persistent DMO.  However the long-
term improvement in visual acuity (12 months) was limited to a small number 
of patients.  
Vitrectomy for eyes without clinically visible traction is reported to be useful 
in eyes with DMO (Tachi and Ogino, 1996;Ikeda et al., 1999;Ikeda et al., 
2000;La Heij et al., 2001).  Following vitrectomy, oxygen transport to retinal 
area and the clearance of VEGF and other cytokines improved (Funatsu et 
al., 2003;Stefansson et al., 1990a). However the anatomical and functional 
recovery in eyes without clinically visible traction can be often be slow and 
unpredictable (Patel et al., 2006b;Patel et al., 2006a;Massin et al., 2003;La 
Heij et al., 2001).  Additionally we sought to assess the VEGF-lowering effect 
of vitrectomy with corticosteroids. 
Although our study was not designed to assess the short-term effects of PPV 
with TA, an OCT was performed at 1 week and 1 months which showed that 
there was an immediate reduction in retinal thickness in most patients 
(results not shown) suggesting that there was a predictable effect of PPV 
with the addition of TA.  
There were no serious long-term consequences of our intervention; however 
4 eyes had a reduction in VA at 12 months.  Although there was no change 
in retinal thickness or in the dimensions of the FAZ in these patients, we 
speculate that the deterioration was due to continuing diabetic maculopathy; 
both DMO and occult macular ischaemia and associated neuronal cell death.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Furthermore, the 2 eyes that required cataract extractions did not have an 
improvement in the BVCA compared to baseline following the additional 
surgery.  
This study was designed with a single intraocular injection of triamcinolone in 
order to test the hypothesis that PPV may reduce the need for repeat 
injections.  Our results suggest that a short-term improvement in visual 
acuity and reduction in retinal thickness can be achieved from the 
combination therapy but in most patients there is a recurrence of the DMO 
and regression in the visual improvement achieved after 4 months 
suggesting that further intervention is necessary.  However, we speculate 
that further injections would add little benefit to these patients.  The vitreous 
acts as a relative barrier to the anterior movement of growth factors and 
drugs and therefore in the absence of the vitreous the half life of TA is 
reduced.  
Furthermore one of the main weaknesses of this trial is the chronicity of the 
macular oedema.  We tried to include patient with a short disease duration 
but in reality the patients we actually recruited had a chronic persistent DMO 
persist.  Most of the patients had had at least previous macular laser 
treatments.  
This study was small and with limited follow-up.  The study population were 
patients with persistent macular oedema despite at least 1 prior laser 
photocoagulation.  However many of our patients had many previous 
macular laser treatments and a long duration of macular oedema and visual 
loss.  Interestingly, the 2 patients who responded well to surgery at 12 
months were younger and had type I diabetes.  It is possible that this 
exploratory treatment could have a beneficial effect at 12 months for patients Diabetic Macular Oedema:  The role of steroids and VEGF
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at an earlier stage of their macular disease; for example younger patients, 
with better visual acuities or with disease duration less than 6 months and 
possibly reversible macular changes.   
In this study we found that combining pars plana vitrectomy with intraocular 
triamcinolone has a transient beneficial effect on improving VA and reducing 
macular oedema.  However, recurrence of macular thickening is still a main 
problem after the combination therapy.  Diabetic Macular Oedema:  The role of steroids and VEGF
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Chapter 3.7
The intraocular concentration of VEGF 
before and after combined vitrectomy and 
intraocular triamcinolone for diabetic 
macular oedema.Diabetic Macular Oedema:  The role of steroids and VEGF
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3.7.1 Introduction
Vascular endothelial growth factor (VEGF) is a vasopermeability agent found 
in eyes with diabetic macular oedema (DMO) as well as active diabetic 
retinopathy (Funatsu et al., 2006;Aiello et al., 1994).  Elevated VEGF 
concentrations in the eye are correlated with progression of diabetic 
retinopathy following vitrectomy (PPV) (Funatsu et al., 2005).  It is unknown 
if elevated concentrations can predict the outcome of treatment for DMO.  
This study assayed VEGF concentrations in the eye before and after 
combined vitrectomy and intravitreal triamcinolone to assess whether pre-
operative vitreous VEGF concentrations were predictive of functional and 
anatomical outcomes.   Diabetic Macular Oedema:  The role of steroids and VEGF
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3.7.2 Baseline characteristics
12 eyes of 11 patients were enrolled in the study.  The baseline 
characteristics are summarised in table 3.7.1.  The median age was 58 
years, (IQR 42.5–64.5), the median duration of diabetes was 15 years, (IQR 
13.5–20) and the median duration of macular oedema was 48 months, (IQR 
23-52).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Table 3.7.1:  Baseline characteristics of patients undergoing 
combined vitrectomy with triamcinolone
Characteristic Median IQR
age 58 42.5,64.5
duration diabetes (yrs) 15 13.5, 20
duration DMO (mths) 48 23, 52
HbA1c 7.3 6.6, 7.6
size FAZ 624 440, 766
BCVA 53.5 (45, 58.5)
retinal thickness 506.5 (364, 527.5)
IQR, interquartile range; HbA1c, glycosylated haemaglobin; DMO, diabetic 
macular oedema; FAZ, Foveal avascular zone; BCVA, best corrected visual 
acuity.Diabetic Macular Oedema:  The role of steroids and VEGF
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3.7.3 Outcome of vitreous surgery
At four months, the visual acuity in 3 eyes had improved by ≥10 ETDRS 
letters.  At twelve months, 2 eyes had improved by ≥10 ETDRS, while 4 eyes 
had deteriorated by ≥10 ETDRS (fig 3.7.1, top).  The median BCVA was 
53.5, 57.5 and 50 letters at baseline, four and twelve months respectively.  
The median central retinal thickness was 506.5, 354 and 387 µm at baseline, 
four and twelve months respectively (fig 3.7.1, bottom).  2 patients 
underwent cataract extraction at 8 months for visually significant lens 
opacities.  
At baseline, the median concentration of VEGF in the vitreous (574.6 pg/ml, 
IQR 123.7, 678.2) was higher than in the aqueous (79.7 pg/ml, IQR 55.6, 
172.5).   At 1 week the median aqueous VEGF concentration had reduced to 
60.9 pg/ml (43.5, 126.9, while at 4 months it had risen from baseline to 91.2 
pg/ml (IQR, 75.6, 120)Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.7.1:  Change in the BCVA letter scores (top) and central retinal 
thickness (bottom) following combined vitrectomy with intraocular 
triamcinolone. The central line illustrates the median value, the box 
illustrates the interquartile range and the extremes illustrate the minimum 
and maximum values.  
BCVA, best corrected visual acuity; ETDRS, early treatment of diabetic 
retinopathy studyDiabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.7.2:  Change in the concentration of VEGF in the aqueous at 
baseline, 1 week and 4 months following combined PPV with intraocular 
triamcinolone.  The central line illustrates the median value, the box 
illustrates the interquartile range and the extremes illustrate the minimum 
and maximum values.  
conc, Concentration; VEGF, vascular endothelial growth factor.  Diabetic Macular Oedema:  The role of steroids and VEGF
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3.7.4 Relationship between VEGF and visual acuity and 
central retinal thickness
There was little evidence of any association between the concentration of 
VEGF in the vitreous and the BCVA at 4 months or at 12 months (fig 4.3, 
top).  
Similarly, there was little evidence of any association between the 
concentration of VEGF in the vitreous and the retinal thickness at 4 months 
or at 12 months, (fig 4.3, bottom)Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 3.7.3:  The relationship between the concentration of VEGF in the 
vitreous and in the BCVA and retinal thickness at 4 months and 12months.
There was no strong relationship between the concentration of VEGF in the 
vitreous and the BCVA at 4 months, ρ= 0.235, P=0.49 (top left) and at 
12months, ρ=0.48, P=0.13 (top right) and in the central retinal thickness at 4 
months, ρ= -0.27, P=0.42 (bottom left), and at 12months, ρ=-0.47, P=0.14 
(bottom right) 
BCVA, best corrected visual acuity; ETDRS, early treatment of diabetic 
retinopathy study; VEGF, vascular endothelial growth factor; CRT, central 
retinal thickness.   
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3.7.5 Discussion
This study demonstrated that the VEGF concentration in the vitreous was 
elevated in eyes with DMO which was in agreement with previous studies
(Patel et al., 2006c;Funatsu et al., 2006), although we did not include a 
control group and therefore were unable to show that our result was greater 
than non-diabetic eyes. 
There was a modest reduction in the aqueous VEGF concentration one 
week following combined vitrectomy with TA.  It is conceivable that 
triamcinolone accounts for this modest decline as TA into an non-
vitrectomised eye leads to a marked reduction in vitreous VEGF 
concentration at 1 month (Brooks, Jr. et al., 2004a).  Conversely elevated 
VEGF concentrations are maintained for 36 days following PPV in patients 
with PDR (Itakura et al., 2004). 
We expected a greater reduction in aqueous VEGF concentration, although
in order to avoid intraoperative complications, the aqueous was taken at the
end of the operation.  We speculate that the aqueous sample was diluted 
and therefore our baseline aqueous VEGF concentration artificially low. 
We were unable to detect a relationship between vitreous VEGF 
concentration and outcome of combined surgery.  All our patients had 
chronic macular oedema and it is possible visual acuity was limited by 
longstanding intraretinal anatomical and functional changes such as 
photoreceptor death and RPE dysfunction.  If we had included patients with 
a better baseline visual acuity and of shorter duration of DMO, then the 
visual outcome may have been improved and an initial VEGF concentration 
may have been predictive of this.Diabetic Macular Oedema:  The role of steroids and VEGF
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It may also be that VEGF concentration is not related to the level of macular 
oedema at all.  DMO and DR are very closely interrelated and therefore it 
maybe possible that the VEGF concentration only reflects the degree of 
overall ischaemia and therefore the level of DR as a whole.  
At four months aqueous VEGF concentrations were increased.  Previous 
studies suggest that increased vitreous VEGF concentrations correlate with 
severity of diabetic retinopathy (Funatsu et al., 2005) and actively leaking 
DMO (Funatsu et al., 2004;Funatsu et al., 2006;Funatsu et al., 2007)   These 
results suggest that despite surgery, our patients continued to show active 
disease.  Although this may have been expected due to chronic nature of
DM and TA pharmacokinetics, it was anticipated that PPV would have 
arrested disease progression and reduce the need for reinjection of TA.
Following combined vitrectomy with intraocular triamcinolone for chronic
DMO, elevated aqueous VEGF concentration recurred at 4 months
demonstrating that PPV and TA together were unable to prevent disease
activity and thus the need for reinjections for TA.  Additionally baseline
intravitreal VEGF concentrations were not predictive of surgical outcome.    Diabetic Macular Oedema:  The role of steroids and VEGF
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4. Conclusions
and PerspectivesDiabetic Macular Oedema:  The role of steroids and VEGF
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4.1 VEGF and mechanisms of vascular hyperpermeability
Vascular permeability is the movement of fluids and molecules between the 
vascular and extravascular compartments.  Normal basal vascular 
permeability refers to the molecular exchange in normal tissues and primarily 
takes place in the capillaries.  The molecules exchanged consist largely of 
gases (O2 and CO2), water, small molecules such as salts and sugars and 
only small amounts of plasma proteins.  The extent of the process varies 
considerably between tissues and is largely a passive process, but can also 
be influenced by factors such as hydrostatic pressure and blood flow (Reed 
et al., 2001;Pietras et al., 2001).  Hydrostatic pressure can be affected by 
arterial blood pressure, altered efflux of fluid through the lymphatic system, 
changes in the extracellular matrix, or by integrins in interstitial cells (Reed et 
al., 2001).
Vascular hyperpermeability is the increase in vascular permeability in 
response to a number of vascular permeabilising factors for example
histamine and VEGF.  Not only is the quantity of extravagated fluid greatly 
increased but its composition is also changed.  The fluid is rich in proteins 
similar in composition to the plasma and is referred to as an exudate.  The 
extravasated proteins include fibrinogen and fibrin, which allow the exudate 
to form a gel, trapping water and resulting in tissue swelling and oedema.  
When vascular hyperpermeability becomes chronic, it usually implies that 
the leaking blood vessels are abnormal for example through new blood 
vessels during neoplasia or ischaemia.
The route of solute flux across the vascular endothelium has been debated 
for some time.  Transcellular flux is undoubtedly important, in particular 
under pathological conditions.  Significantly more perfused horseradish Diabetic Macular Oedema:  The role of steroids and VEGF
Zoe Ockrim MBChB MRCOphth Page 236
peroxidase or albumin is observed in intracellular vesicles in spontaneously 
diabetic rats (Vinores et al., 1993).  Transcellular flux has also been 
attributed to the formation of caveolae and vesiculovacuolar organelles in 
response to VEGF and not through the formation of fenestrations (Feng et 
al., 1999;Dvorak and Feng, 2001;Hofman et al., 2000).  However, the more 
common and intuitive theory of the passage of fluid and proteins through the 
BRB assumes the presence of a regulated paracellular route.  In agreement, 
changes in the junctional proteins have been observed to correlate vascular 
leak (Antonetti et al., 1998;Davidson et al., 2000).  A more direct indication 
arises from observation of mice lacking VEC or Cl-5 in which severe and 
selective vascular leak is observed, respectively (Corada et al., 1999;Nitta et 
al., 2003)
VEGF leads to an increase in permeability both in vivo and in vitro
(Behzadian et al., 2003) and is thought to have a key role in the 
pathogenesis of DMO due to this vasoactivity.  VEGF-induced vascular 
permeability is at least in part mediated via changes in the junctional 
complexes (Gavard and Gutkind, 2006).  Indeed, addition of VEGF to our 
retinal endothelial cells in vitro led to a rapid increase in permeability within 
30 minutes, which correlated with a reversible reduction of junction-
associated proteins such as ZO-1, alpha-catenin and gamma-catenin.  
Prolonged exposure also induced a loss of Cl-5, occludin and VEC.  Down-
regulation of junctional proteins, in particular of occludin, VEC and ZO-1 in 
response to VEGF is in agreement with other reports (Antonetti et al., 
1999;Behzadian et al., 2003;Esser et al., 1998;Wang et al., 2001;Nakamura 
et al., 2008).  Taken together, these results underline that regulation of the 
paracellular space contributes to the endothelial vasoactive response.  
Accordingly, the neutralisation of VEGF function can reduce 
hyperpermeability in animal models of diabetes (Ideno et al., 2007;Ishida et 
al., 2003), again implying a direct role for VEGF in its pathogenesis. 
Additionally, intravitreal injections of VEGF into the primate eye, results in Diabetic Macular Oedema:  The role of steroids and VEGF
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vascular changes comparable to DR.  Neovascularisation was observed in 
the periphery and microaneurysms appeared on arterioles, while areas of 
capillary nonperfusion, vessel dilation and tortuosity were seen on 
angiography (Tolentino et al., 2002).  Thus targeting VEGF to prevent
vascular endothelial permeability during DMO/DR appears like a promising 
therapeutic strategy.
A great number of studies report that intravitreal VEGF levels are very high 
in patients with proliferative diabetic retinopathy (Aiello et al., 
1994;Watanabe et al., 2005;Malik et al., 2005;Funatsu et al., 2004).  Its 
angiogenic growth factor activity is undoubtedly key in inducing the 
neovascularisation seen in these patients.  As outlined and discussed above 
VEGF is also thought to play a prominent role in oedema formation during 
DMO.  In agreement, it was reported that patients with DMO have elevated 
intraocular VEGF in the vitreous and aqueous (Funatsu et al., 2003;Patel et 
al., 2006c).  We found similarly elevated levels of VEGF in our study of 12 
eyes with DMO although our median VEGF level was lower than the 
previous 2 reports (575 vs 957 and 1125 pg/ml).  Taken together, VEGF 
levels in the eye are elevated during DMO but even higher during the 
proliferative phase of the disease. 
VEGF is upregulated by hypoxia, through the induction of hypoxic-inducible 
factors (HIF).  HIF translocates to the nucleus and upregulates the 
transcription of VEGF mRNA  in retinal pericytes, retinal endothelial cells and 
RPE (Ozaki et al., 1999).  Retinal ischaemia increases VEGF levels and 
produces proliferative diabetic retinopathy (PDR) is a direct consequence.  
As DMO and PDR are not independent entities, it is therefore conceivable 
that the elevated VEGF in eyes with DMO is related to the degree of retinal 
hypoxia and not to the degree of oedema / permeability.  This would explain Diabetic Macular Oedema:  The role of steroids and VEGF
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why no relationship between the levels of VEGF in the ocular fluids and 
outcome of PPV with TA for DMO was detected in our trial.    
However not all patients with an elevated VEGF level develop DMO.  Maybe 
VEGF concentrations vary throughout different parts of the vitreous and 
perhaps VEGF gets trapped in mid vitreous or in some patients VEGF is 
unable to get through the inner limiting membrane at macula to invade retina 
and thus increase vascular permeability. The predilection of type 1 diabetic 
to develop proliferative diabetic retinopathy and of type 2 diabetics to 
develop DMO suggests a complex underlying disease pathology involving 
more than vascular hyperpermeabilty and elevated VEGF levels.  Diabetic Macular Oedema:  The role of steroids and VEGF
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4.2 Mechanisms of diabetic macular oedema
Breakdown of the blood-retinal barrier occurs in many diseases and may 
lead to subretinal fluid or retinal oedema.  The inner BRB (iBRB) is primarily 
affected in the diabetic eye and vascular hyperpermeability has been 
proposed as one of the earliest retinal changes in diabetes (Cunha-Vaz et 
al., 1975).  Increased retinal thickness has been shown to coincide with 
increased leak from retinal blood vessels (Lobo et al., 2000) and correlates 
with vision loss in DR (Moss et al., 1998).  Additionally, increased retinal 
vascular permeability is associated with increased permeability in the 
kidneys and increased urinary albumin excretion in type 2 diabetics 
(Knudsen et al., 2002).  
In the normal healthy eye, retinal vascular hyperpermeabiliy is compensated 
for by an efflux of fluid through the retinal pigment epithelium (RPE) and the 
redistribution of electrolytes and thus water via Müller cells (Bringmann et al., 
2004).  Although DM is primarily a retinal microvasculopathy, changes in 
morphology, permeability and electrophysiology of the RPE in experimentally 
diabetic animals have also been described.  The RPE in spontaneously 
diabetic rats shows changes in the basal folding of the plasma membrane 
and increased permeability to horseradish peroxidase (Blair et al., 1984).  
Furthermore there is a loss of ionic autoregulation in RPE cells.  Changes in 
the function of the RPE can be detected clinically as an alteration in the 
RPE-generated c-wave on electroretinography (MacGregor and 
Matschinsky, 1986) and a decrease in amplitude of the fast oscillation (FO) 
on electrooculogram (Schneck et al., 2008).  The FO reflects the ability of 
the RPE to pump fluid and ions from the retina to the choroid and a decrease 
in the FO can be detected in diabetic patients prior to any visible retinopathy 
(Schneck et al., 2008).  Consequently, DMO occurs when, in addition to Diabetic Macular Oedema:  The role of steroids and VEGF
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vascular leakage, the active transport mechanisms of the blood-retinal 
barriersare dysfunctional (Mori et al., 2002).  
One of the first histological changes observed during diabetic retinopathy is 
the loss of capillary pericytes (COGAN et al., 1961).  Hyperglycaemia 
followed abruptly by euglycaemia triggers has been shown to cause pericyte 
apoptosis (Li et al., 1996b).  Loss of pericytes correlates with the formation 
microaneurysms, which are thin outpouchings from the retinal capillary wall 
(Yanoff M, 2002).  Microaneuryms can lead to vascular leakage and retinal 
thickening and oedema.  
Other histological changes in DR include capillary loss, caused by basement 
membrane thickening and occlusion of the vessel by leukocyte adhesion 
(Yanoff M, 2002).  Capillary loss leads to macular and retinal ischaemia.  
Although there are no overt clinical manifestations of macular ischaemia, a 
featureless flat retina, white vessels, deep blot haemorrhages and cotton 
wool spots all suggest it. Fundus fluorescein angiography definitively 
diagnoses capillary loss as increased size of the foveal avascular zone and 
perifoveal capillary loss and is generally associated with retinal 
hyperpermeability.  Experimental ischaemia of the rat retina evokes a 
biphasic water accumulation in the retina.  During ischaemia the oedema is 
thought to be due to neuronal cells swelling (Uckermann et al., 2004) while 
during the reperfusion stage it is thought to be due to the glial cells swelling 
(Pannicke et al., 2004).  
The retina is a compact tissue composed of neural and glial cells (Hogan, 
1971).  Glial cells occupy the interneuronal space and therefore in normal 
situations the extracellular space is virtually absent.  Vascular leakage 
results in serumprotein extravasation and osmotically driven water inflow Diabetic Macular Oedema:  The role of steroids and VEGF
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intothe retinal tissue.  The fluid enters the Müller cells causing intracellular 
swelling in the outer plexiform layer, initially a reversible process (Yanoff et 
al., 1984;Fine et al., 1981).  However, excessive swelling of Müller cells 
results in their rupture and death to produce pockets of extracellular fluid and 
cell debris, which is seen clinically as cystoid macular oedema (Yanoff et al., 
1984;Fine et al., 1981).  Similarly swelling of ganglion cells bodies and their 
processes, precedes the loss of these cells (Duke-Elder and Dobree, 1967).  
With the advent of cell death, the visual loss becomes irreversible.   
Apoptosis of retinal ganglion cells and inner nuclear layer cells are known to 
occur very early in the course of diabetes (Barber et al., 1998;bu-El-Asrar et 
al., 2004).  Although these changes are not detectable by ophthalmoscopy, a 
reduction in the oscillatory potentials seen in electrophysiological studies in 
patients with diabetic retinopathy indicates their loss (Simonsen SE, 1969).  
These changes often precede the onset of microvascular lesions (Parisi and 
Uccioli, 2001) and predict worsening of retinopathy better than clinical 
characteristics (Bresnick and Palta, 1987).  
They are also critical for understanding why patients with DR lose vision, 
even if the macular oedema is treated.  Clearly, visual loss in DMO is 
ultimately related to impaired neuronal function and not solely to vascular 
disease.  At the cellular level, diabetes alters the function and structureof all 
retinal cell types.  
In both our randomised controlled trial of intravitreal TA and laser and in our 
pilot study, we did not show a significant improvement in visual acuity in 
patients with persistent DMO at any time point.  Even in patients who had a 
significant reduction in central retinal thickness in our RCT (both the TA and 
laser groups), there was no change in the mean visual acuity (56.6 vs 57.0 Diabetic Macular Oedema:  The role of steroids and VEGF
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ETDRS letters, P=0,45).  The cause of their visual loss must be more than 
simply DMO.  Therefore we conclude that neuronal death or dysfunction was 
responsible for the lack of improvement in VA in this subset of patients.  Diabetic Macular Oedema:  The role of steroids and VEGF
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4.3 Insights into the therapeutic mechanism of 
Corticosteroids
Corticosteriods (GCs) have been shown to reduce blood-retinal barrier 
breakdown (Wilson et al., 1992) and reduce DMO at least in the short-term 
(Martidis et al., 2002;Jonas and Sofker, 2001), however the mechanism of 
action of remains obscure.  They have an established anti-inflammatory 
effect since they inhibit the release of arachidonic acid from cell membranes 
and hence the production of the inflammatory mediators, prostaglandins and 
leukotrienes.  Additionally, glucorticoidsdown-regulate the inflammatory 
expression of endothelialadhesion molecules ICAM-1 and VCAM-1 (Penfold 
et al., 2000), as wells as inhibit leukocyte-endothelialinteractions in the 
retina of an experimentally-induced diabetic rat (Tamura et al., 2005). 
GCs may also reduce macular oedema by their action on VEGF in vitro and 
in vivo.  HC down-regulates the expression of theVEGF gene in human 
aortic vascular smooth muscle in culture (Nauck et al., 1998), while TA has 
been shown to reduce the secretionof VEGF by pigment epithelial cells 
during oxidative stress (Matsuda et al., 2005).  In vivo, an intravitreal 
injection of TA reduces the vitreal level of VEGF in patients with diabetic
retinopathy (Brooks, Jr. et al., 2004b) while dexamethasone reduces VEGF-
induced BRB breakdown in an animal model (Edelman et al., 2005).  
Furthermore, Uckermann et al (Uckermann et al., 2005) observed that TA 
had an inhibitory effect on the osmotic swelling of Müller glial cells in diabetic 
animals following transient ischemia, by altering the secretion of ions via 
Müller cell end feet into the blood and vitreous. Diabetic Macular Oedema:  The role of steroids and VEGF
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Antonetti et al (Antonetti et al., 2002) show that hydrocortisone has an effect 
on the tight junction proteins, with an increase in the occludin content and a 
decrease in occludin phosphorylation in bovine RMEC in vitro.  Our study 
using rat brain microvascular endothelial cells confirmed this and showed 
that hydrocortisone preserved and increased junctional levels of occludin, 
CL5, VEC and ZO-1.  In addition we observed a concurrent improvement of 
endothelial barrier, which was even more marked in the presence of TA. 
Thus steroids appeared to preserve adherens and tight junction complexes 
and enhance functionality of vascular barrier breakdown.  
Our randomized controlled trial was designed to assess the long-term effects 
of TA on DMO with follow up visits every of months.  In addition to the study 
protocol, an OCT was performed at 1 week and 1 month in all patients in the 
study group (results not shown).   At 1 month (and 1 week) a reduction in the 
retinal thickness was observed, which agrees with previous short-term 
results suggesting that GCs may prove beneficial to control or even 
normalise the vascular dysregulation seen in DMO/DR.
However, DMO is a complex disease, and many factors have been shown to 
be involved in its formation.  In addition to VEGF, PKC, the GH-IGF-1 and 
the RAS have all been shown to be involved.  Over time, DMO leads to cells 
death which accounts for the irreversible nature of some visual loss.  The 
role of GCs in the eye for DMO clearly has limitations.  In our in vitro study, 
both hydrocortisone and TA were able to inhibit VEGF-induced permeability 
but neither steroid was able to inhibit the increase in permeability produced 
by lysophosphatidic acid (LPA).  These results, suggest that steroids can 
normalise vascular endothelial cells in the short-term, but may not counteract 
all vasoactive stimuli.  Diabetic Macular Oedema:  The role of steroids and VEGF
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We observed a reduction in retinal thickness in some patients at 1 months, 
but not all patients showed a complete resolution of DMO.  Furthermore 
there was no significant reduction in retinal thickness following intravitreal TA 
at any study time-point and only 2 patients in our study group achieved our 
primary outcome measure of an improvement of 15 or more ETDRS letters.  
Many of the patient included in this trial had chronic DMO and it could be 
argued that if we had included patients at an earlier stage in the evolution of 
the disease then we would have seen an improvement in visual acuity.  
However, in our experience, TA is usually reserved for patients unresponsive 
to laser treatment and therefore our study population is likely to reflect the 
population of patients most widely treated with TA.  
However, a reduction of retinal thickness even if short-lived may prove 
beneficial as an adjunctive treatment for DMO.  Avitabile et al noted that TA 
and laser photocoagulation lead to a decrease in the number of eyes 
requiring reinjection (Avitabile et al., 2005b), while Shimura et al found that 
combination therapy lead to a lower intensity of laser spots and also 
prevents the decrease in central visual field sensitivity (Avitabile et al., 
2005a) suggesting that a reduction in retinal thickness may increase the 
effect and decrease the side-effect profile of macula laser photocoagulation. 
Studies to assess the efficacy of intravitreal TA as an adjunctive therapy for 
DMO are currently underway (Diabetic retinopathy clinical research 
network).  Diabetic Macular Oedema:  The role of steroids and VEGF
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4.4 Potential novel therapies for DMO including anti-VEGF 
therapies
Anti-VEGF drugs were first used in the eye for their anti-angiogenic effects in 
the treatment of age-related macular degeneration (AMD) (2002) and have 
been proven successful at delaying the progression and even at improving 
VA in patients with AMD (Rosenfeld et al., 2006).  VEGF has also been 
implicated in the development of DMO and neutralisation of VEGF function 
can reduce hyperpermeability in animal models of diabetes (Ideno et al., 
2007;Ishida et al., 2003).  Thus targeting VEGF to prevent DMO with VEGF 
inhibitors such as bevacizumab provides new treatment strategies for DMO.  
Initial pilot studies have generally been optimistic that they can provide short-
term stability or improvement in VA and retinal thickness in patients with 
DMO (Arevalo et al., 2007;Haitoglou et al., 1992).  Again, these studies have 
been typically small groups of patients with relative short follow-up
However, not all results have been so positive (Shimura et al., 2008;Paccola 
et al., 2008)  and there application may be limited for example macular 
ischaemia has negative effect on the visual outcome (Chung et al., 2008).  
Our studies with intravitreal TA stress the importance of early intervention for 
DMO.  Even in patients who had a response to treatment (as measured as a 
reduction in retinal thickness), there was no significant improvement in the 
visual acuity, suggesting that neuronal cell death had already occurred.  
Pilot studies with anti-VEGF agents suggest that they may be beneficial in 
the treatment of DMO.  At the present time there are no data from large 
muticentred randomised controlled trials using such agents and there 
remains unanswered concerns over anti-VEGF therapies such as its effect 
on blood pressure (due to the increased vasoconstriction) and renal function 
proteinuria (due to glomerular dysfunction) even from local intravitreal Diabetic Macular Oedema:  The role of steroids and VEGF
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injections (Simo and Hernandez, 2008;Zhu et al., 2007).  At a local level, 
VEGF blockade may reduce the function of fenestrated vascular beds such 
as the choroicapillaris (Kamba et al., 2006;Baffert et al., 2006;Peters et al., 
2007).  VEGF offers neuroprotection to the retina and protects against 
ischaemia therefore local effects on the neuroretina of VEGF blockage 
should be closely observed (Nishijima et al., 2007).
Some neurons, such as motor neurons in the spinal cord, are strongly 
dependent upon VEGF for survival (Oosthuyse et al., 2001;Storkebaum et 
al., 2005;Wang et al., 2007).  VEGF type 2 receptors have been identified on 
neurons, including retinal neurons, and it has been suggested that their 
activation may promote cell survival (Jin et al., 2000).  A recent report 
suggested that VEGF antagonists may cause death of retinal ganglion cells 
(Nishijima et al., 2007).  
VEGF and steroids had an opposing effect on our microvascular endothelial 
cell.  Similarly, we showed that steroids were able to inhibit VEGF-induced 
permeability in vitro.  Thus, if inhibition of VEGF shows a similar effect in 
vivo, they may prove no more efficacious than steroids at reducing retinal 
thickness and increasing visual acuity in patients with DMO.    
Our results suggest that VEGF affects cellular processes which do not 
directly impinge on permeability (signalling to ZO-1 which does not correlate 
with permeability).  Anti-VEGF treatments have been shown to have an 
effect on vascular tone and possible effects on the local oxygen supply an 
ischaemic tissue have to be considered (Ziemssen et al., 2008).   
Furthermore Systemic absorption from intravitreal TA is not negligible 
(Ziemssen et al., 2008). VEGF is a growth factor that has been implicated in Diabetic Macular Oedema:  The role of steroids and VEGF
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many disease processes but it is important to remember that VEGF also has 
physiological functions.  Data from the 2-year MARINA study shows no 
increase in the incidence of systemic adverse events associated with anti-
VEGF therapy.  However, in the pooled 1-year safety results from the 
MARINA and ANCHOR trials, a slightly higher incidence of myocardial 
infarction and stroke was noted with higher doses of ranibizumab (Rosenfeld 
et al., 2006).  Patients with DM have a higher risk of cardio- and 
cerebrovascular disease, and therefore further prospective studies are 
needed to determine the long-term outcome including safety of anti-VEGF 
treatment for DMO.
VEGF is involved in many vascular responses including permeability, 
angiogenesis and migration of endothelial cells.  VEGF signalling is clearly 
complex and interrelated.  Identifying how VEGF brings about vasoactive 
changes including its intracellular signalling pathway are therefore important 
in order to identify more specific (down stream) targets in its signalling 
cascade.
By correlating signalling of VEGF to junctions on the one hand and to 
permeability on the other, we describe an approach which to our knowledge 
is novel.  We provide evidence that it is suitable to identify whether a 
junctional molecule is likely to be a key mediators of VEGF-induced 
permeability.  Potential targets identified by this method (with high correlation 
in signalling) can subsequently be verified by direct molecular approaches 
such as using small interfering RNA (siRNA). We believe that such vigorous 
testing is required to understand the effect of VEGF onto junctions and the 
development of more targeted and restricted drugs. Diabetic Macular Oedema:  The role of steroids and VEGF
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5.1 Introduction
The aims of this thesis were to improve our understanding of the cellular 
events involved in DMO, and to assess novel therapies to reverse or limit the 
damage of this chronic disease.  Our studies produced primarily negative 
results.  Although these results provide invaluable information in DMO 
management, the ultimate aim of the ideal treatment for DMO has yet to be 
reached.  This research has left many questions unanswered for future work 
and can only be seen as the start to discovering an effective treatment of 
DMO.
5.2 Laboratory work
Our experiments were limited by the relatively few retinal microvascular 
endothelial cells (RMEC) we were able to produce. In addition, they lost 
primary features rapidly in culture and could therefore not be propagated for 
extended times.  Therefore we used brain microvascular endothelial cells 
(BMEC) to develop our experimental systems before repeated key 
experiments on RMEC.  Due to the time constraints, MEC permeability was 
only performed on BMEC
Growing the MEC on filters proved to be a challenge and as a result 
measurements of permeability were prone to artefact.  As a consequence 
transendothelial electrical resistence across MEC monolayers did not 
provide any useful information.  Additionally, we tried to fix and subsequently 
stain the MEC used to measure permeability but the attachment of the cells 
to the filter proved to fragile to survive the fixation process and therefore we 
were unable to perform immunofluorescence the same cells that showed 
changes in permeability.  Diabetic Macular Oedema:  The role of steroids and VEGF
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It is the intention of the laboratory to develop a repeatable method of growing 
MEC on filters and thus accurate methods of measuring permeability could 
be performed.  It is anticipated that this would allow immunofluorence of the 
cell cultures that show a change in permeability and it would also allow the 
experiments to be repeated on RMEC.   
Furthermore, we would like to test the polarity of MEC.  We have made 
some preliminary observations that VEGF application to the basolateral side 
of MEC was more effective in inducing permeability.  This observation has 
already been reported in the literature (Wang et al., 2001) and suggest that 
MEC are functionally polarised.  It is known that epithelial cells are polarised
with receptors such as EGFR on only one surface.  In addition TJ are formed
more apically than AJ.  However in endothelial cells TJ and AJ interdigitate 
and the polarity of retinal endothelial cells has not previously been explored.  
During the work of this thesis we attempted to test this hypothesis further, 
but, we realised that the cultures contained microscopic gaps and areas of 
TJ breakdown.  Thus monolayers were unlikely to be homogenously 
polarised.  Future work should concentrate on optaininig better cultures to 
persue this aim.  
We would also like to continue the work with inhibitors of the signal 
transduction pathway.  Until now we had to rely on work from the literature 
about VEGF-induced permeability and compare this against VEGF-induced 
ZO-1 loss.  A better comparison is to compare VEGF-induced permeability 
with VEGF-induce TJ or AJ protein loss within our own cell systems.  
Clearly, the aim here is to identify a specific intracellular signal transduction 
pathway that is critical for VEGF-induced permeability.  Inhibitors of this Diabetic Macular Oedema:  The role of steroids and VEGF
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pathway could ultimately be utilised to prevent macular oedema without 
systemic complications which may limits its use.  
The scope of the work of this thesis was limited to microvascular endothelial 
cells (MEC) taken in isolation.  The BRB consists of many cells that function 
in tandem and therefore co-culture with other cell types such as pericytes 
may provide a better in-vitro model of the BRB.  
Similarly some of our experimentations could be performed on an animal 
model.  For example BRB permeability on diabetic and control rats can be 
measured using intravenous injection of fluorescent markers  and analysed 
by digital image analysis of retinal sections.  Additionally changes in the 
junctional proteins could be measured by immunofluorescence or 
immunoblotting retinal homogenates. 
We assayed the amount of VEGF in the vitreous (and aqueous) of patients 
undergoing PPV.  This consists of all isoforms of VEGF.  It would be 
interesting to assay the individual isoforms of VEGF and in addition to look at 
the levels of other growth factors that have been implemented in the 
pathegesis of DMO such as Insulin-like growth factors.  
5.3 Clinical Work
We showed a negative effect from TA for the treatment of persistent DMO 
over 12 months.  However, our work and work from previous trials have 
shown that intravitreal TA can reduce macular oedema in the short term.  
This effect may allow other therapies to be more effective in the long term; Diabetic Macular Oedema:  The role of steroids and VEGF
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for example the use of macular photocoagulation to a thinner macula than a 
macula with gross macular oedema.  
In our study we recruited patients with persistent DMO.  Other research 
tends to suggest that therapies used earlier in the evolution of DMO may 
offer better chance of improvement or stablilisation of VA.  However, as we 
found very little change either the VA or retinal thickness of persistent DMO 
with TA alone, a second study using TA as a monotherapy for untreated 
DMO does not seem logical and a study of this nature is probably better 
conducted with anti-VEGF agents such a Bevacizumab. 
The ideal treatment for DMO is one which targets the tissues that influence 
DMO but does has limited effects on the surrounding tissues.  Additionally as 
DM and its complications is a chronic condition, it needs therapeutic agents 
that are easy to administer over the long-term.  Furthermore, DR is an end 
organ disease and therefore the ideal treatment needs to prevents vascular 
changes rather that reverse them.  Therefore an oral medication which 
would prevent other end organ damage (such as protein kinase C inhibition
or perhaps fenofibrate ) or topical eye drop that can penetrate through to the 
posterior segment and provide vascular protection on a daily basis would be 
beneficial.  
The evolution of DMO with OCT would provide invaluable information about 
DMO and would allow us to examine its relationship with both VA and 
ischaemia.  A longitudinal long term study looking a the patterns of OCT in a 
cohort of patients attending diabetic retinal screening and then following the 
appropriate patients through referral to ophthalmology clinics could offer a 
better understanding of the evolution of the disease and any treatment 
effect.   Diabetic Macular Oedema:  The role of steroids and VEGF
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7.1 Negative controls of antibodies 
Microvascular endothelial cells (RMEC and BMEC) were grown to 
confluence and then fixed with methanol or formaldehyde and then stained 
with secondary antibodies and with hoescht.  Images were generated using 
the same settings as the postively stained images (fig 7.1) (BMEC not 
shown).  Diabetic Macular Oedema:  The role of steroids and VEGF
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Figure 7.1:  Negative controls of RMEC:  Retinal microvascular endothelial 
cells  (RMEC) were grown to confluence and then fixed with methanol or 
formaldehyde and then stained with anti –goat FITC conjugated (a), anti-
rabbit rhodamine conjugated (b), anti – mouse cy3 conjugated (c) and anti -  
rabbit FITC conjugated (d) and with hoescht.  Images were generated using 
the same settings as the postively stained images.  
a b
c d